SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [FEE REQUIRED]
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1993
Commission File Number 1-1136
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
Delaware 22-079-0350
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
345 Park Avenue, New York, N.Y. 10154
(Address of principal executive offices)
Telephone: (212) 546-4000
Securities registered pursuant to Section 12(b) of the Act:
Name of each exchange on
Title of each class which registered
Common Stock, $.10 Par Value New York Stock Exchange
Pacific Stock Exchange
$2 Convertible Preferred Stock, New York Stock Exchange
$1 Par Value Pacific Stock Exchange
Preferred Stock Purchase Rights * New York Stock Exchange
Pacific Stock Exchange
* At the time of filing, the Rights were not traded separately from the Common
Stock. For additional information, see "Stockholders' Equity" in the Notes
to Consolidated Financial Statements, included in Part II, Item 8.
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ X ]
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [ X ] No [ ]
The aggregate market value of voting stock held by non-affiliates of the
registrant as of February 28, 1994 was $28,106,944,369. At February 28, 1994
there were 511,175,071 shares of common stock outstanding.
Documents incorporated by reference
Proxy Statement for Annual Meeting of Stockholders on May 3, 1994. Part III
<PAGE>
PART I
------
Item 1.BUSINESS.
DESCRIPTION OF BRISTOL-MYERS SQUIBB COMPANY
- -------------------------------------------
General:
- -------
Bristol-Myers Squibb Company ("Bristol-Myers Squibb" or the "Company") was
incorporated under the laws of the State of Delaware in August 1933 under the
name Bristol-Myers Company as successor to a New York business started in 1887.
In 1989, Squibb Corporation merged with a subsidiary of Bristol-Myers Company,
and Bristol-Myers Company changed its name to Bristol-Myers Squibb Company.
Bristol-Myers Squibb, through its divisions and subsidiaries, is a major
producer and distributor of pharmaceutical products, medical devices,
nonprescription health products, toiletries and beauty aids.
INDUSTRY SEGMENTS
- -----------------
Reference is made to Note 17 Segment Information in the Notes to Consolidated
Financial Statements included in Part II, Item 8 of this Form 10-K Annual
Report.
DESCRIPTION OF SEGMENTS
- -----------------------
Pharmaceutical Products:
- -----------------------
This segment includes sales of prescription medicines, mainly cardiovascular
drugs and anti-infectives, which comprise about forty percent and twenty-five
percent, respectively, of the segment's sales, anti-cancer drugs which amounted
to approximately $1.2 billion in sales, central nervous system drugs,
diagnostic agents and other pharmaceutical products. Cardiovascular drugs
include captopril, an ACE inhibitor sold primarily under the trademarks
CAPOTEN* and CAPOZIDE*; pravastatin sodium, an HMG Co-A reductase inhibitor,
sold primarily under the trademark PRAVACHOL*; nadolol, a once-a-day beta
blocker used in the treatment of hypertension and angina pectoris, sold
primarily under the trademarks CORGARD* and CORZIDE*; cholestyramine, a
cholesterol-reducing agent, sold primarily under the trademark QUESTRAN*;
sotalol, a beta blocker with unique antiarrhythmic qualities, sold primarily
under the trademark SOTACOR*; fosinopril sodium, a second-generation ACE
inhibitor with convenient once-a-day dosage, sold primarily under the trademark
MONOPRIL*; and K-LYTE*. Anti-infective drugs include cefadroxil monohydrate,
an oral cephalosporin, sold primarily under the trademark DURICEF*; amikacin,
an aminoglycoside sold primarily under the trademark AMIKIN*; aztreonam, a
monobactam antibiotic sold primarily under the trademark AZACTAM*; cefprozil,
an oral cephalosporin used in the treatment of respiratory infections, sold
primarily under the trademark CEFZIL*; didanosine, an antiretroviral drug used
in the treatment of adult and pediatric patients with advanced human
immunodeficiency virus (HIV) infection, sold under the trademark VIDEX*;
synthetic penicillins, sold under the trademarks POLYCILLIN* and POLYMOX*; and
cefatrizine, an oral cephalosporin, sold primarily under the trademarks
CEFAPEROS* and ZANITRIN*. Anti-cancer drugs include etoposide, used in the
treatment of small cell lung cancer and refractory testicular cancer, sold
* Indicates brand names of products which are registered trademarks owned by
the Company.
- 1 -
<PAGE>
primarily under the trademark VEPESID*; carboplatin, a chemotherapeutic agent
used in the treatment of ovarian cancer, sold primarily under the trademark
PARAPLATIN*; paclitaxel, used in the treatment of refractory ovarian cancer,
sold under the trademark TAXOL*; PLATINOL*, IFEX*, MEGACE*, BLENOXANE*,
MUTAMYCIN* and CYTOXAN*. Central nervous system drugs include BUSPAR*, an
anxiolytic; DESYREL*, an antidepressant; and STADOL*, a potent prescription
analgesic. Diagnostic agents primarily include ISOVUE*, a nonionic imaging
agent used in cardiology and radiology; and PROHANCE*, a magnetic resonance
imaging agent used in the diagnosis of central nervous system disorders.
Dermatological drugs include LAC-HYDRIN*, used in the treatment of moderate to
severe dry skin. In December 1993, the Company received approval to market
DOVONEX*, a vitamin D3 analogue to treat moderate psoriasis. Other
pharmaceutical products include OVCON*, an oral contraceptive; and ESTRACE*, an
estrogen replacement.
Medical Devices:
- ---------------
This segment includes sales of orthopaedic implants, which comprise about forty
percent of the segment's sales, ostomy and wound care products, surgical
instruments and other medical devices. Some of the principal products in this
segment are the ZIMMER* Total System of artificial hips, the MGII* Total Knee
System and the Insall/Burstein II Modular Total Knee System, orthopaedic
implants; SUR-FIT/COMBIHESIVE*, ACTIVE LIFE/COLODRESS* and ILEODRESS*, ostomy
care products; and DUODERM*, wound care products.
Nonprescription Health Products:
- -------------------------------
This segment includes sales of infant formulas and other nutritional products,
which totaled $1.3 billion and comprise about sixty-five percent of the
segment's sales, analgesics, cough/cold remedies and skin care products. Some
of the principal products in this segment are ENFAMIL*, PROSOBEE*, Gerber Baby
Formula, NUTRAMIGEN* and LACTOFREE*, infant formula products; ENFAPRO* and
ALACTA*, follow-on formula products for older babies; SUSTAGEN*, ISOCAL*,
SUSTACAL* and NUTRAMENT*, nutritional supplements and specialties; THERAGRAN*,
VI-FLOR*, VI-SOL* and NATALINS*, vitamins; EXCEDRIN*, BUFFERIN*, NUPRIN* and
TEMPRA*, analgesics; COMTREX*, a multi-symptom cold reliever; KERI*, a
moisturizing body lotion; PRESUN*, a sun blocking agent; and ALPHA KERI*, a
shower and bath oil.
Toiletries and Beauty Aids:
- --------------------------
This segment includes sales of haircoloring and hair care preparations, which
comprise about sixty-five percent of the segment's sales, deodorants,
anti-perspirants and beauty appliances. Among the principal products in this
segment are NICE 'N EASY*, MISS CLAIROL*, LOVING CARE*, ULTRESS*, GLINTS*
Conditioning Color Enhancer, haircolorings; the CONDITION* line and other
shampoos and after-shampoo treatment products; INFUSIUM 23*, professional hair
care products; FINAL NET*, hair fixatives; VITALIS*, hair preparations; BAN*
and MUM*, anti-perspirants/deodorants; and SEA BREEZE*, skin care products.
SOURCES AND AVAILABILITY OF RAW MATERIALS
- -----------------------------------------
Bristol-Myers Squibb, for the most part, purchases the principal raw materials
and supplies used in each industry segment in the open market. Substantially
all such materials are obtainable from a number of sources so that the loss of
any one source of supply would not have a material adverse effect on the
Company.
- 2 -
<PAGE>
PATENTS, TRADEMARKS AND LICENSES
- --------------------------------
The Company owns or is licensed under a number of patents in the United States
and foreign countries covering products, principally in the pharmaceutical
products and medical devices segments, and has also developed many brand names
and trademarks for products in each industry segment. The Company considers
the overall protection of its patent, trademark and license rights to be of
material value and acts to protect these rights from infringement. The Company
believes that, except for the patent relating to captopril which expires in the
United States and Germany in 1995, no single patent or license is of material
importance in relation to the business as a whole.
COMPETITION, DISTRIBUTION AND CUSTOMERS
- ---------------------------------------
The markets in which Bristol-Myers Squibb competes are generally broad based,
heavily competitive and include many competitors. The principal means of
competition utilized to market the products of Bristol-Myers Squibb include
quality, service, price and product performance. The products of the
pharmaceutical products segment and the medical devices segment are promoted on
a national and international basis in medical journals and directly to the
medical profession. Most of the other products of Bristol-Myers Squibb are
generally advertised and promoted on a national and international basis through
the use of television, radio, print media, consumer offers, and window and
in-store displays. Bristol-Myers Squibb's products are principally sold to the
wholesale and retail trade both nationally and internationally. Certain
products of the pharmaceutical products and medical devices segments are also
sold to other drug manufacturers, hospitals and the medical profession. None
of the segments is dependent upon a single customer, or a few customers, such
that the loss of any one or more would have a material adverse effect on the
segment.
RESEARCH AND DEVELOPMENT
- ------------------------
Research and development is essential to Bristol-Myers Squibb's businesses,
particularly to the pharmaceutical products segment. Management continues to
place great emphasis on these activities. Pharmaceutical research and
development is carried out by the Bristol-Myers Squibb Pharmaceutical Research
Institute which has major facilities in Princeton and New Brunswick, New
Jersey, Wallingford, Connecticut and Seattle, Washington. Pharmaceutical
research and development is also carried out at various other facilities in the
United States and in Belgium, France, Germany, Italy, Japan, and the United
Kingdom.
Bristol-Myers Squibb spent $1,128 million in 1993, $1,083 million in 1992 and
$983 million in 1991 on company sponsored research and development activities.
Pharmaceutical research and development spending, as a percentage of
pharmaceutical sales, increased to 14.9% in 1993 from 14.8% in 1992 and 14.3%
in 1991.
REGULATION
- ----------
Most aspects of the Company's business are subject to some degree of government
regulation in the countries in which its operations are conducted. The
Company's policy is to comply fully with all regulatory requirements applying
to its products and operations. For some products, and in some countries,
- 3 -
<PAGE>
government regulation is significant and, in general, there is a trend to more
stringent regulation. The Company devotes significant time, effort and expense
addressing the extensive governmental regulatory requirements applicable to its
business. Governmental regulatory actions can result in the recall or seizure
of products, suspension or revocation of the authority necessary for the
production or sale of a product, and other civil and criminal sanctions.
In the United States, the drug, medical device, diagnostic, food and cosmetic
industries in which the Company operates have long been subject to regulation
by various federal, state and local agencies, primarily as to product
manufacture, safety, efficacy, advertising and labeling. Assuring compliance
with appropriate laws and regulations requires increasing expenditures of time
and resources.
In addition, governmental bodies in the United States as well as other
countries have expressed concern about costs relating to health care and, in
some cases, have focused attention on the pricing of drugs and on appropriate
drug utilization. Government regulation in these areas already exists in some
countries and may be expanded significantly in the United States and other
countries in the future.
While the Company is unable to predict the extent to which its business may be
affected by future regulatory developments, it believes that its substantial
experience dealing with governmental regulatory requirements and restrictions
on its operations throughout the world and its development of new and improved
products should enable it to compete effectively within this environment.
EMPLOYEES
- ---------
Bristol-Myers Squibb employed approximately 49,500 people at December 31, 1993.
DOMESTIC AND FOREIGN OPERATIONS
- -------------------------------
Reference is made to Note 17 Segment Information in the Notes to Consolidated
Financial Statements included in Part II, Item 8 of this Form 10-K Annual
Report.
International operations are subject to certain risks which are inherent in
conducting business abroad, including possible nationalization or
expropriation, price and exchange controls, limitations on foreign
participation in local enterprises and other restrictive governmental actions.
In addition, changes in the relative value of currencies take place from time
to time and their effects may be favorable or unfavorable on Bristol-Myers
Squibb's operations. There are currency restrictions relating to repatriation
of earnings in certain countries.
Item 2. PROPERTIES.
Bristol-Myers Squibb's world headquarters is located at 345 Park Avenue, New
York, New York, where it leases approximately 841,800 square feet of floor
space, approximately 225,700 square feet of which is sublet to others. The
Company's pharmaceutical world headquarters is located in Princeton, New
Jersey. Other major domestic pharmaceutical facilities are located in
Evansville, Indiana, New Brunswick and Plainsboro, New Jersey and Buffalo and
Syracuse, New York. The Company's major domestic medical devices facilities
- 4 -
<PAGE>
are located in Warsaw, Indiana, Skillman, New Jersey and Greensboro, North
Carolina.
Bristol-Myers Squibb manufactures products at forty-one major worldwide
locations with an aggregate floor space of approximately 11,027,200 square
feet. Thirty-nine are owned by Bristol-Myers Squibb and two facilities are
leased. The U.S. manufacturing facilities total seventeen, of which 42% and
29% are used in the manufacture of pharmaceutical products and medical devices,
respectively. The non-U.S. operations include a total of twenty-four major
owned manufacturing facilities, of which 79% and 4% are used in the manufacture
of pharmaceutical products and medical devices, respectively. These facilities
are located in Australia, Brazil, Canada, China, Colombia, France, Germany,
Ireland, Italy, Japan, Korea, Mexico, the Netherlands, the Philippines, Taiwan,
the United Kingdom and Venezuela, and aggregate approximately 5,929,000 square
feet of space.
Portions of these facilities and other facilities owned or leased by
Bristol-Myers Squibb in the United States and elsewhere are used for research,
administration, storage and distribution. All of Bristol-Myers Squibb's
facilities are well-maintained, adequately insured and in satisfactory
condition.
Capital expenditures for the construction, expansion and modernization of
production, research and administrative facilities aggregrated $580 million,
$654 million and $633 million in 1993, 1992 and 1991, respectively.
Item 3. LEGAL PROCEEDINGS.
DES LITIGATION
- --------------
The Company is a defendant in a number of actions brought against it and other
pharmaceutical companies in federal and state courts by the children or
grandchildren of women who ingested diethylstibelstrol (DES), a product which
had been, but is no longer, manufactured or sold by a subsidiary of the
Company. The Company believes that these actions will not have a material
adverse effect on the Company's consolidated financial position.
BREAST IMPLANT LITIGATION
- -------------------------
Approximately 11,000 plaintiffs have filed suit against the Company, its
subsidiary, Medical Engineering Corporation ("MEC"), and certain other
subsidiaries, in federal and state courts and in Canadian provincial courts,
alleging damages for personal injuries of various types resulting from
polyurethane covered breast implants and smooth walled breast implants.
Certain of these cases are class actions which seek to allege claims on behalf
of all breast implant recipients. All federal court actions have been
consolidated for pre-trial proceedings in federal district court in Birmingham,
Alabama.
In late March 1994, the Company, other defendants and certain plaintiffs
entered into a settlement agreement regarding all pending and future breast
implant product liability claims brought in the United States against certain
defendants, including the Company, MEC and certain other subsidiaries. The
settlement agreement must be submitted for approval to the Hon. Sam C. Pointer,
the federal judge who is presiding over the proceedings in Birmingham, Alabama.
Thereafter, the settlement would not become final until the resolution of any
appeals of Judge Pointer's approval. Claimants are entitled
- 5 -
<PAGE>
to opt out of the settlement and pursue litigation rather than participate in
the settlement. The settlement is also dependent on claimants not opting out
in significant numbers. The settlement provides for the creation of a series
of claims funds to which the settling defendants would contribute various
amounts over approximately 30 years. The aggregate contribution to be made by
the Company, MEC and certain other subsidiaries shall be no more than $1.154
billion.
In the fourth quarter of 1993, the Company recorded a special charge of $500
million before taxes ($310 million after taxes) in connection with pending and
future breast implant product liability claims (See Item 8 of this Report).
The special charge consists of $1.5 billion for potential liabilities and
expenses, offset by $1 billion of expected insurance proceeds. Although the
Company is currently engaged in coverage litigation with certain of its
insurers, such expected insurance proceeds represent the amount of insurance
which the Company considers appropriate to record as recoverable at this time.
The Company believes that ultimately it will obtain substantial additional
amounts of insurance proceeds. Based on the amounts and timing of the payment
obligations under the settlement, the Company's current estimate of potential
liabilities and expenses that may not be covered by the settlement, and the
amount of insurance proceeds that the Company believes will ultimately be
available, the Company believes that the breast implant actions will not have a
material adverse effect on the Company's consolidated financial position.
PATENT PROCEEDINGS
- ------------------
In September 1992, the Company brought an action in the United States District
Court for the Southern District of New York against Danbury Pharmacal, Inc. for
patent infringement following Danbury's filing of an Abbreviated New Drug
Application which asserted that one of the Company's patents for buspirone
(sold under the brand name BUSPAR*) is invalid and unenforceable. On June 30,
1993, the District Court granted Danbury's Summary Judgment motion invalidating
the Company's U.S. Patent No. 4,182,763. The Company appealed the District
Court's decision to the Court of Appeals for the Federal Circuit and awaits the
appellate decision. The Company believes that the District Court's decision
was erroneous as a matter of fact and law and that the Company will prevail on
its appeal.
In 1991, Zenith Laboratories, Inc. brought an action in the United States
District Court for the District of New Jersey in which Zenith sought a
declaratory judgment that its cefadroxil product does not infringe the
Company's patent for cefadroxil monohydrate. In July 1992, following a trial,
the District Court issued a decision finding that the Company's patent for
cefadroxil monohydrate (sold under the brand name DURICEF*) would be infringed
by Zenith's cefadroxil DC. The District Court ordered that the effective date
of Zenith's FDA approvals for cefadroxil DC capsules and tablets shall not be
earlier than March 12, 2002, the expiration date of the Company's cefadroxil
monohydrate patent. Zenith appealed the District Court's decision to the Court
of Appeals for the Federal Circuit, and on March 24, 1994 the Court of Appeals
reversed the District Court's decision and held that, based on the evidence
before it, the District Court erred in finding that Zenith's product infringes
the Company's patent. The Company will ask the Court of Appeals either to
reconsider its decision or remand the case to the District Court for further
consideration.
INFANT FORMULA MATTERS
- ----------------------
The Company, one of its subsidiaries and others are defendants in ten antitrust
- 6 -
<PAGE>
actions in seven states (Alabama, Florida, Kansas, Louisiana, Michigan, Texas
and Wisconsin) filed on behalf of purported statewide classes of indirect
purchasers of infant formula products and by the Attorney General of Texas,
alleging a conspiracy regarding pricing of infant formula products and other
violations of state antitrust or deceptive trade practices laws and seeking
treble damages, statutory and civil penalties and injunctive and other relief.
In one of the Texas actions, the trial court's dismissal of an amended class
action complaint of certain indirect purchasers has been reversed and remanded.
In one of the Alabama actions, the plaintiffs' appeal of the denial of their
motion for class certification was withdrawn. In addition, the State of
Louisiana has filed a federal court action against the Company and others
asserting claims similar to those previously asserted by the State of Florida
and dismissed by the federal court in the Northern District of Florida. The
State of Louisiana's case has been transferred for pre-trial purposes to the
Northern District of Florida where a motion to dismiss is pending. The Nestle
Food Company has filed an action in federal court in the Central District of
California against the Company, one of its subsidiaries and others alleging
that the defendants conspired to restrain competition in and maintain
artificial barriers to entry into the United States infant formula market and
engaged in other violations of federal and state antitrust or other laws.
There are pending investigations of infant formula pricing and marketing by
five state Attorneys General, and the office of the Attorney General of New
Jersey has indicated its intention to begin a similar investigation. The
Canadian Bureau of Competition Policy has commenced a civil inquiry, and is
contemplating a criminal inquiry, into alleged anticompetitive practices among
the Company and certain other members of the Canadian infant formula industry.
The Company believes that the foregoing matters are without merit and that
their ultimate disposition will not have a material adverse effect on the
Company's consolidated financial position.
PHARMACEUTICAL PRICING LITIGATION
- ---------------------------------
The Company, along with more than 30 other major pharmaceutical manufacturers
and drug wholesalers, is a defendant in a number of actions brought in various
federal courts around the country seeking damages and injunctive relief under
the federal antitrust laws for alleged antitrust violations in the pricing and
marketing of brand name prescription drugs. In addition, the Company, along
with several other pharmaceutical manufacturers, wholesalers and a pharmacy
benefit management company, has been named as a defendant in several actions
filed in California state courts, which involve substantially similar factual
allegations as those made in the federal actions. These lawsuits are of three
different varieties: (1) individual actions by independent retail pharmacies;
(2) purported class actions by independent pharmacies seeking to represent a
class comprised of those alleged to be similarly situated; and (3) individual
actions by large retail pharmacy chains and supermarkets. The federal court
cases, along with additional cases making similar claims but not naming the
Company as a defendant, have been consolidated for pre-trial purposes in the
United States District Court for the Northern District of Illinois. These
cases are still in the pleading stage and no discovery has commenced. The
Company believes that these actions are without merit and that their ultimate
disposition will not have a material adverse effect on the Company's
consolidated financial position.
SECURITIES LITIGATION
- ---------------------
The Company is a defendant in a purported class action filed in the U.S.
District Court for the Southern District of New York alleging violations of
federal securities laws and regulations in connection with, among other things,
- 7 -
<PAGE>
earnings projections. The Court has certified this action as a class action on
behalf of all persons (other than defendants) who purchased or otherwise
acquired shares of the Company's common stock between November 18, 1991 and
June 2, 1992. The Company believes that this action will not have a material
adverse effect on the Company's consolidated financial position.
ENVIRONMENTAL MATTERS
- ---------------------
The Company, together with others, is a party to, or otherwise involved in, a
number of proceedings brought by federal or state environmental agencies under
the Comprehensive Environmental Response, Compensation and Liability Act
(CERCLA or Superfund), or State laws analogous to CERCLA, or to statutes and
regulations which otherwise deal with cleanup of contaminated property. The
Company believes that these proceedings will not have a material adverse effect
on the Company's consolidated financial position.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
- 8 -
<PAGE>
PART IA
-------
EXECUTIVE OFFICERS OF THE REGISTRANT
- ------------------------------------
The following are the executive corporate officers and the other executive
officers of the Registrant:
Positions and Offices Presently
Name Age Held With The Registrant
------------------------ --- ---------------------------------------
Richard L. Gelb 69 Chairman of the Board, Director and
Chairman of the Executive Committee
Charles A. Heimbold, Jr. 60 President and Chief Executive Officer
and Director
Michael E. Autera 55 Executive Vice President and Director
Harrison M. Bains, Jr. 50 Treasurer and Vice President, Corporate
Staff
Samuel L. Barker, Ph.D. 51 President, Bristol-Myers Squibb U.S.
Pharmaceuticals
Stephen E. Bear 42 Executive Vice President, Consumer
Products Group - Staff
Andrew G. Bodnar, M.D. 46 President, Oncology/Diagnostics and
Worldwide Strategic Business
Development - Bristol-Myers Squibb
Pharmaceutical Group
Ronald L. Davis 56 President, Zimmer, Inc.
Peter R. Dolan 38 President, Bristol-Myers Products
Richard A. Druckman 54 Vice President, Strategic Planning,
Corporate Staff
Raymond C. Egan 51 Senior Vice President, Health Care
Policy and Business Development,
Corporate Staff
William F. Flatley 52 Senior Vice President, Corporate
Staff
Samuel A. Hamad 52 President, Bristol-Myers Squibb
Pharmaceuticals - Intercontinental
Rodolphe Hamel 64 General Counsel and Senior Vice
President, Corporate Staff
- 9 -
<PAGE>
Positions and Offices Presently
Name Age Held With The Registrant
------------------------ --- ---------------------------------------
E. Lynn Johnson 49 President, Mead Johnson Nutritional
Group
Pamela D. Kasa 50 Corporate Secretary, Associate
General Counsel and Vice President,
Corporate Staff
George P. Kooluris 49 Vice President, Corporate Development,
Corporate Staff
Margaret E. Maruschak 47 Vice President, Issues Management,
Corporate Staff
Michael F. Mee 51 Chief Financial Officer and Senior Vice
President, Corporate Staff
Leon E. Rosenberg, M.D. 61 President, Bristol-Myers Squibb
Pharmaceutical Research Institute
Stephen I. Sadove 42 President, Clairol Incorporated
Frederick S. Schiff 46 Controller and Vice President,
Corporate Staff
John L. Skule 50 Vice President, Public Affairs,
Corporate Staff
Joseph G. Solari, Jr. 49 President, Bristol-Myers Squibb Medical
Products Group
Charles G. Tharp, Ph.D. 42 Senior Vice President, Human Resources,
Corporate Staff
Richard L. Thompson 49 Vice President, Government Affairs,
Corporate Staff
Wesley M. Thompson 52 President, Bristol-Myers Squibb
Consumer Products Group - International
Joachim H. von Roy 48 President, Bristol-Myers Squibb
Pharmaceuticals - Europe
Kenneth E. Weg 55 President, Bristol-Myers Squibb
Pharmaceutical Group
- 10 -
<PAGE>
Persons who hold titles as elected corporate officers of the Registrant
were last elected or reelected to the office held at the general election of
officers by the Registrant's Board of Directors on May 4, 1993. Officers of
the Registrant serve in such capacity at the pleasure of the Board of Directors
of the Registrant.
RICHARD L. GELB - From 1972 to December 1993, Chief Executive Officer, the
Registrant. Mr. Gelb has been Chairman of the Board of Directors of the
Registrant since 1976. Mr. Gelb has been a director of the Registrant since
1960 and Chairman of the Executive Committee of the Board of Directors of the
Registrant since 1976.
CHARLES A. HEIMBOLD, JR. - From 1981 to 1989, Senior Vice President and
from 1989 to 1992, Executive Vice President, the Registrant. Mr. Heimbold has
been a director of the Registrant since 1989, President of the Registrant since
1992 and the Chief Executive Officer of the Registrant since January 1994.
MICHAEL E. AUTERA - From 1977 to March 1994, Chief Financial Officer and
from 1981 to 1989, Senior Vice President, the Registrant. Mr. Autera has been
a director of the Registrant since 1991 and an Executive Vice President of the
Registrant since 1989.
HARRISON M. BAINS, JR. - Mr. Bains has been Treasurer and Vice President,
Corporate Staff of the Registrant since 1988.
SAMUEL L. BARKER, Ph.D. - From 1988 to 1989, Vice President, Operations
Planning, Squibb International, a division of the Registrant. From 1989 to
1990, Vice President, Pacific, Asia & Middle East Area, Squibb Intercontinental,
a division of the Registrant. From 1990 to 1991, Vice President, Asia/Pacific
and from 1991 to 1992, President, Bristol-Myers Squibb Pharmaceuticals -
Intercontinental, a division of the Registrant. From 1992 to 1994, President,
Bristol-Myers Squibb U.S. Pharmaceutical Division, a division of the
Registrant. Dr. Barker has been President, U.S. Pharmaceuticals of the
Bristol-Myers Squibb Pharmaceutical Group, a division of the Registrant since
1994.
STEPHEN E. BEAR - From 1985 to 1988, Senior Vice President, Marketing and
Sales and from 1988 to 1991 President, Bristol-Myers Products, a division of
the Registrant. From 1988 to 1990 Vice President of the Registrant. From 1991
to 1993, Senior Vice President, Strategic Planning, Bristol-Myers Squibb
Consumer Products Group, a division of the Registrant. Mr. Bear has been
Executive Vice President of the Bristol-Myers Squibb Consumer Products Group, a
division of the Registrant since 1993.
ANDREW G. BODNAR, M.D. - From 1985 to 1988, Assistant Physician, from 1986
to 1989, director, Residency Training Program, from 1988 to 1989, Acting Chief,
Cardiac Unit, Department of Medicine, and Associate Chief, Department of
Medicine and from 1988 to the present, Associate Physician, Massachusetts
General Hospital, a health care facility. From 1989 to 1990, Senior Vice
President and Chief Operating Officer, The Squibb Institute for Medical
Research, a division of the Registrant. During 1990, Senior Vice President,
Administration and Planning, Bristol-Myers Squibb Pharmaceutical Research
Institute, a division of the Registrant. From 1990 to 1993, Senior Vice
President, Strategic Management, Bristol-Myers Squibb Pharmaceutical Group, a
division of the Registrant. From 1993 to 1994, President, Bristol-Myers Squibb
Specialty Pharmaceuticals, Bristol-Myers Squibb Pharmaceutical Group, a
division of the Registrant. Dr. Bodnar has been President,
Oncology/Diagnostics and Worldwide Strategic Business Development,
- 11 -
<PAGE>
Bristol-Myers Squibb Pharmaceutical Group, a division of the Registrant since
1994.
RONALD L. DAVIS - From 1988 to 1990, Vice President of the Registrant. Mr.
Davis has been President, Zimmer, Inc., a subsidiary of the Registrant since
1988.
PETER R. DOLAN - From 1988 to 1990, Vice President, Marketing, from 1990 to
1991, Senior Vice President, Marketing and Sales, from 1991 to 1992, Senior
Vice President, Marketing, Sales and Operations and from 1992 to 1993 Executive
Vice President, Bristol-Myers Products, a division of the Registrant. Mr.
Dolan has been President, Bristol-Myers Products, a division of the Registrant
since 1993.
RICHARD A. DRUCKMAN - From 1988 to 1989, Senior Vice President, Strategic
Planning and Quality/Productivity, Squibb Corporation, a predecessor to the
Registrant. From 1990 to 1991, Senior Vice President, Strategic Planning and
Quality/Productivity, Bristol-Myers Squibb Pharmaceutical Group, a division of
the Registrant. Mr. Druckman has been Vice President, Strategic Planning,
Corporate Staff of the Registrant since 1991.
RAYMOND C. EGAN - From 1988 to 1989, President, U.S. Pharmaceutical and
Nutritional Group, a division of the Registrant. From 1989 to 1990, President,
Bristol-Myers U.S. Pharmaceutical, Mead Johnson Worldwide Nutritional and
Squibb Diagnostics Group, a division of the Registrant. From 1990 to 1991,
President, Bristol-Myers Squibb U.S. Pharmaceutical, Diagnostics and Mead
Johnson Worldwide Nutritional Group, a division of the Registrant. From 1991
to 1993, Executive Vice President, Bristol-Myers Squibb Pharmaceutical Group, a
division of the Registrant. From 1985 to 1988, Vice President and from 1988 to
1989, Senior Vice President, the Registrant. Mr. Egan has been Senior Vice
President, Health Care Policy and Business Development, Corporate Staff of the
Registrant since 1993.
WILLIAM F. FLATLEY - From 1985 to 1988, Vice President, Human Resources,
Corporate Staff, and from 1988 to 1991, Senior Vice President, Human Resources,
Corporate Staff, the Registrant. From 1991 to January 1994, President,
Bristol-Myers Squibb Health Care Group, a division of the Registrant. Mr.
Flatley has been a Senior Vice President, Corporate Staff of the Registrant
since January 1994.
SAMUEL A. HAMAD - From 1988 to 1989, President, Asia/Australasia Division,
Bristol-Myers International Group, a division of the Registrant. From 1989 to
1990, Senior Vice President, Bristol-Myers Squibb Pharmaceutical Group, a
division of the Registrant. From 1990 to 1992, President, Bristol-Myers Squibb
Pharmaceuticals - Northern Europe, a division of the Registrant. Mr. Hamad has
been President, Bristol-Myers Squibb Pharmaceuticals - Intercontinental, a
division of the Registrant since 1992.
RODOLPHE HAMEL - From 1978 to 1989, Associate General Counsel, the
Registrant. From 1983 to 1992, Vice President, Corporate Staff, the
Registrant. Mr. Hamel has been General Counsel of the Registrant since 1989
and a Senior Vice President, Corporate Staff of the Registrant since 1992.
E. LYNN JOHNSON - From 1986 to 1989, Vice President, Human Resources,
Bristol-Myers International Group, a division of the Registrant. From 1989 to
1991, Senior Vice President, Human Resources and Administration, Bristol-Myers
Squibb Pharmaceutical Group, a division of the Registrant. From 1991 to 1993,
Senior Vice President, Human Resources, Corporate Staff, the Registrant.
- 12 -
<PAGE>
Mr. Johnson has been President, Mead Johnson Nutritional Group, a division of
the Registrant since 1993.
PAMELA D. KASA - From 1989 to 1990, Assistant General Counsel, the
Registrant. Ms. Kasa has been Corporate Secretary of the Registrant since
1982, Vice President, Corporate Staff of the Registrant since 1985 and
Associate General Counsel of the Registrant since 1990.
GEORGE P. KOOLURIS - Mr. Kooluris has been Vice President, Corporate
Development, Corporate Staff of the Registrant since 1980.
MARGARET E. MARUSCHAK - From 1982 to 1989, Director, Issues Management of
the Registrant. Ms. Maruschak has been Vice President, Issues Management,
Corporate Staff of the Registrant since 1989.
MICHAEL F. MEE - From 1985 to 1990, Vice President of Finance and Chief
Financial Officer and from 1987 to 1990, director of Norton Company, a
manufacturer of abrasives and engineering materials. From 1990 to 1992,
Executive Vice President, Finance and Chief Financial Officer, from 1990 to
1993, director and from 1992 to 1993, Chairman of the Board and Chief Financial
Officer of Wang Laboratories, Inc., a provider of computer-based information
processing products and services. Mr. Mee has been Chief Financial Officer and
a Senior Vice President, Corporate Staff of the Registrant since March 1994.
LEON E. ROSENBERG, M.D. - From 1980 to 1991, C.N.H. Long Professor of Human
Genetics and from 1984 to 1991, Dean, Yale University School of Medicine, an
educational institution. Dr. Rosenberg has been President, Bristol-Myers
Squibb Pharmaceutical Research Institute, a division of the Registrant since
1991.
STEPHEN I. SADOVE - From 1988 to 1989, Group Vice President and General
Manager, Meals Division, from 1989 to 1991, Executive Vice President and
General Manager, Desserts Division, General Foods USA, General Foods
Corporation, a diversified consumer products company. Mr. Sadove has been
President of Clairol Incorporated, a subsidiary of the Registrant since 1991.
FREDERICK S. SCHIFF - From 1987 to 1990, Assistant Controller, Corporate
Staff, the Registrant. Mr. Schiff has been Controller and a Vice President,
Corporate Staff of the Registrant since 1990.
JOHN L. SKULE - From 1988 to 1989, Vice President, Public Affairs, Squibb
Corporation, a predecessor of the Registrant. From 1990 to 1991, Vice
President, Industry & Public Affairs, Bristol-Myers Squibb Pharmaceutical Group,
a division of the Registrant. From 1991 to 1993, Vice President, Corporate
Affairs, American Home Products, a pharmaceutical and consumer products
company. Mr. Skule has been Vice President, Public Affairs, Corporate Staff of
the Registrant since 1993.
JOSEPH G. SOLARI, JR. - From 1987 to 1989, President, ConvaTec, a division
of the Registrant. During 1989, President, Squibb Medical Products, a division
of the Registrant. Mr. Solari has been President, Bristol-Myers Squibb Medical
Products Group, a division of the Registrant since 1990.
CHARLES G. THARP, Ph.D. - From 1987 to 1990, Director, Compensation and
Benefits, Corporate Staff, the Registrant. From 1990 to 1991, Vice President,
Compensation and Human Resource Development, Corporate Staff, the Registrant.
From 1991 to 1993, Vice President, Compensation, Benefits and Human Resource
Development, Corporate Staff, the Registrant. Mr. Tharp has been Senior Vice
President, Human Resources, Corporate Staff of the Registrant since 1993.
- 13 -
<PAGE>
RICHARD L. THOMPSON - From 1983 to 1989, Vice President, Government
Affairs, Squibb Corporation, a predecessor of the Registrant. Mr. Thompson has
been Vice President, Government Affairs, Corporate Staff of the Registrant
since 1989.
WESLEY M. THOMPSON - From 1987 to 1989, President, Bristol-Myers Lion
(Japan), a subsidiary of the Registrant. From 1990 to 1991, President, Japan,
Bristol-Myers Squibb Consumer Products Group - International, a division of the
Registrant. Mr. Thompson has been President, Bristol-Myers Squibb Consumer
Products Group - International, a division of the Registrant since 1992.
JOACHIM VON ROY - From 1988 to 1990, President, Squibb, Central Europe
Region, a division of the Registrant. From 1990 to 1993, President,
Bristol-Myers Squibb Pharmaceuticals - Central Europe, a division of the
Registrant. Mr. von Roy has been President, Bristol-Myers Squibb
Pharmaceuticals - Europe, a division of the Registrant since 1993.
KENNETH E. WEG - From 1983 to 1987, President, Europe, Middle East and
Africa Division, Bristol-Myers International Group, a division of the
Registrant. From 1987 to 1988, President, Squibb International and Group Vice
President, Squibb Corporation, a predecessor of the Registrant. From 1988 to
1989, President, Squibb Pharmaceutical Group and Group Vice President, Squibb
Corporation, a predecessor of the Registrant. From 1989 to 1990, President,
Squibb U.S. and Bristol-Myers Squibb International Pharmaceutical Group, a
division of the Registrant. From 1990 to 1991, President, Bristol-Myers Squibb
International Pharmaceutical Group, a division of the Registrant. From 1991 to
1993, President, Bristol-Myers Squibb Pharmaceutical Operations, a division of
the Registrant. Mr. Weg has been President, Bristol-Myers Squibb
Pharmaceutical Group, a division of the Registrant since 1993.
In addition to the positions and offices heretofore listed, all of the
foregoing executive corporate officers and other executive officers of the
Registrant are directors and/or officers of one or more affiliates of the
Registrant, with the exception of Messrs. Bear, Druckman, Egan, Mee, Skule and
R. L. Thompson and Ms. Maruschak.
- 14 -
<PAGE>
PART II
-------
Item 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED
STOCKHOLDER MATTERS.
MARKET PRICES
- -------------
Bristol-Myers Squibb common and preferred stocks are traded on the New York
Stock Exchange and the Pacific Stock Exchange (symbol: BMY). A quarterly
summary of the high and low market prices is presented below:
1993 1992
-------------------- ---------------------
High Low High Low
Common: ------- ------- ------- -------
First Quarter $67 1/4 $52 7/8 $90 1/8 $75 5/8
Second Quarter 62 3/8 56 1/4 79 1/4 62
Third Quarter 60 1/8 50 7/8 71 1/4 61 7/8
Fourth Quarter 62 1/4 54 3/4 72 3/8 60
1993 1992
-------------------- ---------------------
High Low High Low
Preferred: ------- -------- ------- -------
First Quarter $271 $230 $371 $371
Second Quarter No Trades No Trades
Third Quarter 236 227 1/2 No Trades
Fourth Quarter No Trades No Trades
HOLDERS OF COMMON STOCK
- -----------------------
The approximate number of record holders of common stock at December 31, 1993
was 158,239.
The number of record holders is based upon the actual number of holders
registered on the books of Bristol-Myers Squibb at such date and does not
include holders of shares in "street names" or persons, partnerships,
associations, corporations or other entities identified in security position
listings maintained by depository trust companies.
DIVIDENDS
- ---------
Dividend payments per share in 1993 and 1992 were:
Common Preferred
----------------- -------------------
1993 1992 1993 1992
----- ----- ----- -----
First Quarter $ .72 $ .69 $ .50 $ .50
Second Quarter .72 .69 .50 .50
Third Quarter .72 .69 .50 .50
Fourth Quarter .72 .69 .50 .50
----- ----- ----- -----
Year $2.88 $2.76 $2.00 $2.00
===== ===== ===== =====
- 15 -
<PAGE>
An additional dividend increase was announced in December 1993. The 1994
indicated annual payment of $2.92 per share represents a 1.4% increase over the
$2.88 per share paid in 1993. This increase represents the 22nd consecutive
year that the Company has raised the dividend on its common stock.
Item 6. SELECTED FINANCIAL DATA.
FIVE-YEAR FINANCIAL SUMMARY
- ---------------------------
OPERATING RESULTS
- -----------------
(dollars in millions,
except per share amounts) 1993 1992 1991 1990 1989
------- ------- ------- ------ ------
Net Sales $11,413 $11,156 $10,571 $9,741 $8,578
------- ------- ------- ------ ------
Expenses:
Cost of products sold 3,029 2,857 2,717 2,665 2,418
Marketing, selling and
administrative 3,098 3,075 2,946 2,717 2,461
Advertising and product
promotion 1,255 1,291 1,263 1,189 1,073
Research and development 1,128 1,083 983 873 781
Other (a) 332 863 (122) (136) 661
------- ------- ------- ------ ------
8,842 9,169 7,787 7,308 7,394
------- ------- ------- ------ ------
Earnings from Continuing
Operations Before
Income Taxes 2,571 1,987 2,784 2,433 1,184
Provision for income taxes 612 449 793 742 496
------- ------- ------- ------ ------
Earnings from Continuing
Operations $ 1,959 $ 1,538 $ 1,991 $1,691 $ 688
======= ======= ======= ====== ======
Dividends paid on common
and preferred stock $ 1,485 $ 1,428 $ 1,249 $1,116 $ 722
Earnings from continuing
operations per common
share (a) 3.80 2.97 3.82 3.22 1.32
Dividends per common share 2.88 2.76 2.40 2.12 2.00
(a) In 1993, includes a special charge for pending and future product liability
claims of $500 million before taxes, $310 million after taxes, or $.60 per
share. In 1992, includes a provision for restructuring of $890 million
before taxes, $570 million after taxes, or $1.10 per share. In 1989,
includes a provision for integrating businesses of $855 million before
taxes, $693 million after taxes, or $1.32 per share.
- 16 -
<PAGE>
Item 6. SELECTED FINANCIAL DATA. (con't.)
FIVE-YEAR FINANCIAL SUMMARY
- ---------------------------
FINANCIAL POSITION AT DECEMBER 31
- ---------------------------------
(dollars in millions,
except per share amounts) 1993 1992 1991 1990 1989
------- ------- ------- ------- -------
Current assets $ 6,570 $ 6,621 $5,567 $5,670 $5,552
Property, plant and
equipment - net 3,374 3,141 2,936 2,631 2,350
Total assets 12,101 10,804 9,416 9,215 8,497
Current liabilities 3,065 3,300 2,752 2,821 2,659
Long-term debt 588 176 135 231 237
Total liabilities 6,161 4,784 3,621 3,797 3,413
Stockholders' equity 5,940 6,020 5,795 5,418 5,084
Average common shares
outstanding (in millions) 515 518 521 525 523
Reference is made to Note 2 Special Charge, Note 3 Discontinued Operations,
Note 4 Provision for Restructuring and Note 14 Postretirement Benefit Plans
Other Than Pensions, appearing in the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Form 10-K Annual Report.
- 17 -
<PAGE>
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
SUMMARY
- -------
During 1993, Bristol-Myers Squibb's worldwide sales of $11.4 billion increased
2% over the prior year. Domestic sales increased 4%, while international sales
remained at prior year levels (a 5% increase excluding the unfavorable effect
of foreign currency translation).
Earnings from continuing operations, excluding the 1993 special charge and a
1992 restructuring charge, increased 8% to $2,269 million and 8% to $4.40 per
share. Including these charges, earnings from continuing operations were $1,959
million, or $3.80 per share, in 1993 and $1,538 million, or $2.97 per share, in
1992.
In the fourth quarter of 1993, a special charge of $500 million before taxes,
$310 million after taxes, or $.60 per share, was recorded in connection with
pending and future breast implant product liability claims against the Company,
its subsidiary, Medical Engineering Corporation, and certain other
subsidiaries. The special charge consists of $1.5 billion for potential
liabilities and expenses related to breast implant claims, offset by $1 billion
of expected insurance proceeds. This special charge is further discussed in
Note 2 to the Consolidated Financial Statements included in Part II, Item 8 of
this Form 10-K Annual Report.
In the fourth quarter of 1992, a charge of $890 million before taxes, $570
million after taxes, or $1.10 per share, was recorded in connection with
various restructuring actions taken by the Company to strengthen its four core
businesses in recognition of changing worldwide health care trends. This charge
primarily covered the costs of reducing employment levels, including a
voluntary retirement program for the Company's U.S. employees, and streamlining
worldwide production and distribution operations.
Bristol-Myers Squibb's financial position remains strong. At December 31, 1993,
the Company held $2.7 billion in cash and cash equivalents, time deposits and
marketable securities, and working capital increased to $3.5 billion from $3.3
billion at December 31, 1992 and $2.8 billion at December 31, 1991. Cash
provided by operating activities increased to $2.6 billion in 1993 from $2.0
billion and $1.8 billion in 1992 and 1991, respectively, and continued to
finance research, new product development and introductions, capital spending
and working capital needs, as well as increased dividend payments. In 1993,
dividends per common share were $2.88, an increase of 4% over 1992. In December
1993, an additional dividend increase of 1.4% was announced, with a 1994
indicated annual payment of $2.92. With this payment, Bristol-Myers Squibb
dividends will have increased at a compound annual growth rate of 15% over the
past 10 years. This increase represents the 22nd consecutive year that the
Company has raised the dividend on its common stock.
Bristol-Myers Squibb's strong financial position is further evidenced by its
ability to maintain a triple A credit rating, a substantial unused borrowing
capacity, a return on stockholders' equity of 32.8% in 1993 and a low long-term
debt to equity ratio.
- 18 -
<PAGE>
NET SALES AND EARNINGS
- ----------------------
Worldwide sales increased 2% in 1993 to $11.4 billion, compared to increases of
6% and 9% in 1992 and 1991, respectively. The 1993 consolidated sales growth
resulted from a 3% increase due to volume, a 2% increase due to pricing, offset
in part by a 3% decrease due to the unfavorable effect of foreign currency
translation. Domestic sales increased 4%, while international sales remained at
prior year levels (a 5% increase excluding the unfavorable effect of foreign
currency translation). In 1992, the 6% increase in sales reflected a 4%
increase due to pricing, a 1% increase due to volume and a 1% increase due to
the favorable effect of foreign currency translation. Domestic operations,
which were adversely affected by actions taken by wholesalers in 1992 to reduce
their inventories of pharmaceuticals, reported sales growth of 1% in 1992
compared to 10% in 1991, while international operations reported sales growth
of 12% and 7% in 1992 and 1991, respectively.
In 1993, earnings and earnings per share from continuing operations were $1,959
million and $3.80 per share, respectively, compared to $1,538 million and $2.97
per share in 1992 and $1,991 million and $3.82 per share in 1991. Excluding the
1993 special charge and the 1992 restructuring charge, earnings from continuing
operations increased 8% to $2,269 million and 8% to $4.40 per share in 1993.
The effective income tax rate on earnings from continuing operations before
income taxes was 23.8% in 1993 compared to 22.6% in 1992. Excluding the special
charge in 1993 and the restructuring charge in 1992, the effective income tax
rates were 26.1% and 26.7%, respectively, compared to 28.5% in 1991, reflecting
the continued benefit of increased earnings in lower tax jurisdictions. As a
result of changes approved in the Omnibus Budget Reconciliation Act of 1993,
the Company estimates that its effective tax rate will increase in 1994 to
approximately 30.0%.
EXPENSES
- --------
Total costs and expenses, excluding the 1993 special charge of $500 million and
the 1992 restructuring charge of $890 million, were 73.1% of sales in 1993
compared to 74.2% in 1992 and 73.7% in 1991. As a percentage of sales, cost of
products sold increased in 1993 to 26.5% from 25.6% in 1992 and 25.7% in 1991,
primarily as a result of higher manufacturing costs of newer pharmaceutical
products.
Marketing, selling and administrative expenses, as a percentage of sales,
decreased to 27.1% in 1993 from 27.6% in 1992 and 27.9% in 1991. The decline in
1993 reflects reductions in selling expenses, primarily in the U.S., and the
Company's ongoing commitment to contain administrative costs.
The level of advertising and promotion in support of new and existing products
was $1,255 million in 1993 compared to $1,291 million in 1992 and $1,263
million in 1991. The decline in 1993 reflects lower expenditures in the
nonprescription health and pharmaceutical products segments, offset in part by
increased spending in the toiletries and beauty aids segment.
The Company's investment in research and development expenses reached over $1.1
billion, an increase of 4% over 1992. In 1991, research and development
expenses were $983 million. The increase each year reflects the Company's
continued commitment to research over a broad range of therapeutic areas and
- 19 -
<PAGE>
clinical development in support of newer products. Over the last 10 years,
research and development spending has increased nearly fourfold, resulting in a
compound annual growth rate of 14%. Pharmaceutical research and development
spending, as a percentage of pharmaceutical sales, increased to 14.9% in 1993
from 14.8% in 1992 and 14.3% in 1991.
INDUSTRY SEGMENTS
- -----------------
By the end of 1993, Bristol-Myers Squibb had 27 products with more than $100
million in annual sales, including products from all four of the Company's
industry segments.
In 1993, sales in the PHARMACEUTICAL PRODUCTS SEGMENT, which represents the
largest segment at 57% of total company sales, increased 3% to $6,524 million.
The worldwide sales growth resulted from a 5% increase due to volume and a 1%
increase due to pricing, offset in part by a 3% decrease due to the unfavorable
effect of foreign currency translation. Domestic sales increased 11% primarily
due to the Company's newer products, while international sales decreased 4% (a
2% increase excluding the unfavorable effect of foreign currency translation).
Sales of cardiovascular drugs, the largest product group in the segment at $2.6
billion, were 2% below prior year levels. Captopril, an angiotensin converting
enzyme (ACE) inhibitor and the Company's largest selling product, is sold
primarily under the trademark CAPOTEN* (the patent for which expires in the
U.S. and Germany in 1995). Sales of captopril decreased 11% to $1.5 billion as
a result of unfavorable foreign currency translation, a decline in U.S. market
share and reduced sales in certain European countries reflecting restrictive
government cost-containment measures. In 1993, the U.S. Food and Drug
Administration (FDA) approved CAPOTEN* for a novel and expanded use following
heart attacks in patients with impaired function of the left ventricle.
PRAVACHOL*, the Company's newer cholesterol-lowering agent with worldwide sales
exceeding $500 million, and MONOPRIL*, a second generation ACE inhibitor with
once-a-day dosage, performed exceptionally well, with strong volume growth in
the U.S. and in overseas markets. U.S. sales of nadolol, a beta blocker sold
primarily under the trademark CORGARD* (the patent for which expired in the
U.S. in September 1993), remained at prior year levels. Sales of the Company's
anti-infectives increased 2% to over $1.5 billion as increases in CEFZIL*, an
oral cephalosporin antibiotic, VIDEX*, an antiretroviral agent for patients
with AIDS or HIV disease, and DURICEF*, a broad-spectrum oral cephalosporin
antibiotic, were offset in part by declines in AMIKIN*, which is experiencing
generic competition, and in AZACTAM*. The Company's line of anti-cancer agents
was the fastest growing product group in the segment, strengthening the
Company's leadership position in cancer therapy. In 1993, sales of anti-cancer
agents increased 19% to $1.2 billion. Introductory sales of TAXOL*, the
Company's anti-cancer agent approved in the U.S. and Canada in December 1992
for treatment of patients with ovarian cancer whose first-line or subsequent
chemotherapy has failed, were strong. In the latter part of 1993, TAXOL*
received clearance for marketing in a number of countries in Europe, Latin
America and the Pacific area. Increased sales of VEPESID* (the patent for which
expired in the U.S. in November 1993), PARAPLATIN* and PLATINOL* also
contributed to the growth of anti-cancer agents. Central nervous system drug
sales increased 7%, reflecting domestic growth in sales of BUSPAR*, the
Company's novel anti-anxiety agent, and STADOL NS*, a prescription nasal spray
analgesic. In the area of dermatological drugs, the Company received FDA
approval in December 1993 to market DOVONEX*, a vitamin D3 analogue for the
treatment of moderate psoriasis. Sales of diagnostic agents were below prior
year levels primarily due to ISOVUE*.
- 20 -
<PAGE>
In 1992, pharmaceutical products segment sales increased 7%, with a 4% increase
due to pricing, a 2% increase due to volume and a 1% increase due to the
favorable effect of foreign currency translation. Increases in sales of
CAPOTEN*, PRAVACHOL*, MONOPRIL*, CEFZIL*, VIDEX*, PARAPLATIN* and VEPESID* were
the primary contributors to sales growth. In 1991, sales in the segment
increased 12% primarily as a result of increased cardiovascular,
anti-infective, anti-cancer and central nervous system drug sales.
Operating profit margin in 1993 was 32.7% compared to 31.0% in 1992, excluding
the 1992 charge of $371 million for restructuring pharmaceutical operations.
The increase in 1993 resulted from reductions in selling and advertising
expenses, offset in part by higher manufacturing costs of newer pharmaceutical
products. In 1992, operating profit margin of 31.0%, excluding the
restructuring charge, was lower than the 31.2% reported in 1991 due to
increased selling and promotion expenses for the Company's new and existing
products.
Sales in the MEDICAL DEVICES SEGMENT increased 2% in 1993 to $1,693 million,
reflecting a 3% increase due to pricing, a 1% increase due to volume and a 2%
decrease due to the unfavorable effect of foreign currency translation.
Domestic sales remained at prior year levels, while international sales
increased 4% (9% excluding the unfavorable effect of foreign currency
translation). Worldwide sales of prosthetic implants increased 5%, led by the
Insall/Burstein II Modular Total Knee System, the MGII* Total Knee System and
the CENTRALIGN* Precoat Hip Prosthesis. As a result, the Company continues to
maintain the number one market position worldwide in both the hip and knee
prostheses markets. Sales of ostomy products increased 2% (11% excluding the
unfavorable effect of foreign currency translation) primarily due to volume
growth of the ACTIVE LIFE/COLODRESS* and the SUR-FIT/COMBIHESIVE* product lines
in the U.S. and in international markets. During 1993, the Company introduced
ACTIVE LIFE FLUSHAWAY*, a one-piece, closed-end flushable pouch. In the
Company's line of wound care products, sales increased as a result of strong
volume growth in international markets and the launch of several new DUODERM*
products in the U.S. Sales of the Company's arthroscopy products increased due
to the strong performances of orthopaedic reconstructive systems and power
cutting instruments. In the Company's line of fracture management products, the
Company introduced COLLAGRAFT* Bone Graft Matrix, an alternative to using bone
graft materials from donor bone stock or harvested from the patient.
In 1992, worldwide sales of medical devices increased 7% due to a 5% increase
from pricing, a 1% increase from volume and a 1% increase due to the favorable
effect of foreign currency translation. The sales growth was primarily due to
increased sales of prosthetic implants, ostomy, wound care and arthroscopy
products, offset in part by volume declines of other product lines divested in
1991. In 1991, sales in the segment increased 9% as a result of increases in
knee and hip prostheses and ostomy and wound care products.
During 1993, the Company sold certain assets of Edward Weck Incorporated and
announced the intention to sell its Xomed-Treace subsidiary.
As a result of the $500 million special charge for pending and future breast
implant product liability claims and related expenses, the medical devices
segment recorded an operating loss of $24 million in 1993. Excluding the 1993
special charge and the 1992 restructuring charge of $155 million, operating
profit margin was 28.1% in 1993 compared to 27.6% in 1992. The increase in 1993
reflects declines in selling and administrative expenses. In 1992, operating
profit margin of 27.6%, excluding the restructuring charge, increased from
22.7% in 1991, which included costs associated with the divestiture of certain
- 21 -
<PAGE>
product lines.
In the NONPRESCRIPTION HEALTH PRODUCTS SEGMENT, sales of $1,964 million
remained at prior year levels as a 5% increase due to pricing was offset by a
5% decrease due to volume. Domestic sales decreased 3%, primarily in sales of
EXCEDRIN* and BUFFERIN* analgesics, which were adversely affected by increased
competition in the U.S. market. International sales increased 6%, primarily due
to BUFFERIN*, the leading internal analgesic in Japan, and ISOCAL*, an adult
nutritional product. Worldwide sales of infant formulas increased with the
introduction of LACTOFREE*, a milk-based, lactose-free infant formula
introduced in the U.S. in early 1993, and growth in sales of NUTRAMIGEN* and
Gerber Soy specialty formulas as well as ENFAPRO* and Gerber Baby routine
formulas. These increases were offset in part by reduced sales of ENFAMIL* and
PROSOBEE* under the federal government's Women, Infants and Children (WIC)
program due to the loss of certain sole source contracts in late 1992 and early
1993. In the latter part of 1993, five new WIC contracts, in Pennsylvania,
Missouri, South Carolina, Colorado and Mississippi, became effective.
In 1992, worldwide sales of nonprescription health products increased 3% due to
a 5% increase in pricing, offset in part by a 2% decrease due to volume. The
sales growth was primarily due to increases in international sales of ENFAMIL*,
ENFAPRO* and PROSOBEE* infant formulas and BUFFERIN* analgesics. In 1991, sales
in the segment increased 7% as a result of Gerber Baby Formula, ENFAPRO*,
PROSOBEE*, SUSTAGEN*, EXCEDRIN* IB, EXCEDRIN PM* and BUFFERIN* AF Nite Time.
Operating profit margin of 23.6% in 1993 remained relatively unchanged from the
23.7% reported in 1992, excluding the 1992 charge of $150 million for
restructuring worldwide operations of the nonprescription health products
segment and a $46 million charge for the cost of settlements relating to the
Company's infant formula business. In 1992, operating profit margin of 23.7%,
excluding the 1992 charges, increased from 22.9% in 1991.
Sales in the TOILETRIES AND BEAUTY AIDS SEGMENT increased 1% in 1993 to $1,232
million, reflecting a 2% increase due to pricing, a 1% increase due to volume
and a 2% decrease due to the unfavorable effect of foreign currency
translation. Domestic sales increased 1%, and international sales increased 2%.
Sales of the Company's haircoloring products increased, as GLINTS* Conditioning
Color Enhancer, a new haircoloring product introduced in the U.S. aimed at new
and younger users, performed exceptionally well during its first year, as did
LASTING COLOR BY LOVING CARE* and BRIGHTS BY NICE 'N EASY*. Sales of skin care
products increased due to international growth of SEA BREEZE* and sales from
Laboratori Guieu, an Italian over-the-counter skin care company acquired in
early 1993. In the Company's line of anti-perspirants, sales of BAN* increased,
reflecting the introduction of BAN CLEAR* A.P., a clear solid anti-perspirant,
launched in the U.S. and Canada.
In 1992, sales in the toiletries and beauty aids segment increased 1% due to a
3% increase in pricing, offset in part by a 2% decrease in volume. Increased
sales of anti-perspirants and haircoloring products were partially offset by
declines of beauty appliances and other hair care products. In 1991, sales in
the segment decreased 5% as increased sales of haircoloring products and
anti-perspirants were more than offset by declines in other brands.
In December 1993, the Company sold the beauty appliance division of Clairol.
Operating profit margin in 1993 was 13.2% compared to 13.1% in 1992, after
adjusting for the 1992 charge of $150 million for restructuring the worldwide
toiletries and beauty aids segment. In 1992, operating profit margin of 13.1%,
- 22 -
<PAGE>
excluding the restructuring charge, decreased from 16.9% in 1991 partially due
to increased advertising and promotion expenditures as a percentage of sales.
GEOGRAPHIC AREAS
- ----------------
In 1993, sales of the Company's domestic operations increased 4% primarily as a
result of gains in the pharmaceutical products segment. Operating profit margin
from domestic operations was 23.2% in 1993 compared to 19.9% in 1992. Excluding
the 1993 special charge of $500 million and the 1992 restructuring charge of
$595 million, operating profit margin increased to 29.8% in 1993 from 28.0% in
1992. The increase reflects declines in selling and administrative expenses,
offset in part by increased manufacturing costs of newer pharmaceutical
products. In 1992, domestic sales, which were adversely affected by actions
taken by wholesalers to reduce their inventories of pharmaceuticals, increased
1%. Operating profit margin, after adjusting for the 1992 restructuring charge,
was 28.0% compared to 28.1% in 1991 in part due to increased selling and
promotion expenses.
Internationally, sales in 1993 remained at prior year levels. Excluding the
unfavorable effect of foreign currency translation, international sales
increased 5% in the year. International sales increased 12% in 1992 and 7% in
1991.
Sales in Europe, Mid-East and Africa, net of inter-area sales, decreased 8% in
1993 as a result of unfavorable foreign currency translation as well as lower
pharmaceutical sales in certain European countries reflecting restrictive
government cost-containment measures. Operating profit margin was 19.3%
compared to 21.1% in 1992, excluding the 1992 restructuring charge of $134
million, primarily as a result of declines in the pharmaceutical products
segment. In 1992, sales in Europe, Mid-East and Africa increased 13%,
reflecting growth of PRAVACHOL*, CAPOTEN*, prosthetic implants, ostomy and
wound care products, as well as introductory sales of MONOPRIL* in Italy.
Operating profit margin, excluding the 1992 restructuring charge, was 21.1%
compared to 22.1% in 1991.
Sales in Other Western Hemisphere countries increased 5% in 1993, primarily due
to increased sales of anti-infectives, cardiovasculars, haircoloring products
and anti-perspirants in Latin America. Operating profit margin of 20.0%
remained relatively unchanged from the 20.1% reported in 1992, excluding the
1992 restructuring charge of $51 million. In 1992, sales in Other Western
Hemisphere countries increased 8% primarily due to volume growth of
cardiovasculars, anti-infectives and infant formulas in Latin America.
Operating profit margin was 20.1% in 1992, excluding the restructuring charge,
compared to 19.8% in 1991.
Sales in the Pacific area increased 15% in 1993 as a result of favorable
foreign currency translation and increased sales of prosthetic implants, infant
formulas and anti-cancer drugs. Operating profit margin was 15.8% compared to
12.6% in 1992, excluding the 1992 restructuring charge of $46 million,
primarily as a result of improvements in the pharmaceutical products and
medical devices segments. In 1992, Pacific area sales increased 12% due to
growth of infant formulas, prosthetic implants, cardiovascular drugs and
analgesics. Operating profit margin was 12.6%, excluding the 1992 restructuring
charge, compared to 10.3% in 1991, reflecting improvements in the medical
devices segment.
- 23 -
<PAGE>
FINANCIAL POSITION
- ------------------
The Company considers cash, including cash equivalents, time deposits and
marketable securities as its principal measure of liquidity. These items
totaled $2.7 billion at December 31, 1993, increasing from $2.4 billion and
$1.6 billion at December 31, 1992 and 1991, respectively. The Company also
continues to maintain a high level of working capital, increasing to $3.5
billion at December 31, 1993 from $3.3 billion at December 31, 1992 and $2.8
billion at December 31, 1991. The Company's current ratio at December 31, 1993
increased to 2.14 from 2.01 in 1992 and 2.02 in 1991. Cash and cash
equivalents, time deposits and marketable securities and the conversion of
other working capital items to cash are expected to be adequate to fund the
operations of the Company and any product liability claims and related
expenses.
Short-term borrowings decreased to $177 million from $375 million and $553
million at December 31, 1992 and 1991, respectively, reflecting repayments of
international borrowings. In June 1993, the Company issued $350 million
principal amount of 7.15% Debentures Due 2023, for general corporate purposes,
including stock purchase programs, working capital, capital expenditures,
repayment or refinancing of borrowings and acquisitions.
Internally generated cash from operations continued to increase in 1993 to $2.6
billion from $2.0 billion and $1.8 billion in 1992 and 1991, respectively,
reflecting the Company's ongoing commitment to improve cash flow and working
capital needs. Cash provided by operations continued to be the primary source
for financing expenditures for new plant and equipment. Over the past three
years, the Company has invested $1.9 billion in capital expansion in its
commitment to maintain superior production and research facilities and to
improve plant efficiency. Cash from operations also was used to pay dividends
of nearly $4.2 billion during the past three years, and to fund the $1.1
billion purchase of over 16 million shares of the Company's common stock over
the same period.
- 24 -
<PAGE>
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENT OF EARNINGS
(in millions of dollars except per share amounts)
Year Ended December 31,
--------------------------------
1993 1992 1991
------- ------- -------
Net Sales $11,413 $11,156 $10,571
------- ------- -------
Expenses:
Cost of products sold 3,029 2,857 2,717
Marketing, selling and administrative 3,098 3,075 2,946
Advertising and product promotion 1,255 1,291 1,263
Research and development 1,128 1,083 983
Special charge 500 - -
Provision for restructuring - 890 -
Other (168) (27) (122)
------- ------- -------
8,842 9,169 7,787
------- ------- -------
Earnings from Continuing Operations
Before Income Taxes 2,571 1,987 2,784
Provision for income taxes 612 449 793
------- ------- -------
Earnings from Continuing Operations 1,959 1,538 1,991
Discontinued Operations, net - 670 65
------- ------- -------
Earnings Before Cumulative Effect of
Accounting Change 1,959 2,208 2,056
Cumulative Effect of Accounting Change
(net of income tax benefit of $144) - (246) -
------- ------- -------
Net Earnings $ 1,959 $ 1,962 $ 2,056
======= ======= =======
Per Common Share:
Earnings from continuing operations $3.80 $2.97 $3.82
Discontinued operations - 1.29 .13
----- ----- -----
Earnings before cumulative effect of
accounting change 3.80 4.26 3.95
Cumulative effect of accounting change - (.47) -
----- ----- -----
Net earnings $3.80 $3.79 $3.95
===== ===== =====
The accompanying notes are an integral part of these financial statements.
- 25 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEET
ASSETS
(in millions of dollars)
December 31,
------------------------------
1993 1992 1991
------- ------- ------
Current Assets:
Cash and cash equivalents $ 2,421 $ 2,137 $1,435
Time deposits and marketable securities 308 248 148
Receivables, net of allowances 1,859 1,984 1,971
Inventories 1,322 1,490 1,451
Prepaid expenses 660 762 562
------- ------- ------
Total Current Assets 6,570 6,621 5,567
Property, Plant and Equipment - net 3,374 3,141 2,936
Insurance Recoverable 1,000 - -
Other Assets 966 889 743
Excess of cost over net tangible assets
received in business acquisitions 191 153 170
------- ------- ------
$12,101 $10,804 $9,416
======= ======= ======
The accompanying notes are an integral part of these financial statements.
- 26 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEET
LIABILITIES AND STOCKHOLDERS' EQUITY
(in millions of dollars)
December 31,
------------------------------
1993 1992 1991
------- ------- ------
LIABILITIES
- -----------
Current Liabilities:
Short-term borrowings $ 177 $ 375 $ 553
Accounts payable 649 562 537
Accrued expenses 1,550 1,422 1,167
U.S. and foreign income taxes payable 689 941 495
------- ------- ------
Total Current Liabilities 3,065 3,300 2,752
Product Liability 1,370 63 65
Other Liabilities 1,138 1,245 669
Long-Term Debt 588 176 135
------- ------- ------
Total Liabilities 6,161 4,784 3,621
------- ------- ------
STOCKHOLDERS' EQUITY
- --------------------
Preferred stock, $2 convertible series:
Authorized 10 million shares; issued and
outstanding 25,798 in 1993, 28,517 in
1992 and 30,980 in 1991, liquidation
value of $50 per share - - -
Common stock, par value of $.10 per share:
Authorized 1.5 billion shares; issued
532,688,458 in 1993, 532,673,413 in 1992
and 532,659,944 in 1991 53 53 53
Capital in excess of par value of stock 353 435 485
Cumulative translation adjustments (332) (208) (90)
Retained earnings 7,243 6,769 6,235
------- ------- ------
7,317 7,049 6,683
Less cost of treasury stock - 20,782,281
common shares in 1993, 14,689,052 in 1992
and 13,142,575 in 1991 1,377 1,029 888
------- ------- ------
Total Stockholders' Equity 5,940 6,020 5,795
------- ------- ------
$12,101 $10,804 $9,416
======= ======= ======
The accompanying notes are an integral part of these financial statements.
- 27 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENT OF RETAINED EARNINGS
(in millions of dollars)
Year Ended December 31,
--------------------------------
1993 1992 1991
------- ------- -------
Retained Earnings, January 1 $6,769 $6,235 $5,428
Net earnings 1,959 1,962 2,056
------ ------ ------
8,728 8,197 7,484
Less dividends 1,485 1,428 1,249
------ ------ ------
Retained Earnings, December 31 $7,243 $6,769 $6,235
====== ====== ======
The accompanying notes are an integral part of these financial statements.
- 28 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENT OF CASH FLOWS
(in millions of dollars)
Year Ended December 31,
-----------------------------
1993 1992 1991
------ ------ ------
Cash Flows From Operating Activities:
Earnings from continuing operations $1,959 $1,538 $1,991
Depreciation and amortization 308 295 246
Special charge 500 - -
Provision for restructuring - 890 -
Other operating items 49 50 103
Receivables 41 (125) (269)
Inventories 129 (163) (114)
Prepaid expenses 92 (121) 4
Accounts payable 134 75 40
Accrued expenses and income taxes (276) (150) (194)
Deferred income taxes (27) (196) (31)
Other liabilities (329) (65) 59
------ ------ ------
Net Cash Provided by Operating Activities 2,580 2,028 1,835
------ ------ ------
Cash Flows From Investing Activities:
Proceeds from sales of time deposits and
marketable securities 993 169 4,090
Purchases of time deposits and marketable
securities (1,049) (269) (2,865)
Additions to fixed assets (570) (647) (628)
Proceeds from sales of businesses 98 1,150 -
Other, net (69) 27 (26)
------ ------ ------
Net Cash (Used in) Provided by
Investing Activities (597) 430 571
------ ------ ------
Cash Flows From Financing Activities:
Short-term borrowings (228) (169) 169
Long-term debt 394 40 (96)
Issuances of common stock under stock plans 38 37 46
Purchases of treasury stock (419) (228) (447)
Dividends paid (1,485) (1,428) (1,249)
------ ------ ------
Net Cash Used in Financing Activities (1,700) (1,748) (1,577)
------ ------ ------
Effect of Exchange Rates on Cash 1 (8) 10
------ ------ ------
Increase in Cash and Cash Equivalents 284 702 839
Cash and Cash Equivalents at Beginning of Year 2,137 1,435 596
------ ------ ------
Cash and Cash Equivalents at End of Year $2,421 $2,137 $1,435
====== ====== ======
The accompanying notes are an integral part of these financial statements.
- 29 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 1 ACCOUNTING POLICIES
- ---------------------------
Basis of Consolidation - The consolidated financial statements include the
accounts of Bristol-Myers Squibb Company and all of its subsidiaries.
Cash and Cash Equivalents - Cash and cash equivalents primarily include
securities with a maturity of three months or less at the time of purchase,
recorded at cost, which approximates market.
Time Deposits and Marketable Securities - Time deposits and marketable
securities are available for sale and are recorded at fair value, which
approximates cost.
Inventory Valuation - Inventories are generally stated at average cost, not in
excess of market.
Property and Depreciation - Expenditures for additions, renewals and
betterments are capitalized at cost. Depreciation is generally computed by the
straight-line method based on the estimated useful lives of the related assets.
Excess of Cost over Net Tangible Assets - The excess of cost over net tangible
assets received in business acquisitions subsequent to October 31, 1970 is
being amortized on a straight-line basis over periods not exceeding forty
years.
Earnings Per Share - Earnings per common share are computed using the weighted
average number of shares outstanding during the year. The effect of shares
issuable under stock plans is not significant.
Note 2 SPECIAL CHARGE
- ----------------------
In the fourth quarter of 1993, the Company recorded a special charge of $500
million before taxes, $310 million after taxes, or $.60 per share, in
connection with pending and future breast implant product liability claims
against the Company, its subsidiary, Medical Engineering Corporation, and
certain other subsidiaries. The special charge consists of $1.5 billion for
potential liabilities and expenses related to breast implant claims ($1.4
billion recorded as a long-term liability in Product Liability and $.1 billion
recorded as a current liability in Accrued Expenses), offset by $1 billion of
expected insurance proceeds (recorded as Insurance Recoverable). Although the
Company is currently engaged in coverage litigation with certain of its
insurers, such expected insurance proceeds represent the amount of insurance
which the Company considers appropriate to record as recoverable at this time.
The Company believes that ultimately it will obtain substantial additional
amounts of insurance proceeds. See Note 18.
- 30 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 3 DISCONTINUED OPERATIONS
- -------------------------------
On December 31, 1992, the Company completed the sale of The Drackett Company,
its household products business, to S.C. Johnson & Son, Inc., for $1.15 billion
in cash. The sale resulted in a gain of $952 million before taxes, $605
million after taxes, or $1.17 per share. Drackett has been reported as a
discontinued operation.
Summary results of Drackett's operations in 1992 and 1991 were:
Year Ended
December 31,
-------------------
1992 1991
---- ----
Net sales $571 $588
==== ====
Earnings before income taxes $103 $103
Provision for income taxes 38 38
---- ----
Net earnings $ 65 $ 65
==== ====
Note 4 PROVISION FOR RESTRUCTURING
- -----------------------------------
In the fourth quarter of 1992, a charge of $890 million before taxes was
recorded in connection with various restructuring actions taken by the Company
to strengthen its four core businesses in recognition of changing worldwide
health care trends. This charge primarily covered the costs of reducing
employment levels, including a voluntary retirement program for the Company's
U.S. employees, and streamlining worldwide production and distribution
operations. The after-tax effect of the charge was $570 million, or $1.10 per
share.
Note 5 FOREIGN CURRENCY TRANSLATION
- ------------------------------------
Cumulative translation adjustments, which represent the effect of translating
assets and liabilities of the Company's non-U.S. entities, except those in
highly inflationary economies, were:
1993 1992 1991
---- ---- ----
Balance, January 1 $208 $ 90 $61
Effect of balance sheet translations:
Amount 141 151 38
Tax effect (17) (33) (9)
---- ---- ---
Balance, December 31 $332 $208 $90
==== ==== ===
- 31 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Gains (Losses) reflected in earnings from continuing operations in 1993, 1992
and 1991 of $21 million, $(63) million and $(44) million, respectively, net of
applicable income taxes, resulted from foreign currency transactions and
translation adjustments related to non-U.S. entities operating in highly
inflationary economies. In 1993, the gain reflected $86 million (included in
Other Income and Expenses) from foreign currency transactions and translation
adjustments, offset by $52 million of reductions in gross margin from charging
cost of products sold with inventory at historic rates. In 1992 and 1991, the
losses primarily reflected reductions in gross margins.
Note 6 OTHER INCOME AND EXPENSES
- ---------------------------------
Year Ended December 31,
----------------------------------
1993 1992 1991
---- ---- ----
Interest income $ 96 $78 $139
Interest expense (57) (49) (55)
Other - net (Note 5) 129 (2) 38
---- ---- ----
$168 $27 $122
==== ==== ====
Interest expense was reduced by $14 million in 1993, $13 million in 1992 and
$12 million in 1991 due to interest capitalized on major property, plant and
equipment projects. Cash payments for interest, net of amounts capitalized,
were $51 million, $46 million and $47 million in 1993, 1992 and 1991,
respectively.
Note 7 PROVISION FOR INCOME TAXES
- ----------------------------------
The components of earnings from continuing operations before income taxes were:
Year Ended December 31,
------------------------------
1993 1992 1991
------ ------ ------
U.S. $1,561 $1,248 $2,029
Non-U.S. 1,010 739 755
------ ------ ------
$2,571 $1,987 $2,784
====== ====== ======
- 32 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
The provision for income taxes consisted of:
Year Ended December 31,
----------------------------
1993 1992 1991
---- ---- ----
Current:
U.S. Federal $257 $341 $399
Non-U.S. 307 310 253
State and local 42 60 67
---- ---- ----
606 711 719
---- ---- ----
Deferred:
U.S. (35) (178) 33
Non-U.S. 41 (84) 41
---- ---- ----
6 (262)(a) 74
---- ---- ----
$612 $449 $793
==== ==== ====
(a) Primarily resulted from the provision for restructuring.
Income taxes paid during the year were $783 million, $606 million and $795
million in 1993, 1992 and 1991, respectively.
The Company's provision for income taxes in 1993, 1992 and 1991 was different
from the amount computed by applying the statutory United States Federal income
tax rate to earnings from continuing operations before income taxes, as a
result of the following:
% of Earnings
From Continuing Operations
Before Income Taxes
-----------------------------
1993 1992 1991
----- ----- -----
U.S. statutory rate 35.0% 34.0% 34.0%
Tax exemptions of operations in
Puerto Rico (10.1) (8.7) (7.9)
State and local taxes 1.1 .2 1.6
Non-U.S. operations (.2) (1.8) 1.3
Other (2.0) (1.1) (.5)
----- ----- -----
23.8% 22.6% 28.5%
===== ===== =====
Prepaid taxes at December 31, 1993, 1992 and 1991 were $377 million, $405
million and $268 million, respectively. The deferred income tax asset,
included in Other Assets, at December 31, 1993 and 1992 was $230 million and
$160 million, respectively. The deferred income tax liability, included in
Other Liabilities, at December 31, 1991 was $112 million.
- 33 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
The components of prepaid and deferred income taxes consisted of:
December 31,
---------------------------
1993 1992 1991
---- ---- ----
Postretirement and pension benefits $275 $144 $(10)
Product liability 183 30 40
Restructuring and integrating businesses 149 356 144
Depreciation (198) (166) (158)
Other 198 201 140
---- ---- ----
$607 $565 $156
==== ==== ====
The Company has settled its United States Federal income tax returns through
1987 with the Internal Revenue Service.
United States Federal income taxes have not been provided on substantially all
of the unremitted earnings of non-U.S. subsidiaries, since it is management's
practice and intent to reinvest such earnings in the operations of these
subsidiaries. The total amount of the net unremitted earnings of non-U.S.
subsidiaries was approximately $1,562 million at December 31, 1993.
Note 8 INVENTORIES
- -------------------
December 31,
-----------------------------
1993 1992 1991
------ ------ ------
Finished goods $ 741 $ 846 $ 836
Work in process 239 272 245
Raw and packaging materials 342 372 370
------ ------ ------
$1,322 $1,490 $1,451
====== ====== ======
Note 9 PROPERTY, PLANT AND EQUIPMENT
- -------------------------------------
December 31,
-----------------------------
1993 1992 1991
------ ------ ------
Land $ 148 $ 145 $ 144
Buildings 1,814 1,741 1,568
Machinery, equipment and fixtures 2,779 2,763 2,565
Construction in progress 495 383 441
------ ------ ------
5,236 5,032 4,718
Less accumulated depreciation 1,862 1,891 1,782
------ ------ ------
$3,374 $3,141 $2,936
====== ====== ======
- 34 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 10 ACCRUED EXPENSES AND OTHER LIABILITIES
- -----------------------------------------------
The components of accrued expenses were:
December 31,
-----------------------------
1993 1992 1991
------ ------ ------
Restructuring and integrating
businesses $ 288 $ 326 $ 66
Medicaid and other rebates 173 98 79
Salaries and wages 111 146 153
Other 978 852 869
------ ------ ------
$1,550 $1,422 $1,167
====== ====== ======
The components of other liabilities were:
December 31,
-----------------------------
1993 1992 1991
------ ------ -----
Postretirement benefits $ 452 $ 402 $ -
Pension benefits 305 73 75
Restructuring and integrating
businesses 82 460 175
Deferred income taxes - - 112
Other 299 310 307
------ ------ -----
$1,138 $1,245 $669
====== ====== =====
Note 11 SHORT-TERM BORROWINGS AND LONG-TERM DEBT
- -------------------------------------------------
Short-term borrowings included amounts due to banks and current installments of
long-term debt totaling $14 million, $61 million and $102 million at December
31, 1993, 1992 and 1991, respectively.
The Company has short-term lines of credit with domestic and foreign banks. At
December 31, 1993, the unused portions of these lines of credit were
approximately $200 million and $491 million, respectively.
- 35 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
The components of long-term debt were:
December 31,
---------------------------
1993 1992 1991
---- ---- ----
7.15% Debentures, due in 2023 $343 $ - $ -
5.0% Term Loan, due in 2000 64 - -
6.18% Term Loan, due in 1997 60 53 -
5.3% Term Loan, due in 1996 55 49 -
6 3/8% and 6 1/2% Notes, due
annually from 1995 to 2004 30 30 30
5.906% Term Loan, paid in 1993 - - 47
Capitalized lease obligations,
due in varying amounts
through 2008 18 15 16
Other, due in varying amounts
through 2008 18 29 42
---- ---- ----
$588 $176 $135
==== ==== ====
Long-term debt at December 31, 1993 was payable:
Years Ending December 31,
- -------------------------
1995 $ 12
1996 65
1997 68
1998 7
1999 6
2000 and later 430
----
$588
====
Note 12 FINANCIAL INSTRUMENTS
- ------------------------------
The Company entered into certain financial instruments to reduce its exposure
to fluctuations in foreign currencies and in interest rates. These financial
instruments included foreign exchange contracts of $372 million, $392 million
and $705 million outstanding as of December 31, 1993, 1992 and 1991,
respectively, and interest rate protection agreements of $100 million
outstanding as of December 31, 1991. The foreign exchange contracts
outstanding as of December 31, 1993 mature at various times through 1996.
- 36 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 13 RETIREMENT BENEFIT PLANS
- ---------------------------------
The Company and certain of its subsidiaries have defined benefit pension plans
for regular full-time employees. The principal pension plan is the
Bristol-Myers Squibb Retirement Income Plan. The Company's funding policy is
to contribute amounts to provide for current service and to fund past service
liability.
Cost for the Company's defined benefit plans included the following components:
Year Ended December 31,
-----------------------
1993 1992 1991
---- ---- ----
Service cost - benefits earned during the year $104 $ 94 $ 79
Interest cost on projected benefit obligation 152 144 131
Actual earnings on plan assets (232) (119) (328)
Net amortization and deferral 54 (73) 172
---- ----- -----
Net pension expense $ 78 $ 46 $ 54
==== ===== =====
The weighted average actuarial assumptions for the Company's pension plans were
as follows:
December 31,
-------------------------
1993 1992 1991
---- ---- ----
Discount rate 7.0% 8.2% 8.6%
Compensation increase 4.5% 5.0% 5.0%
Long-term rate of return 11.0% 12.0% 12.0%
The funded status of the plans was as follows:
December 31,
-----------------------------
1993 1992 1991
-------- -------- --------
Actuarial present value of accumulated
benefit obligation:
Vested $(1,758) $(1,354) $(1,226)
Non-vested (201) (155) (147)
-------- -------- --------
$(1,959) $(1,509) $(1,373)
======== ======== ========
- 37 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
December 31,
----------------------------
1993 1992 1991
------- ------- -------
Total projected benefit obligation $(2,339) $(1,892) $(1,730)
Plan assets at fair value 1,702 1,681 1,694
------- ------- -------
Plan assets less than projected benefit
obligation (637) (211) (36)
Unamortized net assets at adoption (103) (129) (145)
Unrecognized prior service cost 96 105 112
Unrecognized net losses 510 313 137
Adjustment required to recognize minimum
pension liability (171) - -
------- ------- -------
(Accrued) Prepaid pension expense $ (305) $ 78 $ 68
======= ======= =======
In 1993, the increase in the actuarial present value of accumulated benefit
obligation and in plan assets less than projected benefit obligation was
primarily due to a lower discount rate and the effect of the voluntary
retirement program offered to the Company's U.S. employees.
In 1993, $112 million of the adjustment required to recognize minimum pension
liability was recorded in Other Assets and $59 million was recorded as a
reduction in Stockholders' Equity.
Plan benefits are primarily based on years of credited service and on
participant's compensation. Plan assets principally consist of equity
securities and fixed income securities.
Note 14 POSTRETIREMENT BENEFIT PLANS OTHER THAN PENSIONS
- ---------------------------------------------------------
The Company provides comprehensive medical and group life benefits to
substantially all U.S. retirees who elect to participate in the Company's
comprehensive medical and group life plans. The medical plan is contributory.
Contributions are adjusted periodically and vary by date of retirement and the
original retiring company. The life insurance plan is non-contributory.
Effective January 1, 1992, the Company adopted the provisions of Statement of
Financial Accounting Standards No. 106, Employers' Accounting for
Postretirement Benefits Other Than Pensions (FAS 106). This statement requires
that the costs of postretirement benefits, primarily health care benefits, be
accrued during an employee's active working career. In prior years, these
costs were expensed as paid. The Company recorded the discounted value of
expected future benefits attributed to employees' service rendered prior to
1992 as a cumulative effect of an accounting change. This one-time non-cash
accounting change was $390 million before taxes, $246 million after taxes, or
$.47 per share.
- 38 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Cost for the Company's postretirement benefit plans included the following
components:
Year Ended
December 31,
-------------------
1993 1992
---- ----
Service cost - benefits earned during the year $ 8 $ 8
Interest cost on accumulated postretirement benefit
obligation 32 30
Actual earnings on plan assets (2) -
---- ----
Postretirement benefit expense $38 $38
==== ====
The status of the plans was as follows:
December 31,
--------------------
1993 1992
----- -----
Accumulated postretirement benefit obligation:
Retirees $(380) $(251)
Fully eligible active plan participants (17) (27)
Other active plan participants (124) (131)
----- -----
(521) (409)
Plan assets at fair value 28 7
----- -----
Accumulated postretirement benefit obligation
in excess of plan assets (493) (402)
Unrecognized prior service cost (1) -
Unrecognized net losses 42 -
----- -----
Accrued postretirement benefit expense $(452) $(402)
===== =====
In 1993, the increase in the accumulated postretirement benefit obligation was
primarily due to a lower discount rate and the effect of the voluntary
retirement program offered to the Company's U.S. employees.
For measurement purposes, an annual rate of increase in the per capita cost of
covered health care benefits of 12.3% for participants under age 65 and 10.2%
for participants age 65 and over was assumed for 1994; the rate was assumed to
decrease gradually to 5.2% in 2007 and to remain at that level thereafter.
Increasing the assumed medical care cost trend rates by 1 percentage point in
each year would increase the accumulated postretirement benefit obligation as
of December 31, 1993 by $28 million and the aggregate of the service and
interest cost components of net postretirement benefit expense for the year
then ended by $2 million. The weighted-average discount rate used in
determining the accumulated postretirement benefit obligation was 7.0% in 1993
and 8.2% in 1992.
- 39 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Plan assets principally consist of equity securities and fixed income
securities. The expected long-term rate of return on plan assets was 11.0% in
1993 and 12.0% in 1992.
The cost of postretirement benefits was expensed as paid prior to the adoption
of FAS 106 and totaled $18 million in 1991.
Note 15 STOCKHOLDERS' EQUITY
- -----------------------------
Changes in capital shares and capital in excess of par value of stock were:
Capital In
Excess
of Par Value
Shares of Common Stock of Stock
------------------------- (in millions
Issued Treasury of dollars)
----------- ---------- ------------
Balance, December 31, 1990 532,603,203 8,784,350 $504
Issued pursuant to stock
plans, options, rights and
warrants 27,570 (1,415,607) (19)
Conversions of preferred
stock 29,171 - -
Purchases - 5,773,832 -
----------- ---------- ----
Balance, December 31, 1991 532,659,944 13,142,575 485
Issued pursuant to stock
plans, options, rights and
warrants 3,052 (1,464,223) (50)
Conversions of preferred stock 10,417 - -
Purchases - 3,010,700 -
----------- ---------- ----
Balance, December 31, 1992 532,673,413 14,689,052 435
Issued pursuant to stock
plans, options, rights and
warrants 3,530 (1,183,365) (23)
Conversions of preferred
stock 11,515 - -
Purchases - 7,276,594 -
Adjustment required to recognize
minimum pension liability - - (59)
----------- ---------- ----
Balance, December 31, 1993 532,688,458 20,782,281 $353
=========== ========== ====
Each share of the Company's preferred stock is convertible into 4.24 shares of
common stock and is callable at the Company's option. The reductions in the
number of issued shares of preferred stock in 1993, 1992 and 1991 were due to
conversions into common stock.
- 40 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Dividends per common share were $2.88 in 1993, $2.76 in 1992 and $2.40 in 1991.
Under the Company's stock option plans, officers, directors and key employees
may be granted options to purchase the Company's common stock at 100% of the
market price on the day the option is granted. Additionally, the plans provide
for the granting of stock appreciation rights whereby the grantee may surrender
exercisable options and receive common stock and/or cash measured by the excess
of the market price of the common stock over the option exercise price.
On May 4, 1993, the stockholders approved amendments to the 1983 Stock Option
Plan extending its term for 10 years, authorizing additional shares in the
amount of 0.9% of the outstanding shares per year for each of the additional 10
years, incorporating the Company's existing long-term performance award plan
and providing for the payment of long-term performance awards in shares of
common stock valued at 100% of the market price on the date of payment.
The Company's restricted stock award plan provides for the granting of up to
3,000,000 shares of common stock to key employees, subject to restrictions as
to continuous employment except in the case of death or normal retirement.
Restrictions generally expire over a five-year period from date of grant. At
December 31, 1993, a total of 834,500 shares were outstanding under the plan.
Stock option and long-term performance award transactions were:
Shares of Common Stock
--------------------------
Available
for Option/ Under
Award Plan
----------- -----------
Balance, December 31, 1990 10,401,171 12,837,201
Granted (3,303,166) 3,303,166
Exercised - (1,730,540)
Lapsed 287,727 (307,096)
---------- ----------
Balance, December 31, 1991 7,385,732 14,102,731
Granted (3,593,775) 3,593,775
Exercised - (2,258,396)
Surrendered - (7,243)
Lapsed 467,773 (475,107)
---------- ----------
Balance, December 31, 1992 4,259,730 14,955,760
Shares authorized 4,661,859 -
Granted (5,464,022) 5,464,022
Exercised - (1,264,638)
Lapsed 787,946 (790,981)
---------- ----------
Balance, December 31, 1993 4,245,513 18,364,163
========== ==========
- 41 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
At December 31, 1993, there were exercisable options outstanding to purchase
9,921,640 shares of common stock at prices ranging from $10.94 to $87.31 per
share. Shares of common stock under option were exercised at prices ranging
from $9.44 to $56.13 in 1993, from $9.34 to $76.38 in 1992 and from $6.43 to
$65.50 in 1991.
There were 17,644 warrants at December 31, 1993 to acquire shares of the
Company's common stock at an exercise price of $18.83 per share, expiring on
December 31, 1994.
At December 31, 1993, 29,372,266 shares of common stock were reserved for
issuance pursuant to stock plans, options and warrants, and conversions of
preferred stock.
Attached to each outstanding share of the Company's common stock is one Right.
The Rights will be exercisable if a person or group acquires beneficial
interest of 15% or more of the Company's outstanding common stock, or commences
a tender or exchange offer for 15% or more of the Company's outstanding common
stock. Each Right will entitle stockholders to buy one one-thousandth of a
share of a new series of participating preferred stock of the Company at an
exercise price of $200. The Rights will expire on December 18, 1997. In the
event of certain merger, sale of assets or self-dealing transactions, each
Right will then entitle its holder to acquire shares having a value of twice
the Right's exercise price. The Company may redeem the Rights at $.01 per
Right at any time until the 15th day following public announcement that a 15%
position has been acquired.
Note 16 LEASES
- ---------------
Minimum rental commitments under all noncancellable operating leases, primarily
real estate, in effect at December 31, 1993 were:
Years Ending December 31,
- ------------------------
1994 $120
1995 100
1996 80
1997 65
1998 56
Later years 322
----
Total minimum payments 743
Less total minimum sublease rentals 195
----
Net minimum rental commitments $548
====
Operating lease rental expense (net of sublease rental income of $21 million in
1993, $20 million in 1992 and $21 million in 1991) was $142 million in 1993,
$141 million in 1992 and $142 million in 1991.
- 42 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 17 SEGMENT INFORMATION
- ----------------------------
The Company's products are reported in four industry segments as follows:
Pharmaceutical Products:
- -----------------------
Prescription medicines, mainly cardiovascular drugs and anti-infectives, which
comprise about forty percent and twenty-five percent, respectively, of the
segment's sales, anti-cancer and central nervous system drugs, diagnostic
agents and other pharmaceutical products.
Medical Devices:
- ---------------
Orthopaedic implants, which comprise about forty percent of the segment's
sales, ostomy and wound care products, surgical instruments and other medical
devices.
Nonprescription Health Products:
- -------------------------------
Infant formulas and other nutritional products, which comprise about sixty-five
percent of the segment's sales, analgesics, cough/cold remedies and skin care
products.
Toiletries and Beauty Aids:
- --------------------------
Haircoloring and hair care preparations, which comprise about sixty-five
percent of the segment's sales, deodorants, anti-perspirants and beauty
appliances.
Unallocated expenses principally consist of general administrative expenses and
net interest income, and in 1992 include a portion of the charge for
restructuring. Other assets are principally cash and cash equivalents, time
deposits and marketable securities. Inter-area sales by geographic area for
each of the three years ended December 31, 1993, 1992 and 1991, respectively,
were: United States - $918 million, $915 million and $807 million; Europe,
Mid-East and Africa - $504 million, $382 million and $448 million; Other
Western Hemisphere - $41 million, $36 million and $28 million; and Pacific -
$43 million, $26 million and $30 million. These sales are usually billed at or
above manufacturing costs.
Net assets relating to operations outside the United States amounted to
approximately $1,511 million, $1,369 million and $1,323 million at December 31,
1993, 1992 and 1991, respectively.
- 43 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
INDUSTRY SEGMENTS Net Sales Profit
- ----------------- ------------------------- ------------------------
1993 1992 1991 1993(a) 1992(b) 1991
------- ------- ------- ------ ------ ------
Pharmaceutical Products $ 6,524 $ 6,313 $ 5,908 $2,133 $1,584 $1,844
Medical Devices 1,693 1,665 1,559 (24) 305 354
Nonprescription
Health Products 1,964 1,959 1,901 463 268 435
Toiletries and Beauty Aids 1,232 1,219 1,203 163 10 203
------- ------- ------- ------ ------ ------
Net sales and operating
profit $11,413 $11,156 $10,571 $2,735 $2,167 $2,836
======= ======= ======= ====== ====== ======
GEOGRAPHIC AREAS Net Sales Profit
- ---------------- ------------------------- ------------------------
1993 1992 1991 1993(c) 1992(d) 1991
------- ------- ------- ------ ------ ------
United States $ 7,645 $ 7,362 $ 7,172 $1,777 $1,467 $2,016
Europe, Mid-East and Africa 3,062 3,163 2,905 591 534 641
Other Western Hemisphere 987 939 862 197 138 171
Pacific 1,225 1,051 945 194 86 97
Inter-area eliminations (1,506) (1,359) (1,313) (24) (58) (89)
------- ------- ------- ------ ------ ------
Net sales and operating
profit $11,413 $11,156 $10,571 2,735 2,167 2,836
======= ======= =======
Unallocated expenses (164) (180) (52)
------ ------ ------
Earnings from
continuing operations
before income taxes $2,571 $1,987 $2,784
====== ====== ======
(a) The 1993 operating profit of the Medical Devices segment included the
special charge for pending and future product liability claims of $500
million.
(b) The 1992 operating profit of the Company's industry segments included the
charge for restructuring as follows: Pharmaceutical Products - $371
million; Medical Devices - $155 million; Nonprescription Health Products -
$150 million; and Toiletries and Beauty Aids - $150 million.
(c) The 1993 operating profit of the United States included the special charge
for pending and future product liability claims of $500 million.
(d) The 1992 earnings from continuing operations before income taxes included
the charge for restructuring as follows: United States - $595 million;
Europe, Mid-East and Africa - $134 million; Other Western Hemisphere - $51
million; Pacific - $46 million; and unallocated expenses - $64 million.
- 44 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
INDUSTRY SEGMENTS Year-End Assets
- ----------------- --------------------------
1993 1992 1991
------ ------ ------
Pharmaceutical Products $4,628 $4,622 $4,215
Medical Devices 2,030 1,063 1,033
Nonprescription Health
Products 872 839 827
Toiletries and Beauty Aids 548 547 745
------ ------ ------
Identifiable segment assets $8,078 $7,071 $6,820
====== ====== ======
GEOGRAPHIC AREAS Year-End Assets
- ---------------- --------------------------
1993 1992 1991
------ ------- ------
United States $ 5,591 $ 4,587 $4,430
Europe, Mid-East and Africa 1,708 1,813 1,858
Other Western Hemisphere 443 426 424
Pacific 829 717 689
Inter-area eliminations (493) (472) (581)
------- ------- ------
Identifiable geographic assets 8,078 7,071 6,820
Other assets 4,023 3,733 2,596
------- ------- ------
Total assets $12,101 $10,804 $9,416
======= ======= ======
INDUSTRY SEGMENTS Capital Expenditures Depreciation
- ----------------- ---------------------- --------------------
1993 1992 1991 1993 1992 1991
---- ---- ---- ---- ---- ----
Pharmaceutical Products $379 $426 $402 $194 $186 $145
Medical Devices 55 84 81 35 34 30
Nonprescription
Health Products 81 70 54 34 28 30
Toiletries and Beauty Aids 23 34 37 24 28 26
---- ---- ----- ---- ---- ----
Identifiable industry
totals 538 614 574 287 276 231
Other 42 40 59 21 19 15
---- ---- ---- ---- ---- ----
Consolidated totals $580 $654 $633 $308 $295 $246
==== ==== ==== ==== ==== ====
- 45 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 18 CONTINGENCIES
- ----------------------
Various lawsuits, claims and proceedings of a nature considered normal to its
businesses are pending against the Company and certain of its subsidiaries.
The most significant of these are described below.
As of December 31, 1993, approximately 10,000 plaintiffs have filed suit
against the Company, its subsidiary, Medical Engineering Corporation, and
certain other subsidiaries, in federal and state courts and in certain Canadian
provincial courts, alleging damages for personal injuries of various types
resulting from polyurethane covered breast implants and smooth walled breast
implants. Certain of these cases are class actions which seek to allege claims
on behalf of all breast implant recipients. All federal court actions have
been consolidated for pre-trial proceedings in federal District Court in
Birmingham, Alabama. See Note 2 relating to the special charge recorded in
connection with this litigation.
The Company is a defendant in a number of actions brought against it and other
pharmaceutical companies in federal and state courts by the children or
grandchildren of women who ingested diethylstilbestrol (DES), a product which
had been, but is no longer, manufactured or sold by an affiliate of the
Company.
The Company is a defendant in several state antitrust actions (one of which has
been removed to federal court) filed on behalf of purported classes of
individual purchasers of infant formula products, and by one State Attorney
General, alleging a conspiracy regarding pricing of infant formula products and
other violations of state antitrust or deceptive trade practice laws and
seeking treble damages, statutory and civil penalties and injunctive relief.
Six other state Attorneys General and the Canadian Bureau of Competitive Policy
have commenced or stated an intention to commence investigations of pricing
practices and marketing activities in the infant formula industry. The Company
is also a defendant in two federal court actions, one filed by the State of
Louisiana on behalf of indirect purchasers of infant formula alleging a
conspiracy regarding pricing of infant formula products and seeking treble
damages, civil penalties and injunctive relief and the other filed by Nestle
Food Company alleging anticompetitive practices in violation of federal and
state antitrust or other laws and seeking treble damages, civil penalties and
injunctive relief.
As of December 31, 1993, the Company was a defendant with other major
pharmaceutical manufacturers and drug wholesalers in 25 actions brought in
various federal courts by retail pharmacies, individually or as representatives
of purported class actions, which allege anticompetitive or unfair practices in
the pricing and distribution of pharmaceuticals in violation of federal and
state laws and which seek treble damages and injunctive relief. As of December
31, 1993, the Company was also a co-defendant in four state court actions in
California brought by retail pharmacies, individually or as representatives of
purported class actions, which allege discrimination in the pricing of
pharmaceuticals in violation of California laws and which seek treble damages
and injunctive relief.
The Company is a defendant in a purported class action filed in June 1992 in
- 46 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
the U.S. District Court for the Southern District of New York alleging
violations of federal securities laws and regulations in connection with, among
other things, earnings projections.
The Company, together with others, is a party to, or otherwise involved in, a
number of proceedings brought by the Environmental Protection Agency under the
Comprehensive Environmental Response, Compensation and Liability Act (CERCLA or
Superfund) directed at the cleanup of Superfund sites.
While it is not possible to predict with certainty the outcome of these cases,
it is the opinion of management that all lawsuits, claims and proceedings which
are pending against the Company are without merit or will not have a material
adverse effect on the Company's consolidated financial position.
- 47 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 19 SUPPLEMENTARY INCOME STATEMENT INFORMATION
- ---------------------------------------------------
Year Ended December 31,
---------------------------------
1993 1992 1991
------ ------ ------
Maintenance and repairs $ 117 $ 115 $ 117
====== ====== ======
Advertising $ 401 $ 440 $ 491
Product promotion 854 851 772
------ ------ ------
$1,255 $1,291 $1,263
====== ====== ======
Royalties $ 143 $ 144 $ 127
====== ====== ======
- 48 -
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions of dollars)
Note 20 SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
- ------------------------------------------------------
First Second Third Fourth
Quarter Quarter Quarter Quarter Year
------- ------- ------- ------- -------
1993:
Net Sales $2,755 $2,802 $2,862 $2,994 $11,413
Gross Profit 2,014 2,085 2,099 2,186 8,384
Net Earnings (a) 575 521 608 255 1,959
Earnings Per Common Share (a) 1.11 1.01 1.18 .50 3.80
1992:
Net Sales $2,641 $2,743 $2,948 $2,824 $11,156
Gross Profit 1,983 2,044 2,180 2,092 8,299
Earnings from Continuing
Operations (b) 534 475 572 (43) 1,538
Net Earnings (c)(d) 302 488 589 583 1,962
Per Common Share:
Continuing operations (b) 1.03 .92 1.10 (.08) 2.97
Net earnings (c)(d) .59 .94 1.14 1.13 3.79
(a) Included in the fourth quarter of 1993 is a special charge of $500 million
before taxes, $310 million after taxes, or $.60 per share, for pending and
future product liability claims.
(b) Included in the fourth quarter of 1992 is a charge for restructuring of
$890 million before taxes, $570 million after taxes, or $1.10 per share.
(c) First quarter 1992 results and earnings per share reflect the cumulative
effect of adopting, effective January 1, 1992, a new accounting standard
for postretirement benefits of $390 million before taxes, $246 million
after taxes, or $.47 per share.
(d) Included in 1992 were the results of The Drackett Company of $65 million
after taxes, or $.12 per share, for the year and, in the fourth quarter,
the gain on its sale of $605 million after taxes, or $1.17 per share.
- 49 -
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
---------------------------------
To the Board of Directors
and Stockholders of
Bristol-Myers Squibb Company
In our opinion, the consolidated financial statements listed in the index
appearing under Item 14(a)(1) and (2) on page 52 present fairly, in all
material respects, the financial position of Bristol-Myers Squibb Company and
its subsidiaries at December 31, 1993, 1992 and 1991, and the results of their
operations and their cash flows for the years then ended in conformity with
generally accepted accounting principles. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with generally accepted auditing
standards which require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management,
and evaluating the overall financial statement presentation. We believe that
our audits provide a reasonable basis for the opinion expressed above.
As discussed in Note 14 to the financial statements, effective January 1, 1992,
the Company adopted Statement of Financial Accounting Standards No. 106,
Employers' Accounting for Postretirement Benefits Other Than Pensions.
/s/ Price Waterhouse
- --------------------
1177 Avenue of the Americas
New York, New York 10036
January 20, 1994
- 50 -
<PAGE>
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
PART III
--------
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
(a) Reference is made to the Proxy Statement for the Annual Meeting of
Stockholders on May 3, 1994 with respect to the Directors of the Registrant
which is incorporated herein by reference and made a part hereof in
response to the information required by Item 10.
(b) The information required by Item 10 with respect to the Executive Officers
of the Registrant has been included in Part IA of this Form 10-K Annual
Report in reliance on General Instruction G of Form 10-K and Instruction 3
to Item 401(b) of Regulation S-K.
Item 11. EXECUTIVE COMPENSATION.
Reference is made to the Proxy Statement for the Annual Meeting of Stockholders
on May 3, 1994 with respect to Executive Compensation which is incorporated
herein by reference and made a part hereof in response to the information
required by Item 11.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
Reference is made to the Proxy Statement for the Annual Meeting of Stockholders
on May 3, 1994 with respect to the security ownership of certain beneficial
owners and management which is incorporated herein by reference and made a part
hereof in response to information required by Item 12.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
Reference is made to the Proxy Statement for the Annual Meeting of Stockholders
on May 3, 1994 with respect to certain relationships and related transactions
which is incorporated herein by reference and made a part hereof in response to
the information required by Item 13.
- 51 -
<PAGE>
PART IV
-------
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
Page
Number
------
(a) 1. Financial Statements 25-29
Notes to Consolidated Financial
Statements 30-49
Report of Independent Accountants 50
2. Financial Statement Schedules
Schedule Page
Number Number
-------- ------
Amounts receivable from related parties
and underwriters, promoters, and employees
other than related parties II S-1
Property, plant and equipment V S-2
Accumulated depreciation and amortization
of property, plant and equipment VI S-3
Valuation and qualifying accounts VIII S-4
Short-term borrowings IX S-5
All other schedules not included with this additional financial data are
omitted because they are not applicable or the required information is
included in the financial statements or notes thereto.
3. Exhibit List
The Exhibits listed below are identified by numbers corresponding to the
Exhibit Table of Item 601 of Regulation S-K. The Exhibits designated by
two asterisks (**) are management contracts or compensatory plans or
arrangements required to be filed pursuant to this Item 14. Unless
otherwise indicated, all Exhibits are part of Commission File Number
1-1136.
3a. Restated Certificate of Incorporation of Bristol-Myers Squibb Company
(incorporated herein by reference to Exhibit 4a to Registration
Statement No. 33-33682 on Form S-3).
3b. Bylaws of Bristol-Myers Squibb Company, as amended through May 4, 1993
(filed herewith).
4a. Letter of Agreement dated March 28, 1984 (incorporated herein by
reference to Exhibit 4 to Form 10-K for the fiscal year ended December
31, 1983).
4b. Rights Agreement, dated as of December 4, 1987, between Bristol-Myers
Squibb Company and Manufacturers Hanover Trust Company, as amended
(incorporated herein by reference to Exhibit 1 to the Form 8-A dated
December 10, 1987 and Exhibit 1 to the Form 8 dated July 27, 1989).
- 52 -
<PAGE>
4c. Indenture, dated as of June 1, 1993, between Bristol-Myers Squibb
Company and The Chase Manhattan Bank (National Association), as
trustee (incorporated herein by reference to Exhibit 4.1 to the Form
8-K dated May 27, 1993 and filed on June 3, 1993).
4d. Form of 7.15% Debenture Due 2023 of Bristol-Myers Squibb Company
(incorporated herein by reference to Exhibit 4.2 to the Form 8-K dated
May 27, 1993 and filed on June 3, 1993).
**10a. Bristol-Myers Squibb Company 1983 Stock Option Plan, as Amended and
Restated as of January 1, 1993, as amended (as adopted and
incorporating amendments as of October 1, 1993, filed herewith).
**10b. Squibb Corporation 1982 Option, Restricted Stock and Performance Unit
Plan, as amended (filed herewith).
**10c. Squibb Corporation 1986 Option, Restricted Stock and Performance Unit
Plan, as amended (as adopted, incorporated herein by reference to
Exhibit 10k to the Squibb Corporation Form 10-K for the fiscal year
ended December 31, 1988, File No. 1-5514; as amended effective July 1,
1993, filed herewith).
**10d. Bristol-Myers Squibb Company Performance Incentive Plan, as amended
(as adopted, incorporated herein by reference to Exhibit 2 to the Form
10-K for the fiscal year ended December 31, 1978; as amended as of
January 8, 1990, incorporated herein by reference to Exhibit 19b to
the Form 10-K for the fiscal year ended December 31, 1990; as amended
on April 2, 1991, incorporated herein by reference to Exhibit 19b to
the Form 10-K for the fiscal year ended December 31, 1991; as amended
effective January 1, 1994, filed herewith).
**10e. Benefit Equalization Plan of Bristol-Myers Squibb Company and its
Subsidiary or Affiliated Corporations Participating in the
Bristol-Myers Squibb Company Retirement Income Plan or the
Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan, as
amended (as amended and restated as of January 1, 1993, as amended
effective October 1, 1993, filed herewith).
**10f. Benefit Equalization Plan of Bristol-Myers Squibb Company and its
Subsidiary or Affiliated Corporations Participating in the
Bristol-Myers Squibb Company Savings and Investment Program, as
amended (as amended and restated as of May 1, 1990, incorporated
herein by reference to Exhibit 19d to the Form 10-K for the fiscal
year ended December 31, 1990; as amended as of January 1, 1991,
incorporated herein by reference to Exhibit 19g to the Form 10-K for
the fiscal year ended December 31, 1990; as amended as of January 1,
1991, incorporated herein by reference to Exhibit 19e to the Form 10-K
for the fiscal year ended December 31, 1991).
**10g. Squibb Corporation Supplementary Pension Plan, as amended (as
previously amended and restated, incorporated herein by reference to
Exhibit 19g to the Form 10-K for the fiscal year ended December 31,
1991; as amended as of September 14, 1993, filed herewith).
**10h. Bristol-Myers Squibb Company Restricted Stock Award Plan, as amended
(as adopted on November 7, 1989, incorporated herein by reference to
Exhibit 10t to the Form 10-K for the fiscal year ended December 31,
1989; as amended on December 4, 1990, incorporated herein by reference
- 53 -
<PAGE>
to Exhibit 19a to the Form 10-K for the fiscal year ended December 31,
1990; as amended effective July 1, 1993, filed herewith).
**10i. Bristol-Myers Squibb Company Retirement Income Plan for Non-Employee
Directors, as amended to October 3, 1989 (incorporated herein by
reference to Exhibit 10u to the Form 10-K for the fiscal year ended
December 31, 1989).
**10j. Bristol-Myers Squibb Company 1987 Deferred Compensation Plan for
Non-Employee Directors, as amended (incorporated herein by reference
to Exhibit 19d to the Form 10-K for the fiscal year ended December 31,
1991).
**10k. Bristol-Myers Squibb Company Non-Employee Directors' Stock Option
Plan, as amended (as approved by the Stockholders on May 1, 1990,
incorporated herein by reference to Exhibit 28 to Registration
Statement No. 33-38587 on Form S-8; as amended May 7, 1991,
incorporated herein by reference to Exhibit 19c to the Form 10-K for
the fiscal year ended December 31, 1991).
**10l. Squibb Corporation Deferral Plan for Fees of Outside Directors, as
amended (as adopted, incorporated herein by reference to Exhibit 10e
to the Squibb Corporation Form 10-K for the fiscal year ended December
31, 1987, File No. 1-5514; as amended effective December 31, 1991,
incorporated herein by reference to Exhibit 10m to the Form 10-K for
the fiscal year ended December 31, 1992).
**10m. Amendment to all of the Company's plans, agreements, legal documents
and other writings, pursuant to action of the Board of Directors on
October 3, 1989 to reflect the change of the Company's name to
Bristol-Myers Squibb Company (incorporated herein by reference to
Exhibit 10v to the Form 10-K for the fiscal year ended December 31,
1989).
11. Computation of Per Share Earnings (filed herewith).
21. Subsidiaries of the Registrant (filed herewith).
23. Consent of Price Waterhouse (filed herewith).
(b) Reports on Form 8-K
The Registrant did not file any reports on Form 8-K during the quarter
ended December 31, 1993.
- 54 -
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized.
BRISTOL-MYERS SQUIBB COMPANY
(Registrant)
By /s/ Richard L. Gelb
------------------------------------
Richard L. Gelb
Chairman of the Board
March 28, 1994
------------------------------------
Date
Pursuant to the requirements of the Securities Exchange Act of 1934, this
Report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
Chairman of the Board
/s/ Richard L. Gelb and Director March 28, 1994
- ---------------------------
(Richard L. Gelb)
President, Chief
Executive Officer
and Director
(Principal Executive
/s/ Charles A. Heimbold, Jr. Officer) March 28, 1994
- ----------------------------
(Charles A. Heimbold, Jr.)
Chief Financial Officer
and Senior Vice President
Corporate Staff
(Principal Financial
/s/ Michael F. Mee Officer) March 28, 1994
- --------------------------
(Michael F. Mee)
Controller
and Vice President
Corporate Staff
(Principal Accounting
/s/ Frederick S. Schiff Officer) March 28, 1994
- ---------------------------
(Frederick S. Schiff)
- 55 -
<PAGE>
Signature Title Date
--------- ----- ----
/s/ Robert E. Allen Director March 28, 1994
- ----------------------------
(Robert E. Allen)
/s/ Michael E. Autera Executive Vice
- ---------------------------- President and Director March 28, 1994
(Michael E. Autera)
/s/ Ellen V. Futter Director March 28, 1994
- ----------------------------
(Ellen V. Futter)
/s/ Louis V. Gerstner, Jr. Director March 28, 1994
- ----------------------------
(Louis V. Gerstner, Jr.)
/s/ John D. Macomber Director March 28, 1994
- --------------------------
(John D. Macomber)
/s/ Alexander Rich, M.D. Director March 28, 1994
- ---------------------------
(Alexander Rich, M.D.)
/s/ James D. Robinson III Director March 28, 1994
- ----------------------------
(James D. Robinson III)
/s/ Andrew C. Sigler Director March 28, 1994
- ---------------------------
(Andrew C. Sigler)
/s/ Louis W. Sullivan, M.D. Director March 28, 1994
- ----------------------------
(Louis W. Sullivan, M.D.)
- 56 -
<PAGE>
EXHIBIT INDEX
-------------
The Exhibits listed below are identified by numbers corresponding to
the Exhibit Table of Item 601 of Regulation S-K. The Exhibits
designated by two asterisks (**) are management contracts or
compensatory plans or arrangements required to be filed pursuant to
this Item 14. An asterisk (*) in the Page column indicates that the
Exhibit has been previously filed with the Commission and is
incorporated herein by reference. Unless otherwise indicated, all
Exhibits are part of Commission File Number 1-1136.
Exhibit Number and Description Page
------------------------------ ----
3a. Restated Certificate of Incorporation of Bristol-Myers *
Squibb Company (incorporated herein by reference to
Exhibit 4a to Registration Statement No. 33-33682 on
Form S-3).
3b. Bylaws of Bristol-Myers Squibb Company, as amended E-1-1
through May 4, 1993.
4a. Letter of Agreement dated March 28, 1984 (incorporated *
herein by reference to Exhibit 4 to Form 10-K for the
fiscal year ended December 31, 1983).
4b. Rights Agreement, dated as of December 4, 1987, between *
Bristol-Myers Squibb Company and Manufacturers Hanover
Trust Company, as amended (incorporated herein by reference
to Exhibit 1 to the Form 8-A dated December 10, 1987 and
Exhibit 1 to the Form 8 dated July 27, 1989).
4c. Indenture, dated as of June 1, 1993, between Bristol- *
Myers Squibb Company and The Chase Manhattan Bank
(National Association), as trustee (incorporated herein
by reference to Exhibit 4.1 to the Form 8-K dated May 27,
1993 and filed on June 3, 1993).
4d. Form of 7.15% Debenture Due 2023 of Bristol-Myers Squibb *
Company (incorporated herein by reference to Exhibit 4.2
to the form 8-K dated May 27, 1993 and filed on June 3, 1993).
** 10a. Bristol-Myers Squibb Company 1983 Stock Option Plan, as E-2-1
Amended and Restated as of January 1, 1993, as amended
(as adopted and incorporating amendments as of October 1, 1993).
- 53 -
<PAGE>
Exhibit Number and Description Page
------------------------------ ----
** 10b. Squibb Corporation 1982 Option, Restricted Stock and E-3-1
Performance Unit Plan, as amended.
** 10c. Squibb Corporation 1986 Option, Restricted Stock and *
Performance Unit Plan, as amended (as adopted, incorporated
herein by reference to Exhibit 10k to the Squibb Corporation
Form 10-K for the fiscal year ended December 31, 1988,
File No. 1-5514).
Amendment, effective July 1, 1993, to the Squibb Corporation E-4-1
1986 Option, Restricted Stock and Performance Unit Plan.
** 10d. Bristol-Myers Squibb Company Performance Incentive Plan, *
as amended (as adopted, incorporated herein by reference
to Exhibit 2 to the Form 10-K for the fiscal year ended
December 31, 1978; as amended as of January 8, 1990,
incorporated herein by reference to Exhibit 19b to the
Form 10-K for the fiscal year ended December 31, 1990; as
amended on April 2, 1991, incorporated herein by reference
to Exhibit 19b to the Form 10-K for the fiscal year ended
December 31, 1991).
Amendment, effective January 1, 1994, to the Bristol-Myers E-5-1
Squibb Company Performance Incentive Plan.
** 10e. Benefit Equalization Plan of Bristol-Myers Squibb Company E-6-1
and its Subsidiary or Affiliated Corporations Participating
in the Bristol-Myers Squibb Company Retirement Income Plan
or the Bristol-Myers Squibb Puerto Rico, Inc. Retirement
Income Plan, as amended (as amended and restated as of
January 1, 1993, as amended effective October 1, 1993).
** 10f. Benefit Equalization Plan of Bristol-Myers Squibb Company *
and its Subsidiary or Affiliated Corporations Participating
in the Bristol-Myers Squibb Company Savings and Investment
Program, as amended (as amended and restated as of May 1,
1990, incorporated herein by reference to Exhibit 19d to the
Form 10-K for the fiscal year ended December 31, 1990; as
amended as of January 1, 1991, incorporated herein by reference
to Exhibit 19g to the Form 10-K for the fiscal year ended
December 31, 1990; as amended as of January 1, 1991,
incorporated herein by reference to Exhibit 19e to the
Form 10-K for the fiscal year ended December 31, 1991).
** 10g. Squibb Corporation Supplementary Pension Plan, as amended *
(as previously amended and restated, incorporated herein
by reference to Exhibit 19g to the Form 10-K for the fiscal
year ended December 31, 1991).
Amendment, as of September 14, 1993, to the Squibb Corporation E-7-1
Supplementary Pension Plan.
- 58 -
<PAGE>
Exhibit Number and Description Page
------------------------------ ----
** 10h. Bristol-Myers Squibb Company Restricted Stock Award Plan, *
as amended (as adopted on November 7, 1989, incorporated
herein by reference to Exhibit 10t to the Form 10-K for the
fiscal year ended December 31, 1989; as amended on December 4,
1990, incorporated herein by reference to Exhibit 19a to the
Form 10-K for the fiscal year ended December 31, 1990).
Amendment, effective July 1, 1993, to the Bristol-Myers Squibb E-8-1
Company Restricted Stock Award Plan.
** 10i. Bristol-Myers Squibb Company Retirement Income Plan for *
Non-Employee Directors, as amended to October 3, 1989
(incorporated herein by reference to Exhibit 10u to the
Form 10-K for the fiscal year ended December 31, 1989).
** 10j. Bristol-Myers Squibb Company 1987 Deferred Compensation *
Plan for Non-Employee Directors, as amended (incorporated
herein by reference to Exhibit 19d to the Form 10-K for the
fiscal year ended December 31, 1991).
** 10k. Bristol-Myers Squibb Company Non-Employee Directors' Stock *
Option Plan, as amended (as approved by the Stockholders on
May 1, 1990, incorporated herein by reference to Exhibit 28
to Registration Statement No. 33-38587 on Form S-8; as
amended May 7, 1991, incorporated herein by reference to
Exhibit 19c to the Form 10-K for the fiscal year ended
December 31, 1991).
** 10l. Squibb Corporation Deferral Plan for Fees of Outside *
Directors, as amended (as adopted, incorporated herein by
reference to Exhibit 10e to the Squibb Corporation Form 10-K
for the fiscal year ended December 31, 1987, File No. 1-5514;
as amended effective December 31, 1991, incorporated herein by
reference to Exhibit 10m to the Form 10-K for the fiscal year
ended December 31, 1992).
** 10m. Amendment to all of the Company's plans, agreements, *
legal documents and other writings, pursuant to action
of the Board of Directors on October 3, 1989 to reflect
the change of the Company's name to Bristol-Myers Squibb
Company (incorporated herein by reference to Exhibit 10v
to the Form 10-K for the fiscal year ended December 31,
1989).
11. Computation of Per Share Earnings. E-9-1
21. Subsidiaries of the Registrant. E-10-1
23. Consent of Price Waterhouse. E-11-1
- 59 -
<PAGE>
SCHEDULE II
BRISTOL-MYERS SQUIBB COMPANY -----------
AMOUNTS RECEIVABLE FROM RELATED PARTIES AND
UNDERWRITERS, PROMOTERS,
AND EMPLOYEES OTHER THAN RELATED PARTIES
(in millions of dollars)
Balance at end
Deductions of period
Balance ------------------- ----------------
at
beginning Amounts
Name of of Amounts written- Non-
debtor period Additions collected off Current Current
- ------------------- --------- --------- --------- -------- ------- -------
For the year ended
December 31, 1991
James T. Treace
President, Linvatec $0.4 $- $0.4 $- $- $-
========= ========= ========= ======== ======= =======
This indebtedness was due on demand and was secured by Bristol-Myers Squibb
common stock. Interest rates ranged from 5.51% to 6.68% during the year ended
December 31, 1991.
S-1
<PAGE>
<TABLE>
SCHEDULE V
BRISTOL-MYERS SQUIBB COMPANY ----------
PROPERTY, PLANT AND EQUIPMENT
(in millions of dollars)
<CAPTION>
Balance at Transfer Balance at
beginning Additions Retirements between Other end
Classification of period at cost or sales classifications changes (a) of period
- -------------- ---------- --------- ----------- --------------- ----------- ----------
<S> <C> <C> <C> <C> <C> <C>
For the year ended December 31, 1993
Land $ 145 $ 1 $ 4 $ 5 $ 1 $ 148
Buildings 1,741 14 69 137 (9) 1,814
Machinery, equipment and fixtures 2,763 67 228 228 (51) 2,779
Construction in progress 383 498 10 (370) (6) 495
---------- --------- ----------- --------------- ----------- ----------
$5,032 $580 $311 $ - $(65) $5,236
========== ========= =========== =============== =========== ==========
For the year ended December 31, 1992
Land $ 144 $ 3 $ 2 $ - $ - $ 145
Buildings 1,568 30 31 215 (41) 1,741
Machinery, equipment and fixtures 2,565 105 144 344 (107) 2,763
Construction in progress 441 516 1 (559) (14) 383
---------- --------- ----------- --------------- ----------- ----------
$4,718 $654 $178 $ - $(162) $5,032
========== ========= =========== =============== =========== ==========
For the year ended December 31, 1991
Land $ 148 $ 2 $ 1 $ - $ (5) $ 144
Buildings 1,355 22 30 233 (12) 1,568
Machinery, equipment and fixtures 2,312 94 95 286 (32) 2,565
Construction in progress 456 515 3 (519) (8) 441
---------- --------- ----------- --------------- ----------- ----------
$4,271 $633 $129 $ - $(57) $4,718
========== ========= =========== =============== =========== ==========
</TABLE>
(a) Primarily reflects translation on account balance and, in 1992, also
reflects the sale of The Drackett Company.
The range of annual rates used in computing provisions for depreciation
was 2% to 20% for buildings and 5% to 33% for equipment.
S-2
<PAGE>
<TABLE>
BRISTOL-MYERS SQUIBB COMPANY SCHEDULE VI
ACCUMULATED DEPRECIATION AND AMORTIZATION -----------
OF PROPERTY, PLANT AND EQUIPMENT
(in millions of dollars)
<CAPTION>
Additions
Balance at charged to Retirements Balance at
beginning costs and renewals and Other end
Description of period expenses replacements Changes (a) of period
- --------------------- ---------- ---------- ------------ ----------- ----------
<S> <C> <C> <C> <C> <C>
For the year ended
December 31, 1993
Buildings $ 487 $ 57 $ 48 $(24) $ 472
Machinery, equipment
and fixtures 1,404 251 199 (66) 1,390
---------- ---------- ------------ ----------- ----------
$1,891 $308 $247 $(90) $1,862
========== ========== ============ =========== ==========
For the year ended
December 31, 1992
Buildings $ 470 $ 70 $ 15 $(38) $ 487
Machinery, equipment
and fixtures 1,312 225 138 5 1,404
---------- ---------- ------------ ----------- ----------
$1,782 $295 $153 $(33) $1,891
========== ========== ============ =========== ==========
For the year ended
December 31, 1991
Buildings $ 441 $ 46 $ 20 $ 3 $ 470
Machinery, equipment
and fixtures 1,199 200 85 (2) 1,312
---------- ---------- ------------ ----------- ----------
$1,640 $246 $105 $ 1 $1,782
========== ========== ============ =========== ==========
</TABLE>
(a) Primarily reflects translation on account balance. In 1993 and 1992,
reflects amounts recorded in connection with the charge for restructuring,
and in 1992, also reflects the sale of The Drackett Company.
S-3
<PAGE>
SCHEDULE VIII
BRISTOL-MYERS SQUIBB COMPANY -------------
VALUATION AND QUALIFYING ACCOUNTS
(in millions of dollars)
Additions
Balance at charged to Deductions- Balance at
beginning costs and bad debts end
Description of period expenses written off of period
- --------------------- ---------- ---------- ------------ ----------
Allowances for
discounts and
doubtful accounts:
For the year ended
December 31, 1993 $106 $19 $45 $80
========== ========== ============ ===========
For the year ended
December 31, 1992 $90 $41 $25 $106
========== ========== ============ ===========
For the year ended
December 31, 1991 $68 $42 $20 $90
========== ========== ============ ===========
S-4
<PAGE>
<TABLE>
SCHEDULE IX
BRISTOL-MYERS SQUIBB COMPANY -----------
SHORT-TERM BORROWINGS
(in millions of dollars)
<CAPTION>
Maximum Average Weighted
Weighted amount amount average
Balance average outstanding outstanding interest rate
Category of aggregate at end of interest during during the during
short-term borrowings year (a) rate the year year (b) the year (c)
- --------------------- --------- -------- ----------- ----------- -------------
<S> <C> <C> <C> <C> <C>
For the year ended
December 31, 1993
Payable to banks $163 8% $302 $225 9%
========= ======== =========== =========== =============
For the year ended
December 31, 1992
Payable to banks $314 9% $434 $358 9%
========= ======== =========== =========== =============
For the year ended
December 31, 1991
Payable to banks $451 11% $451 $362 12%
========= ======== =========== =========== =============
</TABLE>
(a) Excludes the current portion of long-term debt of $14 million, $61 million
and $102 million in 1993, 1992 and 1991, respectively. At December 31,
1993, 1992 and 1991, amounts payable to banks primarily were incurred by
foreign subsidiaries and were payable in foreign currencies.
(b) Represents the arithmetic mean of the month-end balances for the period
outstanding.
(c) The weighted average interest rate during the year was determined by
dividing annual interest expense on short-term borrowings by average
short-term borrowings.
S-5
<PAGE>
Exhibit 3b
BRISTOL-MYERS SQUIBB COMPANY
BYLAWS
As Adopted on November 1, 1965
And as Amended to May 4, 1993
E-1-1
<PAGE>
I N D E X
BYLAW NO. SUBJECT Page No.
- --------- ------- --------
1. Principal Office...........................................E-1-5
2. Other Offices..............................................E-1-5
3. Seal.......................................................E-1-5
4. Meetings of Shareholders -- Date and Time..................E-1-5
5. Meetings of Shareholders -- Place..........................E-1-5
6. Meetings of Shareholders -- No Action By Written
Consent, Call.........................................E-1-5
7. Meetings of Shareholders -- Notice.........................E-1-5
8. Meetings of Shareholders -- Quorum.........................E-1-6
9. Meetings of Shareholders -- Presiding Officer
and Secretary.........................................E-1-6
10. Meetings of Shareholders -- Voting.........................E-1-6
11. Meetings of Shareholders -- Voting List....................E-1-7
12. Annual Meeting of Shareholders -- Statement of Business
and Condition of Company..............................E-1-7
13. Meetings of Shareholders -- Inspectors of Election.........E-1-7
14. Board of Directors -- Powers...............................E-1-7
15. Board of Directors -- Number, Election, Term, Resignation
or Retirement, Removal and Filling Vacancies..........E-1-7
16. Board of Directors -- Location of Meetings and Books.......E-1-9
17. Board of Directors -- Scheduling of Regular Meetings.......E-1-9
18. Board of Directors -- Scheduling of Special Meetings.......E-1-9
19. Board of Directors -- Waiver of Meeting Notice and
Action by Consent.....................................E-1-9
20. Board of Directors -- Quorum for Meeting...................E-1-9
21. Board of Directors -- Meeting Procedure....................E-1-9
E-1-2
<PAGE>
BYLAW NO. SUBJECT Page No.
- --------- ------- --------
22. Board of Directors -- Fees.................................E-1-10
23. Board of Directors -- Indemnification......................E-1-10
24. Committees of the Board -- Executive, Audit, Others........E-1-11
25. Committees of the Board -- Minutes and Reports.............E-1-12
26. Officers...................................................E-1-12
27. Officers -- Election and Term..............................E-1-13
28. Appointment of Other Officers, Committees or Agents........E-1-13
29. Officers -- Removal........................................E-1-13
30. Officers -- Resignation....................................E-1-13
31. Officers -- Unable to Perform Duties.......................E-1-13
32. Officers -- Vacancy........................................E-1-13
33. The Chairman of the Board -- Powers and Duties.............E-1-14
34. Vice Chairman of the Board -- Powers and Duties............E-1-14
35. Duties of President........................................E-1-14
36. Vice Presidents -- Powers and Duties.......................E-1-14
37. The Treasurer -- Powers and Duties.........................E-1-14
38. The Secretary -- Powers and Duties.........................E-1-14
39. The Controller -- Powers and Duties........................E-1-15
40. Assistant Treasurers and Assistant Secretaries -- Powers
and Duties............................................E-1-15
41. Officers -- Compensation...................................E-1-15
42. Contracts, Other Instruments, Authority to
Enter Into or Execute.................................E-1-15
43. Loans and Negotiable Paper.................................E-1-15
44. Checks, Drafts, etc........................................E-1-16
45. Banks -- Deposit of Funds..................................E-1-16
46. Stock Certificates -- Form, Issuance.......................E-1-16
47. Stock -- Transfer..........................................E-1-16
E-1-3
<PAGE>
BYLAW NO. SUBJECT Page No.
- --------- ------- --------
48. Stock Certificates -- Loss, Replacement....................E-1-16
49. Record Dates...............................................E-1-17
50. Registered Shareholders....................................E-1-17
51. Fiscal Year................................................E-1-17
52. Notices....................................................E-1-17
53. Notices -- Waiver..........................................E-1-18
54. Amendments of Bylaws.......................................E-1-18
E-1-4
<PAGE>
BYLAWS
of
BRISTOL-MYERS SQUIBB COMPANY
OFFICES.
1. The registered office of the Company shall be in the City of
Wilmington, County of New Castle, State of Delaware, and the name of
the resident agent in charge thereof is The Corporation Trust Company.
2. The Company may also have offices at such place or places as the Board
of Directors may from time to time appoint or the business of the
Company may require.
SEAL.
3. The corporate seal shall have inscribed thereon the name of the
Company, the year of its organization and the words "Corporate Seal,
Delaware." Said seal may be used in causing it or a facsimile thereof
to be impressed or affixed or reproduced or otherwise.
MEETINGS OF SHAREHOLDERS.
4. The annual meeting of the shareholders for the election of directors
and for the transaction of any other proper business, notice of which
was given in the notice of meeting, shall be held at such time as the
Board of Directors may determine. If the annual meeting for the
election of directors is not held on the date designated therefor, the
directors shall cause the meeting to be held as soon thereafter as
convenient.
5. Meetings of the shareholders may be held at such places either within
or without the State of Delaware as the Board of Directors may
determine.
6. Any action required or permitted to be taken by the stockholders of
the Company must be effected at a duly called annual or special
meeting of such stockholders and may not be effected by any consent in
writing by such stockholders. Except as otherwise required by law and
subject to the rights under Article FOURTH of the Certificate of
Incorporation of the Company of the holders of any class or series of
stock having a preference over the Common Stock as to dividends or
upon liquidation, special meetings of stockholders of the Company may
be called only by the Chairman of the Board or by the Board of
Directors pursuant to a resolution approved by a majority of the
entire Board of Directors.
7. Except as hereinafter provided or as may be otherwise required by law,
notice of the place, date and hour of holding each annual and special
meeting of the shareholders shall be in writing and shall be delivered
personally or mailed in a postage prepaid envelope, not less than ten
days before such meeting, to each person who appears on the books of
the Company as a shareholder entitled to vote at such meeting, and to
any shareholders who, by reason of any action proposed at such
meeting, would be entitled to have their shares appraised if such
E-1-5
<PAGE>
action were taken. The notice of every special meeting, besides
stating the time and place of such meeting, shall state briefly the
purpose or purposes thereof; and no business other than that specified
in such notice or germane thereto shall be transacted at the meeting,
except with the unanimous consent in writing of the holders of record
of all of the shares of the Company entitled to vote at such meeting.
Notice of any meeting of shareholders shall not be required to be
given to any shareholder entitled to participate in any action
proposed to be taken at such meeting who shall attend such meeting in
person or by proxy or who before or after any such meeting shall waive
notice thereof in writing or by telegram, cable or wireless. Notice
of any adjourned meeting need not be given.
8. At all meetings of shareholders of the Company, except as otherwise
provided by law, the holders of a majority in number of the
outstanding shares of the Company, present in person or by proxy and
entitled to vote thereat, shall constitute a quorum for the
transaction of business. In the absence of a quorum the holders of a
majority in number of the shares of stock so present or represented
and entitled to vote may adjourn the meeting from time to time until a
quorum is present. At any such adjourned meeting at which a quorum is
present any business may be transacted which might have been
transacted at the meeting as originally called.
9. The Chairman of the Board shall preside as chairman at every meeting
of shareholders. The Chairman of the Board may designate another
officer of the Company or any shareholder to preside as chairman of a
meeting of shareholders in place of the Chairman of the Board and in
the absence of the Chairman of the Board and an officer or shareholder
designated by the Chairman of the Board to preside as chairman of the
meeting, the Board of Directors may designate an officer or
shareholder to preside as chairman of the meeting. In the event the
Chairman of the Board and the Board of Directors fail to so designate
a chairman of the meeting the shareholders may designate an officer or
shareholder as chairman. The Secretary shall act as secretary of the
meeting, or, in the absence of the Secretary, the presiding officer
shall appoint a secretary of the meeting.
10. At each meeting of the shareholders every shareholder of record
entitled to vote thereat shall be entitled to one vote for each share
of the Company standing in that shareholder's name on the books of the
Company provided that no share of stock shall be voted at any election
of directors which shall have been transferred on the books of the
Company later than the record date announced by the Board of Directors
or fixed by operation of these bylaws The vote on shares may be given
by the shareholder entitled thereto in person or by proxy duly
appointed by an instrument in writing subscribed by such shareholder
or that shareholder's duly authorized attorney, and delivered to the
secretary of the meeting; provided, however, that no proxy shall be
valid after the expiration of three years from the date of its
execution unless the shareholder executing it shall have specified
therein the length of time it is to continue in force, which shall be
for some limited period. At all meetings of shareholders, a quorum
being present, all matters, except as otherwise provided by law or by
the Certificate of Incorporation of the Company or these bylaws, shall
be decided by the holders of a majority in number of the shares of
stock of the Company present in person or by proxy and entitled to
vote. A share vote may be by ballot and each ballot shall state the
E-1-6
<PAGE>
name of the shareholder voting and the number of shares owned by that
shareholder and shall be signed by such shareholder or by that
shareholder's proxy. Except as otherwise required by law or by these
bylaws all voting may be viva voce.
11. The Secretary or other officer in charge of the stock ledger of the
Company shall prepare and make at least ten days before every meeting
of shareholders a complete list of the shareholders entitled to vote
at the meeting arranged in alphabetical order and showing the address
of each shareholder and the number of shares registered in the name of
each shareholder. Such list shall be open to the examination of any
shareholder for any purpose germane to the meeting during ordinary
business hours for a period of at least ten days prior to the meeting
either at a place within the city where the meeting is to be held,
which place shall be specified in the notice of the meeting, or if not
so specified at the place where the meeting is to be held. The list
shall also be produced and kept at the time and place of the meeting
during the whole time thereof and may be inspected by any shareholder
who is present. The stock ledger shall be the only evidence as to who
are the shareholders entitled to examine the stock ledger, the list
required by this bylaw, or the books of the Company or to vote in
person or by proxy at any meeting of shareholders.
12. The Board of Directors shall present at each annual meeting, and when
called for by vote of the shareholders at any special meeting of the
shareholders, a full and clear statement of the business and condition
of the Company.
13. At all elections of directors and when otherwise required by law, the
chairman of the meeting shall appoint two inspectors of election. The
inspectors shall be responsible for receiving, tabulating and
reporting the result of the votes taken. No director or candidate for
the office of director shall be appointed such inspector. The
chairman of the meeting shall open and close the polls.
DIRECTORS.
14. The property, business and affairs of the Company shall be managed by
or under the direction of the Board of Directors, which may exercise
all such powers of the Company and do all such lawful acts and things
as are not by statute or by the Certificate of Incorporation or by
these bylaws directed or required to be exercised or done by the
shareholders.
15. (a) The Board of Directors shall consist of eleven directors. Directors
need not be shareholders. The number of directors may be determined
by a majority vote of the entire Board of Directors.
(b) Except as otherwise provided by the Certificate of Incorporation, by
these bylaws or by law, at each meeting of the shareholders for the
election of directors at which a quorum shall be present, the persons
receiving a plurality of the votes cast shall be directors. Such
election shall be by ballot.
(c) The directors, other than those who may be elected by the holders of
any class or series of stock having a preferenceover the Common Stock
as to dividends or upon liquidation, shall be classified, with respect
to the time for which they severally hold office, into three classes,
E-1-7
<PAGE>
as nearly equal in number as possible, as determined by the Board of
Directors, one class to be originally elected for a term expiring at
the annual meeting of stockholders to be held in 1985, another class
to be originally elected for a term expiring at the annual meeting of
stockholders to be held in 1986, and another class to beoriginally
elected for a term expiring at the annual meeting of stockholders to
be held in 1987, with the directors of each class to hold office until
their successors are elected and qualified. At each annual meeting of
the stockholders, the successors of the class of directors whose term
expires at that meeting shall be elected to hold office for a term
expiring at the annual meeting of stockholders held in the third year
following the year of their election. No decrease in the number of
directors constituting the Board of Directors or change in the
restrictions and qualifications for directors shall shorten the term
of any incumbent director.
(d) Except as otherwise provided in the Certificate of Incorporation or in
these bylaws, each director shall continue in office until the
expiration of his term of office and until a successor shall have been
elected and shall have qualified, or until the director shall have
resigned, or, in the case of a director who is an employee of the
Company, until the director shall have resigned from employment with
the Company or the director's employment shall have been terminated by
the Company. In addition, a director who is not an employee of the
Company or who is the Chief Executive Officer of the Company or a
retired Chief Executive Officer of the Company shall retire from the
position of director at the Annual Meeting following attainment of age
70; an employee who is a director of the Company (other than the Chief
Executive Officer or a retired Chief Executive Officer) shall retire
from the position of director on the effective date of the director's
retirement as an employee of the Company. Any director of the Company
may resign at any time by giving written notice to the Chairman of the
Board or to the Secretary of the Company. Such resignation shall take
effect at the time specified therein; and, unless otherwise specified
therein, the acceptance of such resignation shall not be necessary to
make it effective. Exceptions to the requirements for the retirement
of a director may be made by the Board of Directors.
(e) Subject to the rights under Article FOURTH of the Certificate of
Incorporation of any class or series of stock having a preference over
the Common Stock as to dividends or upon liquidation to elect
directors under specified circumstances, any director or entire class
of directors or the entire Board of Directors may be removed from
office, with or without cause, only by the affirmative vote of the
holders of at least 75% of the outstanding shares of stock of the
Company entitled to vote generally in the election of directors,
voting together as a single class.
(f) Subject to the rights under Article FOURTH of the Certificate of
Incorporation of the Company of the holders of any class or series of
stock having a preference over the Common Stock as to dividends or
upon liquidation to elect directors under specified circumstances,
newly created directorships resulting from any increase in the number
of directors and any vacancies on the Board of Directors resulting
from death, resignation, retirement, disqualification, removal or
other cause shall be filled only by the affirmative vote of a majority
of the remaining directors then in office, even though less than a
quorum of the Board of Directors. Any director elected in accordance
E-1-8
<PAGE>
with the preceding sentence shall hold office for the remainder of the
full term of the class of directors in which the new directorship was
created or the vacancy occurred and until such director's successor
shall have been elected and qualified.
16. The directors may hold their meetings and keep the books of the
Company at such place or places as they may from time to time
determine.
17. Regular meetings of the Board of Directors may be held at such time as
may be fixed from time to time by resolution of the Board of
Directors. Unless required by said resolution, notice of any such
meeting need not be given.
18. Special meetings of the Board of Directors shall be held whenever
called by direction of the Chairman of the Board or any of three of
the directors for the time being in office. Notice of each such
special meeting shall be mailed, postage prepaid, to each director,
addressed to the director at the director's residence or usual place
of business, at least two days before the day on which the meeting is
to be held, or shall be sent to the director at such place by
telegraph, cable, or wireless, or be delivered personally or by
telephone, not later than the day before the day on which the meeting
is to be held. Every such notice shall state the time and place but,
except as provided by these bylaws or by resolution of the Board of
Directors, need not state the purposes of the meetings.
19. Anything in these bylaws or in any resolution adopted by the Board of
Directors to the contrary notwithstanding, notice of any meeting of
the Board of Directors need not be given to any director, if, before
or after any such meeting, notice thereof shall be waived by such
director in writing or by telegraph, cable or wireless. Any meeting
of the Board of Directors shall be a legal meeting without any notice
having been given or regardless of the giving of any notice or the
adoption of any resolution in reference thereto, if all the directors
shall be present thereat or shall have so waived notice thereof. Any
action required or permitted to be taken at any meeting of the Board
of Directors may be taken without a meeting, if prior to such action a
written consent thereto is signed by all members of the Board and such
written consent is filed with the minutes of proceedings of the Board
of Directors.
20. Five of the directors in office at the time of any regular or special
meeting of the Board of Directors shall constitute a quorum for the
transaction of business at such meeting and except as may be otherwise
specifically provided by statute or by the Certificate of
Incorporation or by these bylaws, the act of a majority of the
directors present at any such meeting at which a quorum is present
shall be the act of the Board of Directors. In the absence of a
quorum a majority of the directors present may adjourn any meeting
from time to time until a quorum is present. Notice of any adjourned
meeting need not be given. The directors shall act only as a board
and the individual directors shall have no power as such.
21. At each meeting of the Board of Directors the Chairman of the Board
shall preside. The Chairman of the Board may designate another member
of the Board of Directors to preside as chairman of a meeting in place
of the Chairman of the Board and in the absence of the Chairman of the
E-1-9
<PAGE>
Board and any member of the Board of Directors designated by the
Chairman of the Board to preside as chairman of the meeting a majority
of the directors present may designate a member of the Board of
Directors as chairman to preside at the meeting. The Secretary of the
Company or, in the absence of the Secretary, a person appointed by the
chairman of the meeting, shall act as secretary of the Board of
Directors. The Board of Directors may adopt such rules and
regulations for the conduct of their meetings and the management of
the affairs of the Company as they shall deem proper and not
inconsistent with the law or with these bylaws. At all meetings of
the Board of Directors business shall be transacted in such order as
the Board of Directors may determine.
22. Each director shall be paid such fee, if any, for each meeting of the
Board attended and/or such annual fee as shall be determined from time
to time by resolution of the Board of Directors, provided that nothing
herein contained shall be construed to prevent any director from
serving the Company in any other capacity and receiving compensation
therefor.
23. (a)Definitions. As used herein, the term "director" shall include each
present and former director of the Company and the term "officer" shall
include each present and former officer of the Company as such, and the
terms "director" and "officer" shall also include each employee of the
Company, who, at the Company's request, is serving or may have served as a
director or officer of another corporation in which the Company owns
directly or indirectly, shares of capital stock or of which it is a
creditor. The term "officer" also includes each assistant or divisional
officer. The term "expenses" shall include, but not be limited to,
reasonable amounts for attorney's fees, costs, disbursements and other
expenses and the amount or amounts of judgments, fines, penalties and
other liabilities.
(b)Indemnification Granted. Each director and officer shall be and hereby
is indemnified by the Company, to the full extent permitted by law,
against:
(i)Expenses incurred or paid by the director or officer in connection
with any claim made against such director or officer, or any actual or
threatened action, suit or proceeding (civil, criminal, administrative,
investigative or other, including appeals and whether or not relating to a
date prior to the adoption of this bylaw) in which such director or
officer may be involved as a party or otherwise, by reason of being or
having been a director or officer of the Company, or of serving or having
served at the request of the Company as a director, officer, employee, or
agent of another corporation, partnership, joint venture, trust or other
enterprise, or by reason of any action taken or not taken by such director
or officer in such capacity, and (ii) the amount or amounts paid by
thedirector or officer in settlement of any such claim, action, suit or
proceeding or any judgment or order entered therein, however,
notwithstanding anything to the contrary herein where a director or
officer seeks indemnification in connection with a proceeding voluntarily
initiated by such director or officer the right to indemnification granted
hereunder shall be limited to proceedings where such director or officer
has been wholly successful on the merits.
E-1-10
<PAGE>
(c)Miscellaneous.
(i)Expenses incurred and amounts paid in settlement with respect to
any claim, action, suit or proceeding of the character described in
paragraph (b)(i) above may be advanced by the Company prior to the final
disposition thereof upon receipt of an undertaking by or on behalf of the
recipient to repay such amounts as shall not ultimately be determined to
be payable to such recipient under this bylaw.
(ii)The rights of indemnification herein provided for shall be
severable, shall not be exclusive of other rights to which any director or
officer now or hereafter may be entitled, shall continue as to a person
who has ceased to be an indemnified person and shall inure to the benefit
of the heirs, executors, administrators and other legal representatives of
such a person.
(iii)The provisions of this bylaw shall be deemed to be a contract
between the Company and each director or officer who serves in such
capacity at any time while such bylaw is in effect.
(iv)The Board of Directors shall have power on behalf of the Company to
grant indemnification to any person other than a director or officer to
such extent as the Board in its discretion may from time to time
determine.
COMMITTEES OF THE BOARD.
24. (a)The Board of Directors may, by resolution or resolutions, passed by a
majority of the whole Board of Directors, designate an Executive Committee
(and may discontinue the same at any time) to consist of three or more of
the Directors of the Company. The members shall be appointed by the
Board of Directors and shall hold office during the pleasure of the Board
of Directors; provided, however, that in the absence or disqualification
of any member of the Executive Committee, the member or members thereof
present at any meeting and not disqualified from voting, whether or not
the member or members constitute a quorum, may unanimously appoint another
member of the Board of Directors to act at the meeting in the place of any
such absent or disqualified member. The Executive Committee shall have
and may exercise, during the intervals between the meetings of the Board
of Directors, all of the powers of the Board of Directors in the
management of the business and affairs of the Company (and shall have
power to authorize the seal of the Company to be affixed to all papers
which may require it), except that the Executive Committee shall have no
power to (i) elect Directors to fill any vacancies or appoint any
officers; (ii) fix the compensation of any officer or the compensation of
any Director for serving on the Board of Directors or on any committee;
(iii) declare any dividend or make any other distribution to the
shareholders of the Company; (iv) submit to shareholders any action that
needs shareholder authorization; (v) amend or repeal the bylaws or adopt
any new bylaw; (vi) amend or repeal any resolution of the Board of
Directors which by its terms shall not be so amendable or repealable;
(vii) take any final action with respect to the acquisition or disposition
of any business at a price in excess of $20,000,000.
(b)The Board of Directors shall, by resolution or resolutions, passed by
E-1-11
<PAGE>
a majority of the whole Board of Directors designate an Audit
Committee to consist of three or more non-employee directors of the
Company free from any relationship that, in the opinion of the Board
of Directors, would interfere with the exercise of independent
judgment as a Committee member. Any director who is a former
employee of the Company may not serve on the Audit Committee. The
members of the Audit Committee shall be appointed by and hold office
during the pleasure of the Board of Directors. A majority of the
members of the Audit Committee will constitute a quorum for the
transaction of business. It shall be the duty of the Audit Committee
(i) to recommend to the Board of Directors a firm of independent
accountants to perform the examination of the annual financial
statements of the Company; (ii) to review with the independent
accountants and with the Controller the proposed scope of the annual
audit, past audit experience, the Company's internal audit program,
recently completed internal audits and other matters bearing upon the
scope of the audit; (iii) to review with the independent accountants
and with the Controller significant matters revealed in the course of
the audit of the annual financial statements of the Company; (iv) to
review on an annual basis that the Company's Statement of Business
Conduct and Corporate Policies relating thereto has been communicated
by the Company to all key employees of the Company and its
subsidiaries throughout the world with a direction that all such key
employees certify that they have read, understand and are not aware of
any violation of the Statement of Business Conduct; (v) to review with
the Controller any suggestions and recommendations of the independent
accountants concerning the internal control standards and the
accounting procedures of the Company; (vi) to meet on a regular basis
with a representative or representatives of the Internal Audit
Department of the Company and to review the Internal Audit
Department's Reports of Operations; (vii) to report its activities and
actions to the Board of Directors at least once each fiscal year.
(c) The Board of Directors may, by resolution or resolutions passed by a
majority of the whole Board of Directors, designate such other
committees as may be deemed advisable (and may discontinue the same at
any time), to consist of two or more of the directors of the Company.
The members shall be appointed by and shall hold office during the
pleasure of the Board of Directors, and the Board of Directors shall
prescribe the name or names of such committees, the number of their
members and their duties and powers.
(d) Any action required or permitted to be taken at any meeting of any
committee may be taken without a meeting, if prior to such action a
written consent thereto is signed by all members of the committee and
such written consent is filed with the minutes of proceedings of the
committee.
25. All committees shall keep written minutes of their proceedings and
report the same to the Board of Directors when required.
OFFICERS.
26. The officers of the Company shall be a Chairman of the Board, a Vice
Chairman of the Board, a President, two or more Vice Presidents (which
shall include Senior Vice President, Executive Vice President and
other Vice President titles), a Treasurer, a Secretary, a Controller,
and such other officers as may be appointed in accordance with these
E-1-12
<PAGE>
bylaws. The Secretary and Treasurer may be the same person, or a Vice
President may hold at the same time the office of Secretary,
Treasurer, or Controller.
27. The officers of the Company shall be chosen by the Board of Directors.
Each officer shall hold office until a successor shall have been duly
chosen and shall have qualified or until the death or retirement of
the officer or until the officer shall resign or shall have been
removed in the manner hereinafter provided. The Chairman of the Board
and the Vice Chairman of the Board shall be chosen from among the
directors.
28. The Board of Directors may appoint such other officers, committees or
agents, as the business of the Company may require, including one or
more Assistant Treasurers and one or more Assistant Secretaries, each
of whom shall hold office for such period, and have such authority and
perform such duties as are provided in these bylaws or as the Board of
Directors may from time to time determine. The Board of Directors may
delegate to any officer or committee the power to appoint and to
remove any such subordinate officer or agent.
29. Subject to the provisions of any written agreement, any officer may be
removed, either with or without cause, by a vote of the majority of
the whole Board of Directors at a regular meeting or a special meeting
called for the purpose. Any officer, except an officer elected by the
Board of Directors, may also be removed, with or without cause, by any
committee or superior officer upon whom such power of removal may be
conferred by the Board of Directors.
30. Subject to the provisions of any written agreement, any officer may
resign at any time by giving written notice to the Board of Directors,
the Chairman of the Board or the Secretary of the Company. Any such
resignation shall take effect at the time specified therein; and,
unless otherwise specified therein, the acceptance of such resignation
shall not be necessary to make it effective.
31. Except as otherwise provided in these bylaws, in the event any officer
shall be unable to perform the duties of the office held, whether by
reason of absence, disability or otherwise, the Chairman of the Board
may designate another officer of the Company to assume the duties of
the officer who is unable to carry out the duties of the office; in
the event the Chairman of the Board shall be absent and unable to
perform the duties of the office of Chairman of the Board, the
Chairman of the Board shall designate another officer to assume the
duties of the Chairman of the Board; if another officer has not been
designated by the Chairman of the Board to assume the duties of the
Chairman of the Board, then the Board of Directors shall designate
another officer to assume the duties of the Chairman of the Board; in
the event the Chairman of the Board shall be disabled and unable to
perform the duties of the office of Chairman of the Board, then the
Board of Directors shall designate another officer to assume the
duties of the Chairman of the Board. Any officer designated to assume
the duties of another officer shall have all the powers of and be
subject to all the restrictions imposed upon the officer whose duties
have been assumed.
32. A vacancy in any office because of death, resignation, removal,
disqualification or any other cause shall be filled for the unexpired
E-1-13
<PAGE>
portion of the term in the manner prescribed by these bylaws for the
regular appointment or election to such office.
33. The Chairman of the Board shall be the chief executive officer of the
Company and shall have general supervision of the business and
operations of the Company, subject, however, to the control of the
Board of Directors. The Chairman of the Board shall preside at all
meetings of the shareholders and of the Board of Directors. The
Chairman of the Board shall perform all of the duties usually
incumbent upon a chief executive officer of a corporation and incident
to the office of the Chairman of the Board. The Chairman of the Board
shall also have such powers and perform such duties as are assigned by
these bylaws and shall have such other powers and perform such other
duties, not inconsistent with these bylaws, as may from time to time
be assigned by the Board of Directors.
34. The Vice Chairman shall have such powers and perform such duties as
are assigned by these bylaws and shall have such other powers and
perform such other duties, not inconsistent with these bylaws, as from
time to time may be assigned by the Board of Directors or the Chairman
of the Board.
35. The President shall have such powers and perform such duties as are
assigned by these bylaws and shall have such other powers and perform
such other duties, not inconsistent with these bylaws, as from time to
time may be assigned by the Board of Directors or the Chairman of the
Board.
36. Each Vice President shall have such powers and perform such duties as
are assigned by these bylaws and shall have such other powers and
perform such other duties, not inconsistent with these bylaws, as from
time to time may be assigned by the Board of Directors or the Chairman
of the Board.
37. The Treasurer shall have charge and custody of, and be responsible
for, all funds of the Company. The Treasurer shall regularly enter or
cause to be entered in books to be kept by the Treasurer or under the
Treasurer's direction for this purpose full and adequate account of
all moneys received or paid by the Treasurer for the account of the
Company; the Treasurer shall exhibit such books of account and records
to any of the directors of the Company at any time upon request at the
office of the Company where such books and records shall be kept and
shall render a detailed statement of these accounts and records to the
Board of Directors as often as it shall require the same. The
Treasurer shall also have such powers and perform such duties as are
assigned the Treasurer by these bylaws and shall have such other
powers and perform such other duties, not inconsistent with these
bylaws, as from time to time may be assigned by the Board of
Directors.
38. It shall be the duty of the Secretary to act as Secretary of all
meetings of the Board of Directors and of the shareholders of the
Company, and to keep the minutes of all such meetings in the proper
book or books to be provided for that purpose Secretary shall see that
all notices required to be given by or for the Company or the Board of
Directors or any committee are duly given and served; the Secretary
shall be custodian of the seal of the Company and shall affix the
seal, or cause it to be affixed, to all documents, the execution of
E-1-14
<PAGE>
which on behalf of the Company, under its seal shall have been duly
authorized in accordance with the provisions of these bylaws. The
Secretary shall have charge of the share records and also of the other
books, records, and papers of the Company relating to its organization
and management as a corporation and shall see that the reports,
statements and other documents required by law are properly kept and
filed; and shall in general perform all the duties usually incident to
the office of Secretary. The Secretary shall also have such powers
and perform such duties as are assigned by these bylaws, and shall
have such other powers and perform such other duties, not inconsistent
with these bylaws, as from time to time may be assigned by the Board
of Directors.
39. The Controller shall perform the usual duties pertaining to the office
of the Controller. The Controller shall have charge of the
supervision of the accounting system of the Company, including the
preparation and filing of all reports required by law to be made to
any public authorities and officials, and shall also have such powers
and perform such duties, not inconsistent with these bylaws, as from
time to time may be assigned by the Board of Directors.
40. The Assistant Treasurers and the Assistant Secretaries shall have such
powers and perform such duties as are assigned to them by these bylaws
and shall have such other powers and perform such other duties, not
inconsistent with these bylaws, as from time to time may be assigned
to them by the Treasurer or the Secretary, respectively, or by the
Board of Directors.
41. The compensation of the Chairman of the Board, Vice Chairman of the
Board, President, Vice President, Treasurer, Secretary and Controller
shall be fixed by the Board of Directors. The compensation of such
other officers as may be appointed in accordance with the provisions
of these bylaws may be fixed by the Chairman of the Board. No officer
shall be prevented from receiving such compensation by reason of also
being a director of the Company.
CONTRACTS, CHECKS, DRAFTS, BANK ACCOUNTS, ETC.
42. The Board of Directors except as in these bylaws otherwise provided,
may authorize any officer or officers, agent or agents, in the name of
and on behalf of the Company, to enter into any contract or execute
and deliver any instrument, and such authority may be general or
confined to specific instances; and, unless so authorized by the Board
of Directors or expressly authorized by these bylaws, no officer or
agent or employee shall have any power or authority to bind the
Company by any contract or engagement or to pledge its credit or to
render it pecuniarily liable for any purpose or to any amount.
43. No loans shall be contracted on behalf of the Company and no
negotiable paper shall be issued in its name unless authorized by
resolution of the Board of Directors. When authorized by the Board of
Directors, any officer or agent of the Company thereunto authorized
may effect loans and advances at any time for the Company from any
bank, trust company, or other institution, or from any firm,
corporation or individual, and for such loans and advances may make,
execute and deliver promissory notes, bonds, or other certificates or
evidences of indebtedness of the Company and, when authorized so to
E-1-15
<PAGE>
do, may pledge, hypothecate or transfer any securities or other
property of the Company as security for any such loans or advances.
Such authority may be general or confined to specified instances.
44. All checks, drafts and other orders for the payment of moneys out of
the funds of the Company and all notes or other evidences of
indebtedness of the Company shall be signed on behalf of the Company
in such manner as shall from time to time be determined by resolution
of the Board of Directors.
45. All funds of the Company not otherwise employed shall be deposited
from time to time to the credit of the Company in such banks, trust
companies or other depositories as the Board of Directors may select
or as may be selected by any officer or officers, agent or agents of
the Company to whom such power may from time to time be delegated by
the Board of Directors; and for the purpose of such deposit, the
Chairman of the Board, the Vice Chairman of the Board, the President,
a Vice President, the Treasurer, the Controller, the Secretary or any
other officer or agent or employee of the Company to whom such power
may be delegated by the Board of Directors, may endorse, assign and
deliver checks, drafts and other orders for the payment of moneys
which are payable to the order of the Company.
CERTIFICATES AND TRANSFERS OF SHARES.
46. Certificates for shares of the Company shall be in such form as shall
be approved by the Board of Directors. Such certificates shall be
numbered and registered in the order in which they are issued and
shall be signed by the Chairman of the Board, the Vice Chairman of
the Board, the President or a Vice President and the Secretary or an
Assistant Secretary or the Treasurer or an Assistant Treasurer. Where
any such certificate is countersigned by a transfer agent, other than
the Company or its employee, or by a registrar, other than the Company
or its employee, any other signature on such certificate may be a
facsimile, engraved, stamped or printed. In the event that an officer
whose facsimile signature appears on such certificate ceases for any
reason to hold the office indicated and the Company or its transfer
agent has on hand a supply of share certificates bearing such
officer's facsimile signature, such certificates may continue to be
issued and registered until such supply is exhausted.
47. Transfers of shares of the Company shall be made only on the books of
the Company by the holder thereof, or by the holder's attorney
thereunto duly authorized and on surrender of the certificate or
certificates for such shares properly endorsed. Every certificate
surrendered to the Company shall be marked "Cancelled," with the date
of cancellation, and no new certificate shall be issued in exchange
therefor until the old certificate has been surrendered and cancelled,
except as hereinafter provided.
48. The holder of any shares of the Company shall immediately notify the
Company of any loss, destruction or mutilation of the certificate
therefor and the Company may issue a new certificate in the place of
any certificate theretofore issued by it alleged to have been lost,
destroyed or mutilated. The Board of Directors may, in its
discretion, as conditions to the issue of any such new certificate,
require the owner of the lost or destroyed certificate or the owner's
E-1-16
<PAGE>
legal representatives to make proof satisfactory to the Board of
Directors of the loss or destruction thereof and to give the Company a
bond in such form, in such sum and with such surety or sureties as the
Board of Directors may direct, to indemnify the Company against any
claim that may be made against it on account of any such certificate
so alleged to have been lost or destroyed.
DETERMINATION OF RECORD DATE.
49. In order that the Company may determine the shareholders entitled to
notice of or to vote at any meeting of shareholders or any adjournment
thereof or entitled to receive payment of any dividend or other
distribution or allotment of any rights or entitled to exercise any
rights in respect of any change, conversion or exchange of stock or
for the purpose of any other lawful action, the Board of Directors may
fix in advance a record date which shall not be more than 60 nor less
than 10 days before the date of such meeting nor more than 60 days
prior to any other action.
If no record date is fixed:
(i) The record date for determining shareholders entitled to notice of or
to vote at a meeting of shareholders shall be at the close of business
on the day next preceding the day on which notice is given, or if
notice is waived, at the close of business on the day next preceding
the day on which the meeting is held.
(ii) The record date for determining shareholders for any other purpose
shall be at the close of business on the day on which the Board of
Directors adopts the resolution relating thereto. A determination of
shareholders of record entitled to notice of or to vote at a meeting
of shareholders shall apply to any adjournment of the meeting
provided, however, that the Board of Directors may fix a new record
date for the adjourned meeting.
REGISTERED SHAREHOLDERS.
50. The Company shall be entitled to treat the holder of record of any
share or shares of stock as the holder in fact thereof and,
accordingly, shall not be bound to recognize any equitable or other
claim to or interest in such share on the part of any other person,
whether or not it shall have express or other notice thereof, save as
expressly provided by the laws of Delaware.
FISCAL YEAR.
51. The fiscal year shall begin on the first day of January and end on the
thirty-first day of December in each year.
NOTICES.
52. Whenever under the provision of these bylaws notice is required to be
given to any director or shareholder, it shall be construed to mean
personal notice, but such notice may be given in writing, by mail, by
E-1-17
<PAGE>
depositing the same in a post office or letter box, in a postpaid
sealed wrapper, addressed to such director or shareholder at such
address as appears on the books of the Company, or, in default of
other address, to such director or shareholder, at the General Post
Office in the City of Wilmington, Delaware, and such notice shall be
deemed to be given at the time when the same shall be thus mailed.
53. Any notice required to be given under these bylaws may be waived in
writing, signed by the person or persons entitled to said notice,
whether before or after the time stated therein.
AMENDMENTS.
54. Except as otherwise provided in the Certificate of Incorporation of
the Company and consistent therewith, these bylaws may be altered,
amended or repealed or new bylaws may be made by the affirmative vote
of the holders of record of amajority of the shares of the Company
entitled to vote, at any annual or special meeting, provided that such
proposed action shall be stated in the notice of such meeting, or, by
a vote of the majority of the whole Board of Directors, at any regular
meeting without notice, or at any special meeting provided that notice
of such proposed action shall be stated in the notice of such special
meeting.
E-1-18
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY Exhibit 10a
1983 STOCK OPTION PLAN
(As Amended and Restated effective January 1, 1993)
(As Amended to September 14, 1993)
1. Purpose:The purpose of the 1983 Stock Option Plan (as amended and restated
as of January 1, 1993) (the "Plan") is to secure for the Company and its
stockholders the benefits of the incentive inherent in common stock
ownership by the officers and key employees of the Company and its
Subsidiaries and Affiliates who will be largely responsible for the
Company's future growth and continued financial success and by providing
long-term incentives in addition to current compensation to certain key
executives of the Company and its Subsidiaries and Affiliates who
contribute significantly to the long-term performance and growth of the
Company and such Subsidiaries and Affiliates. It is intended that the
former purpose will be effected through the grant of stock options and
stock appreciation rights under the Plan and that the latter purpose will
be effected through an award conditionally granting performance units under
the Plan, either independently or in conjunction with and related to a
nonqualified stock option grant under the Plan. The Bristol-Myers Squibb
Company Long-Term Performance Award Plan (as amended to January 17, 1983
and in effect as of December 31, 1992) ("LTPAP") has been merged into and
consolidated with the Plan as of January 1, 1993. As used herein, the term
"Prior Plan" shall mean the Bristol-Myers Squibb Company 1983 Stock Option
Plan (as amended through May 1, 1991 and in effect as of December 31, 1992)
prior to its amendment and restatement as of January 1, 1993.
2. Definitions:For purposes of this Plan:
(a)"Affiliate" shall mean any entity in which the Company has an ownership
interest of at least 20%.
(b)"Code" shall mean the Internal Revenue Code of 1986, as amended.
(c)"Common Stock" shall mean the Company's common stock (par value $.10 per
share).
(d)"Company" shall mean Bristol-Myers Squibb Company.
(e)"Disability" or "Disabled" shall mean qualifying for and receiving
payments under a disability pay plan of the Company or any Subsidiary or
Affiliate.
(f)"Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
(g)"Fair Market Value" shall mean the average of the high and low sale
prices of a share of Common Stock on the New York Stock Exchange, Inc.
composite tape on the date of measurement or on any date as determined
E-2-1
<PAGE>
by the Committee and if there were no trades on such date, on the day
on which a trade occurred next preceding such date.
(h) "Retirement" shall mean termination of the employment of an employee
with the Company or a Subsidiary or Affiliate on or after (i) the
employee's 65th birthday or (ii) the employee's 55th birthday if the
employee has completed 10 years of service with the Company, its
Subsidiaries and/or its Affiliates.
Furthermore, an employee who makes an election to retire under Article
19 of the Bristol-Myers Squibb Company Retirement Income Plan (the
"Retirement Income Plan") shall have any additional years of age and
service which are credited under Article 19 of the Retirement Income
Plan taken into account when determining such employee's age and
service under this Section 2(h). Such election shall be deemed a
Retirement for purposes of this Section 2(h) and all other purposes of
this Plan.
(i) "Subsidiary" shall mean any corporation which at the time qualifies as
a subsidiary of the Company under the definition of "subsidiary
corporation" in Section 424 of the Code.
3. Amount of Stock: The amount of stock which may be made subject to grants of
options or awards of performance units under the Plan in
calendar year 1993 shall not exceed an amount equal to (i)
0.9% of the outstanding shares of the Company's Common
Stock on January 1, 1993, plus (ii) the amount of shares
available for, and not made subject to, grants of options
under the Prior Plan as of January 1, 1993, less (iii) the
number of shares subject to options granted in 1993 under
the Prior Plan and (iv) the number of shares corresponding
to awards of performance units outstanding under the LTPAP
on the date the Plan is approved by the stockholders of
the Company. With respect to each succeeding year, the
amount of stock which may be made subject to grants of
options or awards of performance units under the Plan
shall not exceed an amount equal to (i) 0.9% of the
outstanding shares of the Company's Common Stock on
January 1 of such year plus, subject to this Section 3,
(ii) in any year the number of shares equal to the amount
of shares that were available for grants and awards in the
prior year but were not made subject to a grant or award
in such prior year and (iii) the number of shares that
were subject to options or awards granted hereunder or
under the Prior Plan, which options or awards terminated
or expired in the prior year without being exercised.
Common Stock issued hereunder may be authorized and
reissued shares or issued shares acquired by the Company
or its Subsidiaries on the market or otherwise.
4. Administration: The Plan shall be administered under the supervision of
the Board of Directors of the Company which shall exercise
its powers, to the extent herein provided, through the
agency of a Compensation and Management Development
Committee (the "Committee") which shall be appointed by
the Board of Directors of the Company and shall consist of
not less than three directors who shall serve at the
pleasure of the Board. No member of the Committee shall
E-2-2
<PAGE>
have been within one year prior to appointment to, or
while serving on, the Committee granted or awarded equity
securities of the Company pursuant to this or any other
plan of the Company or its Subsidiaries or Affiliates
except to the extent that participation in any such plan
or receipt of any such grant or award would not adversely
affect the Committee member's status as a disinterested
person for purposes of Rule 16b-3 under the Exchange Act.
The Committee, from time to time, may adopt rules and
regulations for carrying out the provisions and purposes
of the Plan and make such other determinations, not
inconsistent with the terms of the Plan, as the Committee
shall deem appropriate. The interpretation and
construction of any provision of the Plan by the Committee
shall, unless otherwise determined by the Board of
Directors, be final and conclusive.
The Committee shall maintain a written record of its
proceedings. A majority of the Committee shall constitute
a quorum, and the acts of a majority of the members
present at any meeting at which a quorum is present, or
acts unanimously approved in writing, shall be the acts of
the Committee.
5. Eligibility: Options and awards may be granted only to present or
future officers and key employees of the Company and its
Subsidiaries and Affiliates, including Subsidiaries and
Affiliates which become such after the adoption of the
Plan. Any officer or key employee of the Company or of
any such Subsidiary or Affiliate shall be eligible to
receive one or more options or awards under the Plan. Any
director who is not an officer or employee of the Company
or one of its Subsidiaries or Affiliates and any member of
the Committee, during the time of the member's service as
such or thereafter, shall be ineligible to receive an
option or award under the Plan. The adoption of this Plan
shall not be deemed to give any officer or employee any
right to an award or to be granted an option to purchase
Common Stock of the Company, except to the extent and upon
such terms and conditions as may be determined by the
Committee.
6. Stock Options: Stock options under the Plan shall consist of incentive
stock options under Section 422 of the Code or
nonqualified stock options (options not intended to
qualify as incentive stock options), as the Committee
shall determine. In addition, the Committee may grant
stock appreciation rights in conjunction with an option,
as set forth in Section 6(b)(11), or may grant awards in
conjunction with an option, as set forth in Section
6(b)(10) (an "Associated Option").
Each option shall be subject to the following terms and conditions:
(a) Grant of Options. The Committee shall (1) select the officers and key
employees of the Company and its Subsidiaries and Affiliates to whom
options may from time to time be granted, (2) determine whether
E-2-3
<PAGE>
incentive stock options or nonqualified stock options, are to be
granted, (3) determine the number of shares to be covered by each
option so granted, (4) determine the terms and conditions (not
inconsistent with the Plan) of any option granted hereunder (including
but not limited to restrictions upon the options, conditions of their
exercise, or on the shares of Common Stock issuable upon exercise
thereof), (5) determine whether nonqualified stock options or incentive
stock options granted under the Plan shall include stock appreciation
rights and, if so, shall determine the terms and conditions thereof in
accordance with Section 6(b)(11) hereof, (6) determine whether any
nonqualified stock options granted under the Plan shall be Associated
Options, and (7) prescribe the form of the instruments necessary or
advisable in the administration of options.
(b) Terms and Conditions of Option. Any option granted under the Plan
shall be evidenced by a Stock Option Agreement executed by the Company
and the optionee, in such form as the Committee shall approve, which
agreement shall be subject to the following terms and conditions and
shall contain such additional terms and conditions not inconsistent
with the Plan, and in the case of an incentive stock option not
inconsistent with the provisions of the Code applicable to incentive
stock options, as the Committee shall prescribe:
(1) Number of Shares Subject to an Option. The Stock Option Agreement
shall specify the number of shares of Common Stock subject to the
Agreement. If the option is an Associated Option, the number of shares
of Common Stock subject to such Associated Option shall initially be
equal to the number of performance units subject to the award, but one
share of Common Stock shall be canceled for each performance unit paid
out under the award.
(2) Option Price. The purchase price per share of Common Stock purchasable
under an option will be determined by the Committee but will be not
less than the Fair Market Value of a share of Common Stock on the date
of the grant of such option.
(3) Option Period. The period of each option shall be fixed by the
Committee, but no option shall be exercisable after the expiration of
ten years from the date the option is granted.
(4) Consideration. Each optionee, as consideration for the grant of an
option, shall remain in the continuous employ of the Company or of one
of its Subsidiaries or Affiliates for at least one year from the date
of the granting of such option, and no option shall be exercisable
until after the completion of such one year period of employment by the
optionee.
(5) Exercise of Option. An option may be exercised in whole or in part
from time to time during the option period (or, if determined by the
Committee, in specified installments during the option period) by
giving written notice of exercise to the Company specifying the number
of shares to be purchased, such notice to be accompanied by payment in
full of the purchase price and Withholding Taxes (as defined in Section
10 hereof) due either by certified or bank check, or in shares of
Common Stock of the Company owned by the optionee having a Fair Market
Value at the date of exercise equal to such purchase price and
Withholding Taxes due, or in a combination of the foregoing; provided,
however, that payment in shares of Common Stock of the Company will not
E-2-4
<PAGE>
be permitted unless at least 100 shares of Common Stock are required
and delivered for such purpose. No shares shall be issued until full
payment therefor has been made. An optionee shall have the rights of a
stockholder only with respect to shares of stock for which certificates
have been issued to the optionee.
(6) Nontransferability of Options. No option or stock appreciation right
granted under the Plan shall be transferable by the optionee otherwise
than by will or by the laws of descent and distribution, and such
option or stock appreciation right shall be exercisable, during the
optionee's lifetime, only by the optionee.
(7) Retirement and Termination of Employment Other than by Death or
Disability. If an optionee shall cease to be employed by the Company
or any of its Subsidiaries or Affiliates for any reason (other than
termination of employment by reason of death or Disability) after the
optionee shall have been continuously so employed for one year after
the granting of the option, the option shall be exercisable only to the
extent that the optionee was otherwise entitled to exercise it at the
time of such cessation of employment with the Company, Subsidiary or
Affiliate, but in no event after the expiration of the option period
set forth therein except that in the case of cessation of employment
other than by reason of Retirement or death, the option shall in no
event be exercisable after the date three months next succeeding such
cessation of employment. The Plan does not confer upon any optionee
any right with respect to continuation of employment by the Company or
any of its Subsidiaries or Affiliates.
(8) Disability of Optionee. An optionee who ceases to be employed by
reason of Disability shall be treated as though the optionee remained
in the employ of the Company or a Subsidiary or Affiliate until the
earlier of (i) cessation of payments under a disability pay plan of the
Company, Subsidiary or Affiliate, (ii) the optionee's death, or (iii)
the optionee's 65th birthday.
(9) Death of Optionee. In the event of the death of the optionee while in
the employ of the Company or of any of its Subsidiaries or Affiliates
or within whichever period after Retirement or cessation of employment
of the optionee specified in subsection (7) or (8) is applicable, and
provided the optionee shall have been continuously so employed for one
year after the granting of the option, the option shall be exercisable
by the executors, administrators, legatees or distributees of the
optionee's estate, as the case may be, at any time following death but
in no event after the expiration of the option period set forth therein
and only to the extent that the optionee would otherwise have been
entitled to exercise it if the optionee were then living, except that
in the case of the death of an optionee after Retirement or other
cessation of employment, the option shall in no event be exercisable
after the later of (i) the date twelve months next succeeding such
death or (ii) the last day of the period after Retirement or other
cessation of employment of the optionee specified in Section 6(b)(7).
In the event any option is exercised by the executors, administrators,
legatees or distributees of the estate of a deceased optionee, the
Company shall be under no obligation to issue stock thereunder unless
and until the Company is satisfied that the person or persons
exercising the option are the duly appointed legal representatives of
the deceased optionee's estate or the proper legatees or distributees
thereof.
E-2-5
<PAGE>
(10) Long Term Performance Awards. The Committee may from time to time
grant nonqualified stock options under the Plan in conjunction with and
related to an award of performance units made under a Long Term
Performance Award as set forth in Section 7(b)(11). In such event,
notwithstanding any other provision hereof, (i) the number of shares to
which the Associated Option applies shall initially be equal to the
number of performance units granted by the award, but such number of
shares shall be reduced on a one share-for-one unit basis to the extent
that the Committee determines pursuant to the terms of the award, to
pay to the optionee or the optionee's beneficiary the performance units
granted pursuant to such award; and (ii) such Associated Option shall
be cancelable in the discretion of the Committee, without the consent
of the optionee, under the conditions and to the extent specified in
the award.
(11) Stock Appreciation Rights. In the case of any option granted under the
Plan, either at the time of grant or by amendment of such option at any
time after such grant there may be included a stock appreciation right
which shall be subject to such terms and conditions, not inconsistent
with the Plan, as the Committee shall impose, including the following:
(A) A stock appreciation right shall be exercisable to the extent, and only
to the extent, that the option in which it is included is at the time
exercisable, and may be exercised within such period only at such time
or times as may be determined by the Committee;
(B) A stock appreciation right shall entitle the optionee (or any person
entitled to act under the provisions of subsection (9) hereof) to
surrender unexercised the option in which the stock appreciation right
is included (or any portion of such option) to the Company and to
receive from the Company in exchange therefor that number of shares
having an aggregate value equal to (or, in the discretion of the
Committee, less than) the excess of the value of one share (provided
such value does not exceed such multiple of the option price per share
as may be specified by the Committee) over the option price per share
specified in such option times the number of shares called for by the
option, or portion thereof, which is so surrendered. The Committee
shall be entitled to cause the Company to settle its obligation,
arising out of the exercise of a stock appreciation right, by the
payment of cash equal to the aggregate value of the shares the Company
would otherwise be obligated to deliver or partly by the payment of
cash and partly by the delivery of shares. Any such election shall be
made within 30 business days after the receipt by the Committee of
written notice of the exercise of the stock appreciation right. The
value of a share for this purpose shall be the Fair Market Value
thereof on the last business day preceding the date of the election to
exercise the stock appreciation right;
(C) No fractional shares shall be delivered under this subsection (11) but
in lieu thereof a cash adjustment shall be made;
(D) If a stock appreciation right included in an option is exercised, such
option shall be deemed to have been exercised to the extent of the
number of shares called for by the option or portion thereof which is
surrendered on exercise of the stock appreciation right and no new
option may be granted covering such shares under this Plan; and
(E) If an option which includes a stock appreciation right is exercised,
E-2-6
<PAGE>
such stock appreciation right shall be deemed to have been canceled to
the extent of the number of shares called for by the option or portion
thereof is exercised and no new stock appreciation rights may be
granted covering such shares under this Plan.
(12) Incentive Stock Options. In the case of any incentive stock option
granted under the Plan, the aggregate Fair Market Value of the shares
of Common Stock of the Company (determined at the time of grant of each
option) with respect to which incentive stock options granted under the
Plan and any other plan of the Company or its parent or a Subsidiary
which are exercisable for the first time by an employee during any
calendar year shall not exceed $100,000 or such other amount as may be
required by the Code. In any year, the maximum number of shares with
respect to which incentive stock options may be granted shall not
exceed 4,000,000 shares.
7. Long-term Performance Awards: Awards under the Plan shall consist of
the conditional grant to the participants of a specified number of
performance units. The conditional grant of a performance unit to a
participant will entitle the participant to receive a specified dollar
value, variable under conditions specified in the award, if the
performance objectives specified in the award are achieved and the
other terms and conditions thereof are satisfied.
Each award will be subject to the following terms and conditions:
(a) Grant of Awards. The Committee shall (1) select the officers and key
executives of the Company and its Subsidiaries and Affiliates to whom
awards may from time to time be granted, (2) determine the number of
performance units covered by each award, (3) determine the terms and
conditions of each performance unit awarded and the award period and
performance objectives with respect to each award, (4) determine the
periods during which a participant may request the Committee to approve
deferred payment of a percentage (50% or 100%) of an award (the
"Deferred Portion") and the interest or rate of return thereon or the
basis on which such interest or rate of return thereon is to be
determined, (5) determine whether payment with respect to the portion
of an award which has not been deferred (the "Current Portion") and the
payment with respect to the Deferred Portion of an award shall be made
entirely in cash, entirely in Common Stock or partially in cash and
partially in Common Stock, (6) determine whether the award is to be
made independently of or in conjunction with a nonqualified stock
option granted under the Plan, and (7) prescribe the form of the
instruments necessary or advisable in the administration of the awards.
(b) Terms and Conditions of Award. Any award conditionally granting
performance units to a participant shall be evidenced by a Performance
Unit Agreement executed by the Company and the participant, in such
form as the Committee shall approve, which Agreement shall contain in
substance the following terms and conditions and such additional terms
and conditions as the Committee shall prescribe:
(1) Number of Performance Units. The Performance Unit Agreement shall
specify the number of performance units conditionally granted to the
participant. If the award has been made in conjunction with the grant
of an Associated Option, the number of performance units granted shall
initially be equal to the number of shares which the participant is
granted the right to purchase pursuant to the Associated Option, but
E-2-7
<PAGE>
one performance unit shall be canceled for each share of the Company's
Common Stock purchased upon exercise of the Associated Option or for
each stock appreciation right included in such option that has been
exercised.
(2) Value of Performance Units. The Performance Unit Agreement shall
specify the threshold, target and maximum dollar values of each
performance unit and corresponding performance objectives as provided
under Section 7(b)(5).
(3) Award Periods. For each award, the Committee shall designate an award
period with a duration to be determined by the Committee in its
discretion but in no event less than three calendar years within which
specified performance objectives are to be attained. There may be
several award periods in existence at any one time and the duration of
performance objectives may differ from each other.
(4) Consideration. Each participant, as consideration for the award of
performance units, shall remain in the continuous employ of the Company
or of one of its Subsidiaries or Affiliates for at least one year after
the date of the making of such award, and no award shall be payable
until after the completion of such one year of employment by the
participant.
(5) Performance Objectives. The Committee shall establish performance
objectives with respect to the Company for each award period on the
basis of such criteria and to accomplish such objectives as the
Committee may from time to time determine. Performance objectives may
include objective and subjective criteria. During any award period,
the Committee may adjust the performance objectives for such award
period as it deems equitable in recognition of unusual or nonrecurring
events affecting the Company, changes in applicable tax laws or
accounting principles, or such other factors as the Committee may
determine.
(6) Determination and Payment of Performance Units Earned. As soon as
practicable after the end of an award period, the Committee shall
determine the extent to which awards have been earned on the basis of
the Company's actual performance in relation to the established
performance objectives as set forth in the Performance Unit Agreement.
The Performance Unit Agreement shall specify that as soon as
practicable after the end of each award period, the Committee shall
determine whether the conditions of Sections 7(b)(4) and 7(b)(5) hereof
have been met and, if so, shall ascertain the amount payable to the
participant in respect of the performance units. As promptly as
practicable after it has determined that an amount is payable in
respect of an award, the Committee shall cause the Current Portion of
such award to be paid to the participant or the participant's
beneficiaries, as the case may be, in the Committee's discretion,
either entirely in cash, entirely in Common Stock or partially in cash
and partially in Common Stock. The Deferred Portion of an award shall
be contingently credited and payable to the participant over a deferred
period and shall be credited with interest or a rate of return, as
determined by the Committee. The Committee, in its discretion, shall
determine the conditions upon, and method of, payment of such deferred
portions and whether such payment will be made entirely in cash,
entirely in Common Stock or partially in cash and partially in Common
Stock.
E-2-8
<PAGE>
In making the payment of an award in Common Stock hereunder, the cash
equivalent of such Common Stock shall be determined by the Fair Market
Value of the Common Stock on the day the Committee designates the
performance units shall be paid.
(7) Nontransferability of Awards and Designation of Beneficiaries. No
award under the Plan shall be transferable by the participant other
than by will or by the laws of descent and distribution, except that a
participant may designate a beneficiary pursuant to the provisions
hereof.
If any participant or the participant's beneficiary shall attempt to
assign the participant's rights under the Plan in violation of the
provisions thereof, the Company's obligation to make any further
payments to such participant or the participant's beneficiaries shall
forthwith terminate.
A participant may name one or more beneficiaries to receive any payment
of an award to which the participant may be entitled under the Plan in
the event of the participant's death, on a form to be provided by the
Committee. A participant may change the participant's beneficiary
designation from time to time in the same manner.
If no designated beneficiary is living on the date on which any payment
becomes payable to a participant's beneficiary, such payment will be
payable to the person or persons in the first of the following classes
of successive preference:
(i) Widow or widower, if then living,
(ii) Surviving children, equally,
(iii) Surviving parents, equally,
(iv) Surviving brothers and sisters, equally,
(v) Executors or administrators
and the term "beneficiary" as used in the Plan shall include such
person or persons.
(8) Retirement and Termination of Employment Other Than by Death or
Disability. In the event of the Retirement prior to the end of an
award period of a participant who has satisfied the one year employment
requirement of Section 7(b)(4) with respect to an award prior to
Retirement, the participant, or his estate, shall be entitled to a
payment of such award at the end of the award period, pursuant to the
terms of the Plan and the participant's Performance Unit Agreement,
provided, however, that the participant shall be deemed to have earned
that proportion (to the nearest whole unit) of the value of the
performance units granted to the participant under such award as the
number of months of the award period which have elapsed since the first
day of the calendar year in which the award was made to the end of the
month in which the participant's Retirement occurs, bears to the total
number of months in the award period. The participant's rights in any
remaining performance units shall be canceled and forfeited.
Subject to Section 7(b)(6) hereof, the Performance Unit Agreement shall
specify that the rights of the participant in the performance units
granted to such participant shall be conditional and shall be canceled,
forfeited and surrendered if the participant's continuous employment
with the Company and its Subsidiaries and Affiliates shall terminate
E-2-9
<PAGE>
for any reason, other than the participant's death, Disability or
Retirement prior to the end of the award period.
The Committee may, in its discretion, waive, in whole or in part, the
cancellation, forfeiture and surrender of any performance units.
(9) Disability of Participant. For the purposes of any award a participant
who becomes Disabled shall be deemed to have suspended active
employment by reason of Disability commencing on the date the
participant becomes entitled to receive payments under a disability pay
plan of the Company or any Subsidiary or Affiliate and continuing until
the date the participant is no longer entitled to receive such
payments. In the event a participant becomes Disabled during an award
period but only if the participant has satisfied the one year
employment requirement of Section 7(b)(4) with respect to an award
prior to becoming Disabled, upon the determination by the Committee of
the extent to which an award has been earned pursuant to Section
7(b)(6) the participant shall be deemed to have earned that proportion
(to the nearest whole unit) of the value of the performance units
granted to the participants under such award as the number of months of
the award period in which the participant was not Disabled bears to the
total number of months of the award period. The participant's rights
in any remaining performance units shall be canceled and forfeited.
The Committee may, in its discretion, waive, in whole or in part, such
cancellation and forfeiture of any performance units.
(10) Death of Participant. In the event of the death prior to the end of an
award period of a participant who has satisfied the one year employment
requirement with respect to an award prior to the date of death, the
participant's beneficiaries or estate, as the case may be, shall be
entitled to a payment of such award upon the end of the award period,
pursuant to the terms of the Plan and the participant's Performance
Unit Agreement, provided, however, that the participant shall be deemed
to have earned that proportion (to the nearest whole unit) of the value
of the performance units granted to the participant under such award as
the number of months of the award period which have elapsed since the
first day of the calendar year in which the award was made to the end
of the month in which the participant's death occurs, bears to the
total number of months in the award period. The participant's rights
in any remaining performance units shall be canceled and forfeited.
The Committee may, in its discretion, waive, in whole or in part, such
cancellation and forfeiture of any performance units.
(11) Grant of Associated Option. If the Committee determines that the
conditional grant of performance units under the Plan is to be made to
a participant in conjunction with the grant of a nonqualified stock
option under the Plan, the Committee shall grant the participant an
Associated Option under the Plan subject to the terms and conditions of
this subsection (11). In such event, such award under the Plan shall
be contingent upon the participant's being granted such an Associated
Option pursuant to which: (i) the number of shares the optionee may
purchase shall initially be equal to the number of performance units
conditionally granted by the award, (ii) such number of shares shall be
reduced on a one share-for-one unit basis to the extent that the
Committee determines, pursuant to Section 7(b)(6) hereof, to pay to the
participant or the participant's beneficiaries the performance units
E-2-10
<PAGE>
conditionally granted pursuant to the award, and (iii) the Associated
Option shall be cancelable in the discretion of the Committee, without
the consent of the participant, under the conditions and to the extent
specified herein and in Section 7(b)(6) hereof.
If no amount is payable in respect of the conditionally granted
performance units, the award and such performance units shall be deemed
to have been canceled, forfeited and surrendered, and the Associated
Option, if any, shall continue in effect in accordance with its terms.
If any amount is payable in respect of the performance units and such
units were granted in conjunction with an Associated Option, the
Committee shall, within 30 days after the determination of the
Committee referred to in the first sentence of Section 7(b)(6),
determine, in its sole discretion, either:
(A) to cancel in full the Associated Option, in which event the value of
the performance units payable pursuant to Sections 7(b)(5) and (6)
shall be paid;
(B) to cancel in full the performance units, in which event no amount shall
be paid to the participant in respect thereof but the Associated Option
shall continue in effect in accordance with its terms; or
(C) to cancel some, but not all, of the performance units, in which event
the value of the performance units payable pursuant to Sections 7(b)(5)
and (6) which have not been canceled shall be paid and the Associated
Option shall be canceled with respect to that number of shares equal to
the number of conditionally granted performance units that remain
payable.
Any action taken by the Committee pursuant to the preceding sentence
shall be uniform with respect to all awards having the same award
period. If the Committee takes no such action, it shall be deemed to
have determined to cancel in full the award in accordance with clause
(B) above.
8. Determination of Breach of Conditions: The determination of the
Committee as to whether an event has occurred resulting in a forfeiture
or a termination or reduction of the Company's obligations in
accordance with the provisions of the Plan shall be conclusive.
9. Adjustment in the Event of Change in Stock: In the event of changes in
the outstanding Common Stock of the Company by reason of stock
dividends, recapitalization, mergers, consolidations, split-ups,
combinations or exchanges of shares and the like, the aggregate number
and class of shares available under the Plan, and the number, class and
the price of shares subject to outstanding options and/or awards and
the number of performance units and/or the dollar value of each unit
shall be appropriately adjusted by the Committee, whose determination
shall be conclusive.
10. Taxes: In connection with the transfer of shares of Common Stock to an
optionee, subject to Section 16 of the Exchange Act, as the result of
the exercise of a nonqualified stock option or a stock appreciation
right, or to a participant subject to Section 16 of the Exchange Act,
upon payment of an award, the Company shall have the right to retain or
sell without notice, or to demand surrender of, shares of Common Stock
having a Fair Market Value (taking into account any commissions or
E-2-11
<PAGE>
other expenses the Company may incur upon the sale of such shares) on
the date that the amount required by any governmental entity to be
withheld or otherwise deducted and paid with respect to such transfer
("Withholding Tax") is to be determined (the "Tax Date") sufficient to
cover the amount of any Applicable Tax (the amount of Withholding Tax
plus the incremental amount determined on the basis of the highest
marginal tax rate applicable to such optionee or participant, Federal
Insurance Contribution Act taxes or other governmental impost or levy),
and to make payment (or to reimburse itself for payment made) to the
appropriate taxing authority of an amount in cash equal to the amount
of such Applicable Tax, remitting any balance to the optionee or
participant.
An optionee or participant who is not an executive officer of the
Company subject to Section 16 of the Exchange Act shall be entitled to
satisfy the obligation to pay any Withholding Tax or Applicable Tax, by
providing the Company with funds sufficient to enable the Company to
pay such Withholding Tax or Applicable Tax or by requiring the Company
to retain or to accept upon delivery thereof by the optionee or
participant shares of Common Stock sufficient in value (determined in
accordance with the last sentence of the preceding paragraph), to cover
the amount of such Withholding Tax or Applicable Tax. Each election by
an optionee or participant to have shares retained or to deliver shares
for this purpose shall be subject to the following restrictions: (i)
the election must be in writing and be made on or prior to the Tax
Date; (ii) the election must be irrevocable; (iii) the election shall
be subject to the disapproval of the Committee.
11. Amendment of the Plan: The Board of Directors may amend or suspend the
Plan at any time and from time to time. No such amendment of the Plan
may, however, increase the maximum number of shares to be offered under
options or awards, or change the manner of determining the option
price, or change the designation of employees or class of employees
eligible to receive options or awards, or permit the transfer or issue
of stock before payment therefor in full, or, without the written
consent of the optionee or participant, alter or impair any option or
award previously granted under the Plan, Prior Plan or LTPAP.
12. Amendment of Options Outstanding Under the Prior Plan: The Prior Plan
and certain nonqualified options granted and outstanding thereunder are
hereby amended to provide that any nonqualified option which is
outstanding on the date this Plan is adopted by a vote of the holders
of a majority of the shares of the Company's Common Stock and $2.00
Convertible Preferred Stock present in person or by proxy at a duly
held shareholders meeting at which a quorum representing a majority of
all outstanding voting stock is present shall be exercisable in
accordance with Sections 6(b)(7) and 6(b)(9), except that for the
purpose of such options "Retirement" shall additionally mean
termination of the employment of an employee after completing 35 years
of service with the Company or its Subsidiaries. Furthermore, an
employee who makes an election to retire under Article 19 of the
Retirement Income Plan shall have any additional years of age and
service which are credited under Article 19 of the Retirement Income
Plan taken into account when determining such employee's age and years
of service with the Company or its Subsidiaries under this Section 12.
Such election shall be deemed a Retirement for purposes of this Section
12 and all other purposes of this Plan.
E-2-12
<PAGE>
13. Miscellaneous: By accepting any benefits under the Plan, each optionee
or participant and each person claiming under or through such optionee
or participant shall be conclusively deemed to have indicated
acceptance and ratification of, and consent to, any action taken or
made to be taken or made under the Plan by the Company, the Board, the
Committee or any other Committee appointed by the Board. No
participant or any person claiming under or through him shall have any
right or interest, whether vested or otherwise, in the Plan or in any
option, or stock appreciation right or award thereunder, contingent or
otherwise, unless and until all of the terms, conditions and provisions
of the Plan and the Agreement that affect such participant or such
other person shall have been complied with. Nothing contained in the
Plan or in any Agreement shall require the Company to segregate or
earmark any cash or other property. Neither the adoption of the Plan
nor its operation shall in any way affect the rights and powers of the
Company or any of its Subsidiaries or Affiliates to dismiss and/or
discharge any employee at any time.
14. Term of the Plan: The Plan shall become effective as of January 1,
1993 by action of the Board of Directors conditioned on and subject to
approval of the Plan, by a vote of the holders of a majority of the
shares of Common Stock and $2.00 Convertible Preferred Stock of the
Company present in person or by proxy at a duly held shareholders
meeting at which a quorum representing a majority of all outstanding
voting stock is present. The Plan shall terminate on December 31,
2002, or at such earlier date as may be determined by the Board of
Directors. Termination of the Plan, however, shall not affect the
rights of optionees under options theretofore granted to them or the
rights of participants under awards theretofore granted to them, and
all unexpired options and awards shall continue in force and operation
after termination of the Plan except as they may lapse or be terminated
by their own terms and conditions.
E-2-13
<PAGE>
SQUIBB CORPORATION Exhibit 10b
1982 OPTION, RESTRICTED STOCK AND PERFORMANCE UNIT PLAN
1. Definitions.
The following terms shall have the following meanings for purposes of the
Plan:
"Award Cycle" means a period of not less than three fiscal years over
which the performance units granted during a particular year are to be
earned out.
"Committee" means the Committee described in Paragraph 4 which shall
administer the Plan.
"Common Stock" means the Common Stock of the Corporation.
"Corporation" means Squibb Corporation.
"Designated Beneficiary" means the person or persons designated in writing
by a Participant as a legal recipient of any payments due under a
performance unit award in the event of the Participant's death, or in the
absence of such designation, the Participant's estate. Such designation
must be on file with the Committee in order to be effective but, unless
the Participant has made an irrevocable designation, may be changed from
time to time by the Participant.
"Participant" means an employee who has received an award of performance
units under the Plan.
"Payment Schedule" means the schedule adopted by the Committee in
accordance with Paragraph 6 with respect to each Award Cycle to govern
determination of the Payment Value of a performance unit at the end of
each Award Cycle in accordance with Paragraph 6.
"Payment Value" means the value, expressed in dollars, of a performance
unit at the conclusion of an Award Cycle, determined in accordance with
Paragraph 6.
"Restricted Stock" means the shares of Common Stock referred to in
Paragraph 8.
"Unit Base Value" means the average (rounded to the next highest cent in
the case of fractions of a cent) of the high and low sales prices of the
Common Stock of the Corporation on the New York Stock Exchange on the day
on which performance units are awarded or, if there are no such sales of
Common Stock on that day, the highest asked price therefor on the New York
Stock Exchange on that day.
2. Stock Subject to the Plan.
There are reserved for issuance upon the payment of performance units
awarded and the exercise of options granted under the Plan 3,500,000
authorized and unissued shares of Common Stock and for issuance as
Restricted Stock 200,000 authorized and unissued shares of Common Stock.
If any option granted under the Plan shall expire or terminate for any
reason (including, without limitation, by reason of its surrender,
E-3-1
<PAGE>
pursuant to the provisions of the fourth paragraph of Paragraph 7(b) or
otherwise, or cancellation, in whole or in part, pursuant to the
provisions of Paragraph 7(g) or otherwise, or the substitution in place
thereof of a new option) without having been exercised in full the shares
subject thereto shall again be available for the purposes of issuance upon
the payment of performance units awarded and the exercise of options
granted under the Plan. If Restricted Stock shall become subject to
forfeiture and be returned to the Corporation pursuant to the provisions
of Paragraph 8 hereof, such shares shall again be available for the
purposes of issuance as Restricted Stock under the Plan. In no event shall
authorized and unissued shares of Common Stock which, under the Plan, are
authorized to be used in payment of performance unit awards be deemed to
be unavailable for purposes of the Plan until such shares shall have been
issued in payment thereof in accordance with the provisions of Paragraph
6(g).
3. Administration.
The Plan shall be administered by the Committee. Subject to the express
provisions of the Plan, the Committee shall have plenary authority, in its
discretion, to determine the individuals to whom, and the time or times,
at which performance units or Restricted Stock shall be awarded and
options shall be granted (including without limitation whether such
options shall be Incentive Stock Options or Non-Qualified Stock Options or
a combination thereof as such terms are hereinafter defined) and the
number of units and/or shares to be covered by each such award or grant,
provided, however, that in no event shall a Restricted Stock award be made
to an employee who, at the time of such award is an officer or director of
the Corporation. In making such determinations, the Committee may take
into account the nature of the services rendered by the respective
employees, their present and potential contributions to the Corporation's
success and such other factors as the Committee in its discretion may deem
relevant. Subject to the express provisions of the Plan, the Committee
shall also have plenary authority to interpret the Plan, to prescribe,
amend and rescind rules and regulations relating to it, to determine the
terms and provisions of the respective Restricted Stock, performance unit
and option agreements (which need not be identical) and to make all other
determinations necessary or advisable for the administration of the Plan.
The Committee's determinations of the matters referred to in this
Paragraph 3 shall be conclusive; provided, however, that the Committee of
the Board administering the Plan shall not have the authority to interpret
the Plan or to prescribe, amend, or rescind rules and regulations to it
that are inconsistent with the provisions of the Plan prohibiting (i) the
acceleration of payments under the Plan, or (ii) the modification of the
interest rate to be credited under the Plan.
4. The Committee.
The Committee shall consist of three or more members of the Board of
Directors of the Corporation who are not eligible to receive options,
Restricted Stock or performance units under the Plan. The Committee shall
be appointed by the Board of Directors, which may from time to time
appoint members of the Committee in substitution for members previously
appointed and may fill vacancies, however caused, in the Committee. The
Committee shall select one of its members as its Chairman and shall hold
its meetings at such times and places as it may determine. A majority of
its members shall constitute a quorum. All determinations of the
Committee shall be made by not less than a majority of its members. Any
E-3-2
<PAGE>
decision or determination reduced to writing and signed by all the members
shall be fully as effective as if it had been made by a majority vote at a
meeting duly called and held. The Committee may appoint a secretary, shall
keep minutes of its meetings and shall make such rules and regulations for
the conduct of its business as it shall deem advisable.
5. Eligibility.
Performance units and Restricted Stock may be awarded and options granted
only to key employees (which term as used herein includes officers) of the
Corporation and of its present and future subsidiary corporations (herein
called subsidiaries). A director of the Corporation or of a subsidiary
who is not also an employee of the Corporation or of a subsidiary will not
be eligible to receive a performance unit or Restricted Stock award or an
option. Any such employee may receive one or more performance unit awards
or one or more options or one or more Restricted Stock awards, or a
combination thereof, as the Committee shall from time to time determine,
and such determinations may be different as to different employees and may
vary as to different awards and grants. Notwithstanding the foregoing, a
Restricted Stock award may in no event be made to an employee who, at the
time the award is made, is an officer or director of the Corporation.
6. Performance Unit Awards.
(a) Performance units which are awarded to a Participant shall have a
Payment Value at the end of the applicable Award Cycle contingent
upon performance of the Corporation and/or of such Participant's
subsidiary, division or department over the Award Cycle. The
performance measures may include, but shall not be limited to,
cumulative growth in pre-tax profits, earnings per share, return on
shareholders' equity or return on capital employed. Such measures
may be applied on an absolute basis or relative to industry indices
and shall be defined in a manner which the Committee shall deem
appropriate. For each Award Cycle, the Committee shall establish a
Payment Schedule based upon the performance measures determined for
such Award Cycle and the length of such Award Cycle. If during the
course of an Award Cycle there should occur, in the opinion of the
Committee, significant changes in economic conditions or in the
nature of the operations of the Corporation or subsidiary, division
or department which the Committee did not foresee in establishing the
performance measures for such Cycle and which, in the Committee's
sole judgment have, or are expected to have, a substantial effect on
the performance of the Corporation or a Participant's subsidiary,
division or department during such Cycle, the Committee may revise
the Payment Schedule and performance measures formerly determined by
it in such manner, as the Committee, in its sole judgment, may deem
appropriate.
(b) In determining the number of performance units to be awarded, the
Committee shall take into account an employee's responsibility level,
performance, potential, cash compensation level and such other
considerations as it deems appropriate.
(c) An award of performance units to a Participant shall terminate for
all purposes if the Participant does not remain, during the Award
Cycle, continuously in the employ of the Corporation or one of its
subsidiaries, except in the case of death, disability or retirement
under the Corporation's pension plan (including early retirement at
E-3-3
<PAGE>
the request of the Corporation), in which case (and provided that the
Participant at the time of death, disability or retirement as
aforesaid, shall have been continuously in the employ of the
Corporation or one of its subsidiaries during the period commencing
on the date the award was granted and ending on the first anniversary
thereof) the Participant will be entitled to payment (such payment to
be made in accordance with the provisions of Paragraph 6(d)) of the
same portion of the Payment Value of the award the Participant would
otherwise have been paid (such Payment Value, if any, to be
determined at the conclusion of the applicable Award Cycle in
accordance with the provisions of Paragraphs 6(a) and 6(e)) as the
portion of the Award Cycle during which the Participant was employed
bears to the full Award Cycle. Under particular circumstances the
Committee may make other determinations with respect to Participants
whose services do not meet the foregoing requirements, including the
waiver of any of the requirements of this subparagraph (c) relating
to periods of employment.
(d) Unless the Committee otherwise determines, no payment with respect to
performance units will be made to a Participant prior to the end of
such Participant's Award Cycle; provided, however, that if a
Participant should die during an Award Cycle and the Participant's
award shall not have been terminated hereunder prior to death, such
Participant's Designated Beneficiary may elect instead, subject to
the approval of the Committee, to have the pro rata portion of the
Payment Value determined by the Committee as of the end of the year
during which such Participant's death occurred, based upon
application of the Payment Schedule to the part of the Award Cycle
which shall have elapsed (for such purpose, the cumulative growth
rate achieved to the end of the fiscal year in which death occurs
will be assumed to continue for the Award Cycle), in which event such
pro rata portion shall be paid in cash or Common Stock, as provided
in paragraph 6(g), as soon as practicable following such year (or in
such number of installments as shall have been requested by the
Participant and approved by the Committee) to such Participant's
Designated Beneficiary.
(e) Except as otherwise provided in Paragraph 6(d) in the case of death,
a Participant's interest in any performance units awarded to the
Participant shall mature on the last day of the Award Cycle for such
award. The Payment Value of a performance unit shall be the dollar
amount calculated on the basis of the Payment Schedule applicable to
such Award Cycle.
(f) The total amount of Payment Value due a Participant at the conclusion
of an Award Cycle shall be paid on such date following the conclusion
of such Award Cycle as the Committee shall designate, except as
specifically otherwise provided in the Plan; provided, however, that
the Committee shall have authority, if it deems appropriate, to defer
payment (in cash or in stock or both in specified percentages) of the
Payment Value due a Participant if the Participant shall request the
Committee to do so at any time prior to the 180th day preceding the
last day of the Award Cycle for such award. In respect of awards
made or to be made in one or more deferred installments in cash,
interest shall be credited semi-annually on each such award at a rate
to be determined semi-annually by the Committee, but in no event
shall such rate be less than the average rate on 10-year AAA new
industrial corporate bonds during each such semi-annual period as
E-3-4
<PAGE>
calculated on the basis of the average of such rates for each
calendar week ending during the period January 1 through June 30 and
July 1 through December 31, provided that awards made during any such
six-month period shall be credited on the basis of the average rate
for that period and provided that installments paid during any such
six-month period shall be credited on the basis of the average rate
for the next preceding six-month period, in each case adjusted for
the number of days such award was to be credited. Unless paid to the
recipient of such award at the time credited, interest at the
foregoing rate shall be credited on the interest so credited until so
paid. The foregoing minimum interest rate for any award that is
payable in one or more deferred installments under the Plan may not
be modified without the prior written consent of the Participant.
Whenever an award is made in one or more deferred installments in
stock, the Committee may determine that there shall be credited on
such award an amount equivalent to the dividends which would have
been paid with respect to such shares of stock if they had been
issued and outstanding. Such dividend equivalents shall be credited
on the dividend record dates until certificates for such shares shall
have been delivered to the recipient of such award or until such
earlier date as the Committee may determine.
Such interest and dividend equivalents shall be paid to the recipient
of any such award in cash (or in property if the related dividend
shall have been in property) at such time or times during the
deferred period of such award or at the same time as the cash or
shares of stock to which such interest and dividend equivalents
apply, all as the Committee shall determine. The Committee may also
determine that any such dividend equivalents may be used to purchase
additional shares of outstanding stock (such shares to be valued for
such purpose at the mean of the high and low sales prices of such
stock on the New York Stock Exchange on the dividend record date) to
be added to the shares of stock covered by such award and held
subject to the same terms and conditions, including provisions
relating to the payment of amounts equivalent to dividends thereon.
(g) Payment of the Payment Value due a Participant shall be made, at the
election of the Committee as to each Participant, (i) in cash, (ii)
in shares of Common Stock of the Corporation (to be determined by
dividing the Payment Value of all matured performance units by the
average of the high and low sales prices of such stock on the New
York Stock Exchange during the five trading days immediately
preceding the date of payment) or (iii) in a combination of cash and
shares of Common Stock so valued.
(h) If the payment of any award shall be deferred until after the
termination of the employment of the recipient by the Corporation or
one of its subsidiaries, the cash or stock covered by such award,
together with any deferred interest or dividend equivalents thereon,
shall be delivered in not more than 20 annual installments,
commencing not later than the January 31 after the termination of
employment (or such other date as the Committee from time to time
shall determine), all as the Committee may determine. If the payment
of an award under the Plan is deferred, such payment thereafter may
be accelerated so that such payment shall be made immediately or at
such earlier time or in such lesser number of installments, in each
case as the Committee may from time to time determine, but only with
E-3-5
<PAGE>
the prior written consent of the Participant.
(i) A person to whom any payment in consideration of an award has been
made (whether or not the same has been deferred) shall not have any
interest in the cash or stock awarded, or in any interest or dividend
equivalents credited, until the cash has been paid or the
certificates for the stock have been delivered, as the case may be,
in accordance with the provisions of this Plan.
(j) In the event of any changes in the outstanding stock of the
Corporation by reason of stock dividends, stock splits,
recapitalizations, mergers, consolidations, combinations or exchanges
of shares, split-ups, split-offs, spin-offs, liquidations or other
similar changes in capitalization, or any distribution to
shareholders other than cash dividends, the Committee shall make such
adjustments, if any, in the light of the change or distribution as
the Committee in its sole discretion shall determine to be
appropriate, (i) in the number of shares of stock covered by any
award for which certificates have not been delivered and (ii) in any
dividend equivalents to which deferred awards of stock are entitled.
(k) The recipient of a deferred award may file with the Committee a
designation of a beneficiary or beneficiaries on a form to be
provided by the Committee, which designation may be changed or
revoked by the recipient's sole action, provided the change or
revocation is filed with the Committee on a form provided by it. In
the case of the death of the recipient of an award, before or after
the termination of employment, any unpaid installments of such
deferred award shall pass to the Designated Beneficiary. Unpaid
installments of a deferred award shall be paid either in the same
installments as originally provided or otherwise as the Committee may
determine in individual cases.
(l) The Corporation shall have the right, in lieu of delivering the
certificate or certificates for any of or all the stock which would
otherwise be deliverable to the Participant pursuant to this Plan, to
pay to such Participant on the date on which such certificate or
certificates would otherwise be deliverable an amount in cash equal
to the mean of the high and low sales prices of such stock on the New
York Stock Exchange on such date or dates as may be determined by the
Committee, but not more than five trading days prior to such date,
and after withholding or deducting any required amount of tax, all as
the Committee may determine in individual cases.
7. Option Grants.
(a) The purchase price of the Common Stock under each option granted
under the Plan shall be determined by the Committee, but shall be not
less than 100% of the fair market value of the stock at the time such
option is granted. Such fair market value shall be determined by the
Committee and shall be taken at not less than the mean (rounded to
the next highest cent in the case of fractions of a cent) of the high
and low prices of the Common Stock on the New York Stock Exchange on
the date of the grant of the option.
(b) The Committee shall be authorized in its discretion to prescribe in
the option grant the installments, if any, in which an option granted
under the Plan shall become exercisable, provided that no option
E-3-6
<PAGE>
shall be exercisable, prior to the first anniversary of the date of
grant thereof except as provided in Paragraph 7(e) or except as the
Committee otherwise determines. In no case may an option be exercised
as to less than 10 shares at any one time (or the remaining shares
covered by the option if less than 10) during the term of the option.
The Committee shall also be authorized to establish the manner and
the effective date of the exercise of an option. The term of each
option shall be not more than ten years from the date of grant
thereof, or such shorter period as is prescribed in Paragraphs 7(d)
and (e). Except as provided in Paragraphs 7(d) and (e), no option may
be exercised at any time unless the holder thereof is then an
employee of the Corporation or of a subsidiary.
Upon exercise, the option price is to be paid in full in cash or, at
the discretion of the Committee, in shares of Common Stock owned by
the optionee having a market value on the date of exercise equal to
the aggregate option price, or, at the discretion of the Committee,
in a combination of cash and such shares of Common Stock; provided,
however, that no such payment in shares of Common Stock shall be made
unless said shares shall have been owned by the optionee for a period
of at least three months prior to the date of payment. For purposes
of this paragraph, the market value of shares of Common Stock
delivered in payment of the option price shall be the mean between
the highest and lowest selling prices per share of Common Stock on
the New York Stock Exchange on the exercise date; if shares of Common
Stock are not traded on the exercise date, the fair market value on
such date shall be determined under Treasury Regulation section
20.2031-2. For purposes of this paragraph, an optionee can effect
delivery of shares of Common Stock by delivering certificates for
such shares to the Corporation, by furnishing the Corporation the
registration numbers on the certificates for such shares or, if such
shares are held of record by a nominee for the benefit of the
optionee, by furnishing the Corporation a notarized statement
attesting to the number of such shares the optionee intends to be
delivered.
On such terms and conditions as shall be approved by the Committee,
the Corporation or any of its subsidiaries may directly or indirectly
lend money to any optionee or other person to accomplish the purposes
of the Plan, including to assist such person to acquire shares of
Common Stock acquired upon the exercise of options, and separately to
tend money to any optionee or other lend person to pay taxes with
respect to any of the transactions contemplated by the Plan.
In lieu of requiring an optionee to pay cash and/or stock, and
receive certificates for shares of Common Stock of the Corporation
upon the exercise of a Non-Qualified Stock Option, as hereinafter
defined, if the option so provides, the Committee may elect to
require the optionee to surrender the option to the Corporation for
cancellation as to all or any portion of the number of shares covered
by the intended exercise and receive in exchange for such surrender a
payment, at the election of the Committee, in cash, in shares of
Common Stock of the Corporation, or a combination of cash and shares
of Common Stock of the Corporation, equivalent to the appreciated
value of the shares covered by the option surrendered for
cancellation. Such appreciated value shall be the difference between
the option price of such shares (as adjusted pursuant to Paragraph
10) and the fair market value of such shares which shall be
E-3-7
<PAGE>
determined by the Committee and shall be taken at not less than the
mean of the high and low prices of the Common Stock on the New York
Stock Exchange on the date on which the optionee's notice of exercise
is received by the Corporation. Upon delivery to the Corporation of
a notice of exercise of option, the Committee may avail itself of its
right to require the optionee to surrender the option to the
Corporation for cancellation as to shares covered by such intended
exercise. The Committee's right of election shall (i) be conditional
upon its so notifying the optionee in writing immediately on the date
of the Corporation's receipt of the optionee's notice of exercise and
(ii) expired, if not exercised, at the close of business on the fifth
business day following the delivery to the Corporation of such
notice. Should the Committee not exercise such right of election,
the delivery of the aforesaid notice of exercise shall constitute an
exercise by the optionee of the option to the extent therein set
forth, and payment for the shares covered by such exercise shall then
become due.
(c) In the event that an individual receiving a Non-Qualified Stock
Option, as hereinafter defined, shall not remain in the employ of the
Corporation or of one of its subsidiaries for a period of at least
one year from the date of grant of the option and the termination of
such individual's service during such period is either (i) for cause
or (ii) voluntary on the part of such individual and without the
written consent of the Corporation or such subsidiary, the option
shall forthwith terminate on the date of such termination of
employment. Retirement at the early or normal retirement date as
prescribed from time to time by the Corporation shall be deemed to be
a termination of employment with the Corporation's written consent.
An individual receiving an Incentive Stock Option, as hereinafter
defined, may exercise it only after one year of employment following
the grant date (and then only to the extent provided in the option
grant) and termination of such employment in such one-year period
will terminate all rights under such option.
(d) In the event of the termination of the employment of the holder of
any option, other than by reason of normal or early retirement in
accordance with the provisions of a pension plan of the Corporation
or one of its subsidiaries or affiliates (hereinafter "Retirement"),
or death, the optionee may (unless the option shall have been
previously terminated pursuant to the provisions of Paragraph 7(c) or
unless otherwise provided in the option grant) exercise the option at
any time within three months after such termination, but not after
the expiration of the option, to the extent of the number of shares
covered by the option which were purchasable by the optionee at the
date of the termination of employment.
In the event of the termination of the employment of the holder of
any option because of Retirement before May 5, 1987, the optionee,
may (unless the options shall have been previously terminated
pursuant to the provisions of Paragraph 7(c) or unless otherwise
provided in the option grant) exercise the option at any time during
the remaining term of the option but not after the expiration of the
option, to the extent of the number of shares covered by the option
which were purchasable by the optionee at the date of termination of
employment.
In the event of the termination of the employment of the holder of
E-3-8
<PAGE>
any option because of Retirement on or after May 5, 1987, the option
shall (unless the option shall have been previously terminated
pursuant to the provisions of Paragraph 7(c) or unless otherwise
provided in the option grant) continue to become exercisable in
accordance with its terms and the provisions of this Paragraph 7 and
of the option grant, and the holder thereof may exercise the option
at any time and from time to time during the remaining term thereof,
but not after the expiration of the option, to the extent it is at
such time exercisable; provided, however, that if the holder becomes
employed by a direct competitor of the Corporation or any of its
subsidiaries, any option held by the optionee which is not, on the
date of becoming so employed, fully exercisable shall forthwith
terminate as to all shares not then purchasable by such optionee
thereunder, and, thereafter, such optionee may so exercise the option
only to the extent of the number of shares covered by the option
which were purchased by such optionee at the date of employment by
such direct competitor.
Notwithstanding the foregoing provisions hereof but subject to the
provisions of Paragraph 7(c), the Committee may determine, in its
sole discretion, in the case of any termination of employment that
the holder of an option may exercise such option to the extent of the
remaining shares covered thereby whether or not such shares had
become purchasable by such an individual at the date of the
termination of employment. Options granted under the Plan shall not
be affected by any change of employment so long as the holder
continues to be an employee of the Corporation or of a subsidiary.
The option grant may contain such provisions as the Committee may
approve with reference to the effect of approved leaves of absence.
Nothing in the Plan or in any option granted pursuant to the Plan
shall confer on any individual any right to continue in the employ of
the Corporation or any of its subsidiaries or interfere in any way
with the right of the Corporation or any of its subsidiaries to
terminate his employment at any time.
(e) In the event of the death of an individual to whom an option has been
granted under the Plan while such individual is employed by the
Corporation or a subsidiary, the option theretofore granted (unless
the option shall have been previously terminated pursuant to the
provisions of Paragraph 7(c) or unless otherwise provided in the
option grant) may be exercised by a legatee or legatees of the option
holder under the optionee's last will or by the personal
representatives or distributees of the optionee, (i) if such
individual's death occurs prior to May 5, 1987, at any time within a
period of one year after death or (ii) if such individual's death
occurs on or after May 5, 1987, during the remaining term of the
option, but in neither event after the expiration of the option, to
the extent of the remaining shares covered by the option whether or
not such shares had become purchasable by such an individual at the
date of death.
In the event of the death of an individual during the three-month
period following the termination of employment (where said
termination was for reasons other than Retirement), the option (if
not previously terminated pursuant to the provisions of Paragraph
7(c) or unless otherwise provided in the option grant) may be
exercised by a legatee or legatees of the option holder under the
optionee's last will or by the optionee's personal representatives or
E-3-9
<PAGE>
distributees but only to the extent of the number of shares
purchasable by such employee pursuant to the provisions of Paragraph
7(d) at the date of termination of the optionee's employment and
within one year after the date of the death, but not after expiration
of the option.
In the event that an individual to whom an option has been granted
under the Plan dies following Retirement, the option theretofore
granted to such individual (if not previously terminated pursuant to
the provisions of Paragraph 7(c) or unless otherwise provided in the
option grant) may be exercised by a legatee or legatees of the option
holder under the optionee's last will, or by the optionee's personal
representatives or distributees, at any time during the remaining
term of the option, but not after expiration of the option, (i) if
Retirement commenced prior to May 5, 1987, only to the extent of the
number of shares purchasable by such individual pursuant to the
provisions of Paragraph 7(d) at the date of termination of employment
or (ii) if Retirement commenced on or after May 5, 1987, to the
extent of the number of shares covered by the option whether or not
such shares had become purchasable by such individual at the date of
death, subject, however, to the limitations described in Paragraph
7(1).
(f) Subject to the provisions of Paragraph 7(h), the date of grant of an
option pursuant to the Plan shall be the date specified by the
Committee at the time it grants such option, provided that such date
shall not be prior to the date of such action by the Committee. The
Committee shall promptly notify a grantee of an award and a written
option grant shall promptly be duly executed and delivered by or on
behalf of the Corporation.
(g) The Committee shall be authorized, in its absolute discretion, to
permit optionees to surrender outstanding options in exchange for the
grant of new options or require optionees to surrender outstanding
options as a condition precedent to the grant of new options. The
number of shares covered by the new options, the option price, the
option period and other terms and conditions of the new options shall
all be determined in accordance with the Plan and may be different
from the provisions of the surrendered options. However, if an
Incentive Stock Option is surrendered, it will nevertheless be
considered outstanding for purposes of Paragraph 7(h).
(h) Each option granted or modified hereunder which is intended to be an
Incentive Stock Option (when used herein, the term "Incentive Stock
Option" shall be as defined in Section 422A of the United States
Internal Revenue Code and all other options granted hereunder are
referred to as "Non-Qualified Stock Options") shall not be
exercisable while there is outstanding any Incentive Stock Option
which was granted, before the granting of such option, to the
optionee to purchase stock in the optionee's employer corporation or
in a corporation which (at the time of the granting of such option)
is a parent or subsidiary of the employer corporation, or is a
predecessor of any of such corporations. For purposes of this
Paragraph 7(h), an Incentive Stock Option shall be treated as
outstanding until such option is exercised in full or expires by
reason of lapse of time. In the case of an option which is modified
and which did not meet the requirements applicable to Incentive Stock
Options prior to such modifications but does thereafter, the date of
E-3-10
<PAGE>
such modification shall be treated as the date of grant for purposes
of this Paragraph 7(h). In determining whether any Incentive Stock
Option is exercisable at the time of an optionee's retirement, the
restrictions on order of exercise set forth in this Paragraph 7(h)
shall be disregarded, but such restrictions shall continue to apply
with respect to the order in which such options may be exercised.
(i) In no event shall any optionee be granted during the calendar year
1982 or any subsequent year an Incentive Stock Option or Incentive
Stock Options entitling such optionee to purchase stock of the
Corporation, any parent corporation or any subsidiaries of the
Corporation, having an aggregate fair market value (determined as of
the time such option or options are granted) in excess of $100,000
plus the amount of any unused limit carryover to such calendar year.
In the case of any option which is modified and which did not meet
the requirements applicable to Incentive Stock Options prior to such
modification but does thereafter, the date of such modification shall
be treated as the date of grant for purposes of this Paragraph 7(i).
Eligibility of an optionee for any unused limit carryover to any year
and the amount thereof shall be determined in accordance with
applicable provisions of the Internal Revenue Code.
8. Restricted Stock Awards.
(a) The consideration to be received for shares of Restricted Stock
issued hereunder out of authorized but unissued shares shall be equal
to cash in an amount equal to the par value thereof and the continued
employment by the participant during the "Restricted Period" (as
hereafter defined). The recipient of Restricted Stock shall be
recorded as a stockholder of the Corporation and shall have, subject
to the provisions hereof, all the rights of a stockholder with
respect to such shares and receive all dividends or other
distributions made or paid with respect to such shares; provided that
the shares themselves and any new, additional or different shares or
securities which the recipient may be entitled to receive with
respect to such shares by virtue of a stock split or stock dividend
or any other change in the corporate or capital structure of the
Corporation, shall be subject to the restrictions hereinafter
described.
(b) During a period of years following the date of grant, as determined
by the Committee, which shall in no event be less than four
(hereinafter referred to as the "Restricted Period"), the Restricted
Stock may not be sold, assigned, transferred, pledged, hypothecated
or otherwise encumbered or disposed of by the recipient, except in
the event of (i) death as hereinafter provided or (ii) the transfer
thereof to the Corporation under the provisions of the next
succeeding paragraph. In the event of the death of the recipient
during the said Restricted Period, the aforesaid restrictions on the
Restricted Stock shall immediately lapse and the legal
representative(s) of the estate of the recipient shall be free to
transfer, encumber or otherwise dispose of the Restricted Stock.
In the event that, during the Restricted Period, the employment of
the recipient by the Corporation or one of its subsidiaries is
terminated for any reason (including termination with or without
cause by the Corporation or such subsidiary, resignation by the
recipient, or retirement under a pension plan of the Corporation or
E-3-11
<PAGE>
one of its subsidiaries), other than termination of employment due to
the death of the recipient, then the shares of Restricted Stock held
by such recipient shall be forfeited to the Corporation and the
recipient shall immediately transfer and return to the Corporation
the certificates representing all the Restricted Stock and the
recipient's rights as a stockholder with respect to the Restricted
Stock shall cease, effective with such termination of employment.
The recipient's rights to the Restricted Stock may not be assigned or
transferred except by will or by the laws of descent or distribution.
In the event of any attempt to sell, exchange, transfer, pledge or
otherwise dispose of said shares by the recipient in violation of the
provisions hereof, such shares shall be forfeited to the Corporation.
(c) The Committee shall have authority, if it deems appropriate, to
extend the Restricted Period with respect to any award of Restricted
Stock if the recipient shall request the Committee to do so at any
time prior to the 180th day preceding the date on which the
Restricted Period is originally scheduled to lapse. In the event
that the Restricted Period is so extended (the "Extended Restricted
Period") until after the termination of the employment of the
recipient by the Corporation or one of its subsidiaries, the
restrictions on the Restricted Stock shall lapse in not more than
twenty annual installments, commencing not later than the January 31
after the termination of employment (or such other date as the
Committee from time to time shall determine), all as the Committee
may determine. If the Restricted Period is so extended, such lapsing
of restrictions thereafter may be accelerated so that all such
restrictions shall lapse immediately or at such earlier time or in
such less number of installments, in each case as the Committee may
from time to time determine, but only with the prior written consent
of the recipient. In the event of the death of the recipient during
the Extended Restricted Period, all restrictions on the Restricted
Stock shall immediately lapse and the legal representative(s) of the
estate of the recipient shall be free to transfer, encumber or
otherwise dispose of the Restricted Stock.
9. Transferability and Shareholder Rights of Holders of Performance Units and
Options.
No performance unit awarded and no option granted under the Plan shall be
transferable otherwise than pursuant to Paragraph 6(k) or by will or by
the laws of descent and distribution, and an option may be exercised,
during the lifetime of the holder thereof, only by such holder. The
holder of a performance unit award or of an option shall have none of the
rights of a shareholder until (i) in the case of performance unit awards,
the recipient has an interest therein in accordance with Paragraph 6(i),
or (ii) in the case of options, the shares subject thereto shall have been
registered in the name of the person or persons exercising such option on
the transfer books of the Corporation upon such exercise.
10. Adjustments upon Changes in Capitalization.
Notwithstanding any other provisions of the Plan, the option grants may
contain such provisions as the Committee may determine as appropriate for
the adjustment of the number and class of shares subject to the options
and the option prices of the options covered thereby, in the event of
E-3-12
<PAGE>
changes in the outstanding Common Stock by reason of stock dividends,
stock splits, recapitalizations, merger & consolidations, combinations, or
exchanges of shares, split-ups, split-offs, spin-offs, liquidations or
other similar changes in capitalization, or any distribution to common
shareholders other than cash dividends, and, in the event of any such
change in the outstanding Common Stock, the aggregate number and class of
shares available under the Plan and the maximum number of shares as to
which options may be granted and performance units awarded and the maximum
number of shares of Restricted Stock which may be awarded shall be
appropriately adjusted by the Committee.
11. Amendment and Termination.
Unless the Plan shall theretofore have been terminated as hereinafter
provided, the Plan shall terminate on, and no awards of Performance Units
or Restricted Stock or options shall be made after, December 31, 1987, and
provided further that the said Plan termination shall have no effect on
awards of Performance Units or Restricted Stock or options made prior
thereto. The Plan may be terminated, modified or amended by the
stockholders of the Corporation. The Board of Directors of the
Corporation may also terminate the Plan, or modify or amend the Plan in
such respects as it shall deem advisable in order to conform to any change
in any law or regulation applicable thereto, or in other respects which
shall not change (i) the total number of shares as to which options may be
granted or which may be used in payment of performance unit awards under
the Plan or which may be issued as Restricted Stock, (ii) the class of
employees eligible to receive awards of performance units, Restricted
Stock and options, (iii) the manner of determining the Unit Base Value and
minimum option prices, (iv) the period during which awards of performance
units or Restricted Stock may be made or options may be granted or
exercised, (v) the minimum period of four years set forth in Paragraph
8(b), (vi) the provisions relating to the administration of the Plan by a
Committee consisting of directors of the Corporation not eligible to
participate in the Plan; provided further that, with respect to awards
previously granted under the Plan, the Board of Directors shall not have
the authority to modify or amend the provisions of the Plan prohibiting
(i) the acceleration of payments under the Plan, or (ii) the modification
of the interest rate to be credited under the Plan.
12. Withholding
In connection with the transfer of shares of Common Stock as a result of
the exercise of a Non-Qualified Stock Option, the payment of performance
units or the payment of a Restricted Stock Award, the Corporation shall
have the right to retain or sell without notice, or to demand surrender
of, shares of Common Stock in value sufficient to cover the amount of any
Withholding Tax (that is, that portion of any Applicable Tax, as defined
below, required by any governmental entity to be withheld or otherwise
deducted and paid with respect to such reimburse itself for payment made)
to the transfer), and to make payment (or to reimburse itself for payment
made) to the appropriate taxing authority of an amount in cash equal to
the amount of such Withholding Tax, remitting any balance to the employee.
For purposes of this paragraph, the value of shares of Common Stock so
retained or surrendered shall be the average of the high and low sales
prices per share on the New York Stock Exchange on the date that the
amount of the Withholding Tax is to be determined (the "Tax Date"), and
the value of shares of Common Stock so sold shall be the actual net sale
price per share (after deduction of commissions) received by the
E-3-13
<PAGE>
Corporation.
Notwithstanding the foregoing, the employee shall be entitled to satisfy
the obligation to pay any Withholding Tax (or, if the employee is an
officer of the Corporation within the meaning of Section 16 of the
Securities Exchange Act of 1934 ("Section 16"), to satisfy the obligation
to pay any tax to any governmental entity in respect of such transfer,
including any Federal, state or local income tax up to an amount
determined on the basis of the highest marginal tax rate applicable to
such employee, Federal Insurance Contribution Act taxes or other
governmental impost or levy (an "Applicable Tax")), in whole or in part,
by providing the Corporation with funds sufficient to enable the
Corporation to pay such Withholding Tax (or Applicable Tax) or by
requiring the Corporation to retain or to accept upon delivery thereof by
the employee shares of Common Stock sufficient in value (determined in
accordance with the last sentence of the preceding paragraph) to cover the
amount of such Withholding Tax (or Applicable Tax). Each election by an
employee to have shares retained or to deliver shares for this purpose
shall be subject to the following restrictions: (i) the election must be
in writing and be made on or prior to the Tax Date; (ii) the election must
be irrevocable; (iii) the election shall be subject to the disapproval of
the Committee; (iv) if the employee is an officer of the Corporation
within the meaning of Section 16, the election may not be made within six
months of the grant of the related stock option or the award of the
related performance units or Restricted Stock (except that this
restriction shall not apply in the event the death or disability of the
employee occurs within six months of such grant or award); and (v) if the
employee is an officer of the Corporation within the meaning of Section
16, the election must be made at least six months prior to the Tax Date or
in any ten-business day "window period" (beginning on the third business
day following the date on which the Corporation releases for publication
its annual or quarterly statements of sales and earnings and ending on the
twelfth business days following the date of release thereof) prior to the
Tax Date.
13. Effectiveness of the Plan.
The Plan shall become effective on the date of its adoption by the Board
of Directors of the Corporation and performance unit and Restricted Stock
awards may be made and options granted immediately thereafter, but no
performance unit award may be paid or Restricted Stock issued or option
exercised under the Plan unless and until the Plan shall have been
approved by the vote of the holders of a majority of the outstanding
shares of Common Stock at a meeting of the shareholders within twelve
months after the date of adoption of the Plan by the Board of Directors.
If such approval is not obtained within said period, the Plan and any
awards made or options granted under the Plan shall be null and void. The
Committee may in its discretion authorize the awarding of performance
units and Restricted Stock and the granting of options, the payment,
issuance of exercise of which, respectively, shall be expressly subject to
the conditions that (i) the shares of Common Stock reserved for issue
under the Plan shall have been duly listed, upon official notice of
issuance, upon each stock exchange in the United States upon which the
Common Stock is traded and (ii) a registration statement under the
Securities Act of 1933 with respect to such shares shall have become
effective.
E-3-14
<PAGE>
AMENDMENT TO THE SQUIBB CORPORATION Exhibit 10c
1986 OPTION, RESTRICTED STOCK AND PERFORMANCE UNIT PLAN
The Squibb Corporation 1986 Option, Restricted Stock and Performance
Unit Plan (the "Plan") is hereby amended effective July 1, 1993 by deleting
Section 12 in its entirety and inserting therefor the following:
12. Withholding.
-----------
In connection with the transfer of shares of Common Stock, par value $.10
per share, of Bristol-Myers Squibb Company ("BMS Stock") to a Participant
as the result of the exercise of Non-Qualified Stock Option, the payment
of performance units or the payment of a Restricted Stock Award, the
Corporation shall have the right to retain or sell without notice, or to
demand surrender of, shares of BMS Stock in value sufficient to cover the
amount of any Withholding Tax (that is, that portion of any Applicable
Tax, as defined below, required by any governmental entity to be withheld
or otherwise deducted and paid with respect to such transfer) or
Applicable Tax, and to make payment (or to reimburse itself for payment
made) to the appropriate taxing authority of an amount in cash equal to
the amount of such Withholding Tax or Applicable Tax, remitting any
balance to the Participant. For purposes of this paragraph, the value of
shares of BMS Stock so retained or surrendered shall be the average of the
high and low sales prices per share on the New York Stock Exchange on the
date that the amount of the Withholding Tax is to be determined (the "Tax
Date"), and the value of shares of BMS Stock so sold shall be the actual
net sale price per share (after deduction of commissions) received by the
Corporation.
Notwithstanding the foregoing, the Participant shall be entitled to
satisfy the obligation to pay any Withholding Tax (or, if the employee is
an officer of the Corporation within the meaning of Section 16 of the
Securities Exchange Act of 1934 (the "1934 Act"), to satisfy the
obligation to pay any tax to any governmental entity in respect of such
transfer, including any Federal, state or local income tax up to an amount
determined on the basis of the highest marginal tax rate applicable to
such Participant, Federal Insurance Contribution Act taxes or other
governmental impost or levy (an "Applicable Tax")), in whole or in part,
by providing the Corporation with funds sufficient to enable the
Corporation to pay such Withholding Tax or Applicable Tax or by requiring
the Corporation to retain or to accept upon delivery thereof by the
Participant shares of Page Two of Amendment to Squibb Corp. 1986 Option,
Restricted Stock and Performance United Plan.
BMS Stock sufficient in value (determined in accordance with the last
sentence of the preceding paragraph) to cover the amount of such
Withholding Tax or Applicable Tax. Each election by a Participant to have
shares retained or to deliver shares for this purpose shall be subject to
the following restrictions: (i) the election must be in writing and be
made on or prior to the Tax Date; (ii) the election must be irrevocable;
(iii) the election shall be subject to the disapproval of the Committee;
(iv) if the Participant is an officer of the Corporation within the
meaning of Section 16 of the 1934 Act, the election may not be made within
six months of the grant of the related option or the award of the related
performance units or Restricted Stock (except that this restriction shall
not apply in the event the death or disability of the Participant occurs
E-4-1
<PAGE>
AMENDMENT TO THE SQUIBB CORPORATION
1986 OPTION, RESTRICTED STOCK AND PERFORMANCE UNIT PLAN
within six months of such grant or award); and (v) if the Participant is
an officer of the Corporation within the meaning of Section 16 of the 1934
Act, the election must be made at least six months prior to the Tax Date
or in any ten-business day "window period" beginning on the third business
day following the date on which the Corporation releases for publication
its annual or quarterly statements of sales and earnings and ending on the
twelfth business day following the date of release thereof) prior to the
Tax Date."
E-4-2
<PAGE>
AMENDMENT TO THE EXHIBIT 10d
BRISTOL-MYERS SQUIBB COMPANY
PERFORMANCE INCENTIVE PLAN
----------------------------
Effective January 1, 1994, the Bristol-Myers Squibb Company Performance
Incentive Plan (the "Plan") is hereby amended as follows:
1.Section 2 of the Plan shall be, and hereby is, amended in its entirety
to provide as follows:
"2. Regulations: The Compensation and Management Development Committee
of the Board of Directors of the Company (hereinafter referred to as
the "Committee" and the "Board", respectively) shall have the power
to adopt rules and regulations (hereinafter referred to as
"Regulations") not inconsistent with the provisions of the Plan for
the administration thereof and to alter, amend or revoke any
Regulations so adopted."
2.Section 3 of the Plan shall be, and hereby is, amended in its entirety
to provide as follows:
"3. Administration: The Committee shall interpret and administer the
Plan."
3.Section 5 of the Plan shall be, and hereby is, amended in its entirety
to provide as follows:
"5. Participation: Participants in the Plan shall be such key executives
of the Company and of its Subsidiaries as may be designated by the
Executive Compensation Committee of Bristol-Myers Squibb Company to
participate in the Plan with respect to each fiscal year."
4.The final sentence of Section 7, paragraph (a), subparagraph (vi) shall
be, and hereby is, deleted in its entirety.
5.Section 7, paragraph (b) of the Plan shall be, and hereby is, amended in
its entirety to provide as follows:
"(b) At any time after the commencement of a fiscal year for which a
Reserve is to be determined, but prior to the close thereof, the
Committee may, in its discretion, eliminate or add Participants, or
increase or decrease the Award of any Participant, except as
otherwise provided in the Award of any Participant; but the Committee
may not allot a Deferred Portion of an Award for any Participant so
added, increase the ratio of the Deferred Portion to the Cash Portion
of any Award, or change the allotment of any Deferred Portion from
one Performance Incentive Fund to the other, and any increase in an
Award shall be allotted only to the Cash Portion of such Award."
6.Section 8, paragraph (a), subparagraph (i) of the Plan shall be, and
hereby is, amended by adding the following to the end of the first
sentence thereof:
E-5-1
<PAGE>
";provided, however, that an Award may provide that no payment
shall be made to a Participant prior to certification in writing
by the Committee that the performance goals or objectives have,
in fact, been satisfied."
E-5-2
<PAGE>
BENEFIT EQUALIZATION PLAN Exhibit 10e
of
BRISTOL-MYERS SQUIBB COMPANY
AND ITS SUBSIDIARY OR AFFILIATED CORPORATIONS
PARTICIPATING IN THE BRISTOL-MYERS SQUIBB COMPANY
RETIREMENT INCOME PLAN OR
THE BRISTOL-MYERS SQUIBB PUERTO RICO, INC.
RETIREMENT INCOME PLAN
(as amended and restated effective as of January 1, 1993,
---------------------------------------------------------
and as amended to October 1, 1993)
----------------------------------
I. Purpose of the Plan
-------------------
The purpose of this Plan is to provide benefits for certain employees
participating in the Bristol-Myers Squibb Company Retirement Income Plan
(the "Retirement Income Plan") or the Bristol-Myers Squibb Puerto Rico,
Inc. Retirement Income Plan (the "Puerto Rico Plan") (referred to herein
collectively as the "Retirement Plans") whose funded benefits under the
Retirement Plans are or will be limited by application of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA") and the
Internal Revenue Code of 1986, as amended (the "Code"). The Plan is
intended to be an "excess benefit plan" as that term is defined in Section
3(36) of ERISA with respect to those participants whose benefits under the
Retirement Plans have been limited by Section 415 of the Code, and a "top
hat" plan meeting the requirements of Sections 201(2), 301(a)(3),
401(a)(1) and 4021(b)(6) of ERISA with respect to those participants whose
benefits under the Retirement Plans have been limited by Section
401(a)(17) of the Code and with respect to certain employees covered by
the Squibb Corporation Supplementary Pension Plan (the "Squibb Plan") on
December 31, 1990. This Plan is a continuation and successor plan to the
Benefit Equalization Plan of Bristol-Myers Company and Its Subsidiary and
Affiliated Corporations Participating in the Bristol-Myers Company
Retirement Income Plan and the Bristol-Myers Company Savings and
Investment Program, as in effect on January 1, 1983 and as amended
thereafter (the "Prior Plan"). All amounts accrued under Part IV of the
Prior Plan continue to be accrued under this Plan.
Effective as of January 1, 1991, the Plan assumed the liabilities for all
benefits payable under the Squibb Plan with respect to all active and
former employees (other than foreign employees) which had accrued as of
December 31, 1990, with respect to benefits provided under the Squibb Plan
other than benefits due to a Squibb employee's election to defer an annual
incentive award or benefits payable to foreign employees of Squibb.
Therefore, this Plan is a continuation and successor plan to the Squibb
Plan with respect to all such benefits accrued thereunder prior to
January 1, 1991 with respect to employees who participated in the Squibb
Corporation Pension Plan. Employees who were participants in the Squibb
Plan who accrue benefits under this Plan on or after January 1, 1991,
shall be entitled to the benefits provided by this Plan with respect to
all service covered under either the Retirement Income Plan or the Puerto
Rico Plan.
E-6-1
<PAGE>
II. Administration of the Plan
--------------------------
The Pension Committee (the "Committee") appointed by the Board of
Directors of Bristol-Myers Squibb Company (the "Company") to administer
the Retirement Plans shall also administer this Plan. The Committee shall
have full authority to determine all questions arising in connection with
the Plan, including its interpretation, may adopt procedural rules, and
may employ and rely on such legal counsel, such actuaries, such
accountants and such agents as it may deem advisable to assist in the
administration of the Plan. Decisions of the Committee shall be
conclusive and binding on all persons.
III. Participation in the Plan
-------------------------
Each member of the Retirement Income Plan or the Puerto Rico Plan who is
employed by a corporation participating in either Retirement Plan
(hereinafter referred to as a "participating employer" which term also
includes the Company) shall be eligible to participate in this Plan
whenever (a) his benefit under the applicable Retirement Plan, as from
time to time in effect, would exceed the limitations on benefits and
contributions imposed by Section 415 of the Code calculated from and after
September 2, 1974, (b) amounts of his compensation would be excluded from
his "Final Average Compensation" determined under the Retirement Plan by
reason of the application of Section 401(a)(17) of the Code or (c) he
participates in the Bristol-Myers Squibb Company Performance Incentive
Plan (the "Performance Incentive Plan").
IV. Equalization Benefits Related to the Retirement Plan
----------------------------------------------------
A. Each participant in this Plan or his beneficiaries shall be entitled
to receive under this Plan a supplemental pension benefit equal to
the excess of (1) the benefit that would have been payable to such
participant or his beneficiaries under the applicable Retirement Plan
determined (a) without regard for any provision therein incorporating
limitations imposed by Section 415 of the Code, and (b) by deeming as
"compensation" for purposes of determining Final Average Compensation
under such Retirement Plan amounts elected to be deferred under the
Bristol-Myers Squibb Company Savings and Investment Program ("Savings
and Investment Program") but which due to Section 415 limitations
were, in accordance with the participant's election, credited to the
Benefit Equalization Plan of Bristol-Myers Squibb Company and Its
Subsidiary or Affiliated Corporations Participating in the
Bristol-Myers Squibb Company Savings and Investment Program (the
"Savings and Investment BEP"), over (2) the actual benefit payable to
such participant or his beneficiaries under the applicable Retirement
Plan.
B. Each participant whose compensation under the applicable Retirement
Plan is limited by Section 401(a)(17) of the Code or who participates
in the Performance Incentive Plan shall be entitled to receive an
additional supplemental pension benefit under this Plan equal to the
amount, if any, by which the supplemental pension benefit determined
under paragraph A of this Article IV would be greater if the
hypothetical benefit calculated under clause (1) of such paragraph
were determined (a) by disregarding, in addition to Section 415
limitations, any limitations on such participant's Final Average
Compensation imposed by reason of Section 401(a)(17) of the Code, (b)
by including in his "annual rate of compensation" for purposes of
E-6-2
<PAGE>
determining Final Average Compensation under such Retirement Plan
amounts elected to be deferred under the Savings and Investment
Program but, due to Section 401(a)(17) limitations, were, in
accordance with such participant's election, credited to the Savings
and Investment BEP and (c) by recalculating his "annual rate of
compensation" for each year used in determining Final Average
Compensation under such Retirement Plan, by substituting for the cash
award paid under the Performance Incentive Plan during such calendar
year the cash award earned by such participant under the Performance
Incentive Plan for such calendar year. For purposes of clause (c) of
the preceding sentence, any performance incentive award for the
calendar year in which the participant retires or otherwise
terminates employment shall be assumed to be fully earned as though
all performance goals and other conditions to full payment had been
attained as of such retirement or termination date.
C. The supplemental pension benefits determined under paragraphs A and B
of this Article IV shall be calculated utilizing the same actuarial
assumptions used to compute the participant's Retirement Plan benefit
payments or such other assumptions as may be determined by the
Committee from time to time and shall be payable to the participant
(or his beneficiary) upon his election:
(i) in the case of a participant who is a Member of the Retirement Income
Plan who elects between October 1, 1993 and December 30, 1993,
inclusive, to retire under Article 19 of the Retirement Income Plan,
the supplemental pension benefits determined under paragraphs A and B
of this Article IV shall be payable to the participant (or his
beneficiary) in the same form as the participant's benefit under the
Retirement Income Plan is payable (utilizing the same actuarial
assumptions used to compute the participant's Retirement Income Plan
benefit payments or such other assumptions as may be determined by
the Committee from time to time), commencing within 60 days after the
earlier of (a) his retirement entitling him to receive payments under
the Retirement Income Plan, (b) his death, (c) his total disability
as defined in the Retirement Income Plan, or (d) if the participant's
employment terminates prior to the date he is entitled to receive
payments under the Retirement Income Plan, the date he attains his
Early Retirement Date under the Retirement Income Plan; or
(ii) in the case of all other participants,
(a) in either the lifetime benefit, 50% joint and survivor, 100% joint
and survivor, or the Variable Retirement Income annuity forms of
payment as provided under the applicable Retirement Plan, commencing
within 60 days after the earlier of (1) his retirement entitling him
to receive payments under the applicable Retirement Plan, (2) his
death, (3) his total disability as defined in the applicable
Retirement Plan, or (4) if the participant's employment terminates
prior to the date he is entitled to receive payments under the
applicable Retirement Plan, the date he attains his Early Retirement
Date under such Retirement Plan. Such election shall be made, in
writing, concurrent with the participant's benefit election under the
applicable Retirement Plan and shall become irrevocable as of the
retirement date; or
(b) in a lump sum provided that one year prior to retirement, the
participant irrevocably elects, in writing, to receive supplemental
E-6-3
<PAGE>
pension benefits in such form, which payment shall be made within 60
days after his retirement entitling him to receive payments under the
applicable Retirement Plan, except that, in the case of a participant
who is eligible to retire under the applicable Retirement Plan who
has an involuntary termination or unplanned retirement and who
irrevocably elects, in writing, 90 days prior to retirement to
receive supplemental pension benefits in such form, such payment
shall be made on the first anniversary of his retirement.
Any other provision of this Article IV to the contrary notwithstanding, if
upon a participant's termination of employment or retirement the present
value of the amount of the supplemental pension benefits determined under
paragraphs A and B of this Article IV is not more than $3,500 (or if
payments would be less than $50 per month), such benefit shall be paid in
cash to the participant in a single sum at the time of such termination or
retirement.
Each participant's supplemental pension benefits under this Plan shall be
paid by his participating employer. If the participant was employed by
more than one such participating employer, the proportion to be paid by
each such participating employer shall be in the ratio which the "Credited
Service" (as defined in the applicable Retirement Plan) of the participant
with a participating employer bears to the total "Credited Service" of
such participant with all participating employers.
V. Designation of Beneficiaries in the Event of Death
--------------------------------------------------
Upon the death of a participant prior to receipt of all or part of the
amount on his account, the balance remaining on his account shall be paid
as follows: If the participant has designated a joint annuitant or
beneficiary under the applicable Retirement Plan, such person shall be
deemed the joint annuitant or beneficiary for purposes of this Plan. If
the participant has not designated a joint annuitant or beneficiary under
such Retirement Plan, or if no such joint annuitant or beneficiary is
living at the time of the participant's death, the amount in the
participant's account that is distributable upon his death shall be
distributed to the same person or persons who would otherwise be entitled
to receive a distribution of the participant's Retirement Plan benefits.
Payment to one or more of such persons shall completely discharge the Plan
with respect to the amount so paid.
VI. Miscellaneous
-------------
This Plan may be terminated at any time by the Board of Directors of the
Company, in which event the rights of participants to their accrued
supplemental pension benefits under this Plan shall become
non-forfeitable. The Company or any participating employer may terminate
this Plan with respect to its employees participating in the Retirement
Plans, in which event the rights of participants to their accrued
supplemental pension benefits under this Plan and payable by such
terminating corporation shall become non-forfeitable.
If the Plan is terminated, no distribution shall be made to a participant
or beneficiary which is attributable to the termination during the 90 day
period following such termination. Thereafter, providing the Company is
not subject to an insolvency or bankruptcy proceeding, all amounts then
accrued on behalf of a participant shall be distributed to him (or his
beneficiary) within 60 days after the end of such 90-day period. If the
E-6-4
<PAGE>
Company is subject to an insolvency or bankruptcy proceeding, distribution
of such amounts shall be suspended subject to the pendency of such
proceeding.
No right to payment or any other interest under this Plan may be
alienated, sold, transferred, pledged, assigned, or made subject to
attachment, execution, or levy of any kind.
Nothing in this Plan shall be construed as giving any employee the right
to be retained in the employ of any participating employer. Each
participating employer in the Plan expressly reserves the right to dismiss
any employee at any time without regard to the effect which such dismissal
might have upon him under the Plan.
This Plan may be amended at any time by the Board of Directors of the
Company, except that no such amendment shall deprive any participant of
his supplemental pension benefit accrued at the time of such amendment.
To the extent that a grantor trust is established by the Company, the
Committee may from time to time reserve unto itself the right to vote any
shares of equity securities held in a Pension Trust Fund or may permit
such other committee, or Investment Manager or Managers as it may
designate to exercise such responsibility.
Benefits payable under this Plan shall not be funded and shall be made out
of the general funds of the participating employers or any grantor trust
established for this purpose. The participating employers shall not be
required to segregate any contributions made by participants under this
Plan. They shall become a part of the general funds of the participating
employers.
This Plan shall be construed, administered and enforced according to the
substantive internal laws (and not the conflict of laws provisions) of the
State of New York.
VII. Effective Date
--------------
This amended and restated Plan shall be effective as of January 1, 1993,
for retirements or other terminations of employment on and after such
date, upon its adoption by the Board of Directors of Bristol-Myers Squibb
Company.
E-6-5
<PAGE>
AMENDMENT TO THE EXHIBIT 10g
SQUIBB CORPORATION
SUPPLEMENTARY PENSION PLAN
Effective January 1, 1992, the Squibb Corporation Supplementary Pension
Plan is hereby amended as follows:
1. All references in the Plan to the "Bristol-Myers Key International
Pension Plan are hereby amended to "Bristol-Myers Squibb Company Key
International Pension Plan".
2. Section 1 of the Plan is hereby amended to add the following
paragraph at the end thereof:
"Effective as of January 1, 1992, all benefit liabilities accrued
under the Squibb Universal Retirement Income Plan (the "Squibb
Universal Plan") were assumed by and became payable under the
Bristol-Myers Squibb Company Key International Pension Plan. For
Plan Years beginning on and after January 1, 1992, all foreign
employees as described in clause (ii) of Section 3 hereunder became
eligible under the terms of the Bristol-Myers Squibb Company Key
International Pension Plan. Accordingly all benefit accruals for
such foreign employees under this Plan will cease as of December 31,
1991."
3.Section 3 is amended to add the following paragraph at the end thereof:
"Effective January 1, 1992, employees described in clause (ii) of
this Section 3 shall no longer be covered by this Plan and benefits
accrued as of December 31, 1991, for such employees shall be assumed
by the Bristol-Myers Squibb Company Key International Pension Plan."
E-7-1
<PAGE>
AMENDMENT TO THE BRISTOL-MYERS Exhibit 10h
SQUIBB COMPANY 1989 RESTRICTED
STOCK AWARD PLAN
The Bristol-Myers Squibb Company Restricted Stock Award Plan (the
"Plan") is hereby amended effective July 1, 1993 by deleting Section 8 in its
entirety and inserting therefor the following:
8. Taxes
-----
Each Participant shall, no later that the Tax Date (as defined below), pay
to the Company, or make arrangements satisfactory to the Committee
regarding payment of, any Withholding Tax (as defined below) with respect
to an Award, and the Company and its subsidiaries shall, to the extent
permitted by law, have the right to deduct such amount from any payment of
any kind otherwise due to the Participant. The Company shall also have
the right to retain or sell without notice, or to demand surrender of,
shares of Common Stock in value sufficient to cover the amount of any
Withholding Tax (that is, that portion of any Applicable Tax, as defined
below, required by any governmental entity to be withheld or otherwise
deducted and paid with respect to such Award), and to make payment (or to
reimburse itself for payment made) to the appropriate taxing authority of
an amount in cash equal to the amount of such Withholding Tax, remitting
any balance to the Participant. For purposes of the paragraph, the value
of shares of Common Stock so retained or surrendered shall be the average
of the high and low sales prices per share on the New York Stock Exchange
on the date that the amount of the Withholding Tax is to be determined
(the "Tax Date"), and the value of shares of Common Stock so sold shall be
the actual net sale price per share (after deduction of commissions)
received by the Company.
Notwithstanding the foregoing, the Participant shall be entitled to
satisfy the obligation to pay any Withholding Tax or to satisfy the
obligation to pay any tax to any governmental entity in respect of such
Award, including any Federal, state or local income tax up to an amount
determined on the basis of the highest marginal tax rate applicable to
such Participant, Federal Insurance Contribution Act taxes or other
governmental impost or levy (an "Applicable Tax"), in whole or in part, by
providing the Company with funds sufficient to enable the Company to pay
such Withholding Tax or Applicable Tax or by requiring the Company to
retain or to accept upon delivery thereof by the Participant shares of
Common Stock sufficient in value (determined in accordance with the last
sentence of the preceding paragraph) to cover the amount of such
Withholding Tax or Applicable Tax or in a Page Two of Amendment to
Bristol-Myers Squibb Company 1989 Restricted Stock Award Plan. greater
amount as deemed appropriate by the Company. Each election by a
Participant to have shares retained or to deliver shares for this purpose
shall be subject to the following restrictions: (i) the election must be
in writing and be made on or prior to the Tax Date; (ii) the election must
be irrevocable; (iii) the election shall be subject to the disapproval of
the Committee; (iv) if the Participant is an officer of the Company within
the meaning of Section 16 of the 1934 Act, the election may not be made
within six months of the Award Date (except that this restriction shall
not apply in the event the death or disability of the Participant occurs
within six months of such Award Date); and (v) if the Participant is an
officer of the Company within the meaning of Section 16 of the 1934 Act,
E-8-1
<PAGE>
AMENDMENT TO THE BRISTOL-MYERS
SQUIBB COMPANY 1989 RESTRICTED
STOCK AWARD PLAN
the election must be made at least six months prior to the Tax Date or in
any ten-business day "window period" (beginning on the third business day
following the date on which the Company releases for publication its
annual or quarterly statements of sales and earnings and ending on the
twelfth business day following the date of release thereof) prior to the
Tax Date."
E-8-2
<PAGE>
EXHIBIT 11
BRISTOL-MYERS SQUIBB COMPANY
Exhibit With Respect to Omission of Dilutive Elements
In Primary and Fully Diluted Earnings Per Share
<TABLE>
EFFECT OF EXERCISE OF STOCK OPTIONS AND WARRANTS ON PRIMARY EARNINGS PER SHARE:
- -------------------------------------------------------------------------------
<CAPTION>
1993 1992 1991
------------ ------------ ------------
<S> <C> <C> <C>
(1) Average market price of Common
Stock during year $58.42 $69.79 $79.27
(2) Number of shares under option
and warrant at year-end for which
exercise price is below (1) 11,978,432 8,632,047 14,034,715
(3) Aggregate proceeds to be received
upon exercise of shares in (2) $600,689,306 $407,281,454 $751,575,832
(4) Shares deemed repurchased under
treasury stock method (3) divided
by (1) 10,282,254 5,835,814 9,481,214
(5) Additional shares deemed outstanding
(2) - (4) 1,696,178 2,796,233 4,553,501
(6) (5) as a percentage of number of
shares used in computing earnings
per share .33% .54% .87%
</TABLE>
In view of the above percentages, the effect of assumed exercise of stock
options and warrants was considered not dilutive in accordance with
Footnote 2 to paragraph 14 of APB Opinion #15.
E-9-1
<PAGE>
EXHIBIT 11
BRISTOL-MYERS SQUIBB COMPANY
Exhibit With Respect to Omission of Dilutive Elements
In Primary and Fully Diluted Earnings Per Share
<TABLE>
EFFECT OF CONVERSION OF PREFERRED STOCK AND EXERCISE OF STOCK OPTIONS AND
- --------------------------------------------------------------------------
WARRANTS ON FULLY DILUTED EARNINGS PER SHARE:
- ---------------------------------------------
<CAPTION>
1993 1992 1991
-------------- ------------- --------------
<S> <C> <C> <C>
Restatement of Shares:
(1) Shares used in computing earnings per
share 515,245,655 517,966,931 520,869,183
(2) Additional shares deemed outstanding:
(a) Upon issuance pursuant to stock
plans, options, rights and warrants
after assumed repurchase of shares 2,442,546 2,929,858 5,566,205
(b) Upon conversion of preferred stock
outstanding at conversion rate of
424/100 per common share 109,384 120,912 131,355
-------------- ------------- --------------
(3) Shares assumed to be outstanding for
fully diluted computation 517,797,585 521,017,701 526,566,743
============== ============= ==============
Restatement of Earnings:
(4) Net earnings applicable to Common
Stock:
Earnings from Continuing Operations $1,959,128,000 $1,537,853,000 $1,990,794,000
Earnings Before Cumulative Effect of
Accounting Change 1,959,128,000 2,207,710,000 2,055,505,000
Cumulative Effect of Accounting Change - (246,012,000) -
-------------- -------------- --------------
Net Earnings 1,959,128,000 1,961,698,000 2,055,505,000
(5) Dividends on Preferred Stock 54,000 60,000 69,000
-------------- -------------- --------------
(6) Pro forma earnings applicable to
Common Stock $1,959,182,000 $1,961,758,000 $2,055,574,000
============== ============== ==============
(7) Pro forma fully diluted earnings per
share:
Earnings from Continuing Operations $3.78 $2.95 $3.78
Earnings Before Cumulative Effect of
Accounting Change 3.78 4.24 3.90
Cumulative Effect of Accounting Change - (0.47) -
-------------- -------------- --------------
Net Earnings $3.78 $3.77 $3.90
============== ============== ==============
</TABLE>
E-9-2
<PAGE>
EXHIBIT 11
BRISTOL-MYERS SQUIBB COMPANY
Exhibit With Respect to Omission of Dilutive Elements
In Primary and Fully Diluted Earnings Per Share
<TABLE>
EFFECT OF CONVERSION OF PREFERRED STOCK AND EXERCISE OF STOCK OPTIONS AND
- --------------------------------------------------------------------------
WARRANTS ON FULLY DILUTED EARNINGS PER SHARE:
- ---------------------------------------------
<CAPTION>
1993 1992 1991
-------------- ------------- --------------
<S> <C> <C> <C>
(8) Reported per share:
Earnings from Continuing Operations $3.80 $2.97 $3.82
Earnings Before Cumulative Effect of
Accounting Change 3.80 4.26 3.95
Cumulative Effect of Accounting Change - (0.47) -
-------------- -------------- --------------
Net Earnings $3.80 $3.79 $3.95
============== ============== ==============
(9) Dilution:
Earnings from Continuing Operations .53% .67% 1.05%
Earnings Before Cumulative Effect of
Accounting Change .53% .47% 1.27%
Cumulative Effect of Accounting Change - - -
Net Earnings .53% .53% 1.27%
</TABLE>
In view of the above percentages, the effect of assumed issuance pursuant
to stock plans, options, rights and warrants and conversions of Preferred
Stock was considered not dilutive in accordance with Footnote 2 to
paragraph 14 of APB Opinion #15.
E-9-3
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY Exhibit 21
----------------------------
SUBSIDIARY LIST
---------------
Alive & Well, Inc. (Delaware)
A/S Carmen Curlers (Denmark)
Allard Laboratories, Inc. (Delaware)
Bristol-Myers Squibb (Thailand) Ltd. (Delaware)
Apothecon, Inc. (Delaware)
The B-M Group (Proprietary) Limited (Republic of South Africa)
Bristolabs (Proprietary) Ltd. (Republic of South Africa)
Blisa, Inc. (Delaware)
Bristol-Myers Limited (Thailand)
Bristol Laboratories International, S.A. (Delaware)
B.L. Pharmaceuticals (Proprietary) Limited
(Republic of South Africa)
Bristol Laboratories Products, Inc. (Panama)
Bristol-Myers Squibb S.A. (Colombia)
Bristol-Myers Squibb (Taiwan) Limited (Taiwan)
Bristol Pharmaceutical Information Center, S.A. (Panama)
Laboratorios Bristol del Ecuador, C.A. (Ecuador)
Bristol-Myers Ecuatoriana, S.A. (Ecuador)
Laboratorios Industriales Grove S.A. (Ecuador)
G.I.E. Centre de Recherche de Biologie Moleculaire (France)
Grove Limited (Thailand)
BMS French Holding Company (Delaware)
Boclaro Inc. (New York)
Bristol Caribbean, Inc. (Delaware)
Bristol Farmaceutica Portuguesa Lda. (Portugal)
Bristol Iran Private Company Limited (Iran)
Bristol (Iran) S.A. (Delaware)
Bristol Laboratories Corporation (Delaware)
Bristol Laboratories Inc. (New York)
Bristol Laboratories Medical Information Systems Inc. (Delaware)
Bristol-Myers Squibb Aktiebolag (Sweden)
Bristol Laboratorier Aktiebolag (Sweden)
Bristol-Myers (Bangladesh) Inc. (Delaware)
Bristol-Myers Barceloneta, Inc. (Delaware)
Bristol-Myers Company (Delaware)
Bristol-Myers de Colombia, S.A. (Delaware)
Bristol-Myers de Mexico, S.A. de C.V. (Mexico)
Bristol-Myers Foreign Sales Corporation (Virgin Islands)
Bristol-Myers Industrial (Dominicana), Inc. (Delaware)
Bristol-Myers International s.r.l. (Italy)
Bristol-Myers (Japan) Limited (Japan)
Bristol-Myers Lion Ltd. (Japan)
Bristol-Myers Middle East S.A.L. (Lebanon)
Bristol-Myers Nederland Inc. (Delaware)
Bristol-Myers (N.Z.) Limited (New Zealand)
Bristol-Myers Overseas Corporation (Delaware)
Bristol-Myers Pakistan (Pvt.) Limited (Pakistan)
Bristol-Myers (Private) Ltd. (Zimbabwe)
Bristol-Myers (Zaire) Ltd. (Delaware)
Bristol-Myers Squibb A.E.B.E. (Greece)
Bristol-Myers Squibb Asia/Pacific, Inc. (Delaware)
Bristol-Myers Squibb Belgium (Belgium)
Bristol-Myers Squibb Brasil, S.A. (Brazil)
E-10-1
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
----------------------------
SUBSIDIARY LIST
---------------
Bristol-Myers Squibb de Venezuela, S.A. (Venezuela)
Servicios Administrativos Bristol-Myers, S.A. (Venezuela)
Bristol-Myers Squibb Canada Inc. (Canada)
Bristol-Myers Squibb Dominicana, S.A. (Delaware)
Bristol-Myers Squibb (Philippines) Inc.
Bristol-Myers Squibb Peruana, S.A. (Peru)
Bristol-Myers Squibb Service Ltd. (Bermuda)
Bristol-Myers Squibb Sp. z.o.o. (Poland)
Bristol-Myers Squibb (Scandinavia) Ltd. (Delaware)
Bristol-Myers Squibb Global Properaties Ltd. (Delaware)
Bristol-Myers Squibb Holdings B.V. (Netherlands)
Bristol-Myers Squibb B.V. (Netherlands)
Mead Johnson B.V. (Netherlands)
Zimmer B.V. (Netherlands)
Bristol-Myers Squibb (Hong Kong) Limited (Hong Kong)
Bristol-Myers Squibb International Corporation (New York)
Bristol-Myers Squibb K.K. (Japan)
Bristol-Myers Squibb (Malaysia) Sendirian Berhad (Malaysia)
Bristol-Myers Squibb Products S. A. (Switzerland)
Bristol-Myers Squibb (Proprietary) Limited (South Africa)
Bristol-Myers Squibb Puerto Rico, Inc. (Delaware)
Bristol-Myers Squibb (Singapore) Pte. Ltd. (Singapore)
Bristol-Myers Squibb (West Indies) Ltd. (Delaware)
Bristol-Myers Superannuation Limited (Australia)
Cancer Research, Inc. (Washington)
Oncogen limited Partnership (Washington)
Clairol de Mexico, S.A. de C.V. (Mexico)
Clairol (Japan) Limited (Japan)
Clairol Incorporated (Delaware)
Clairol Appliances, Inc. (Delaware)
Duart Industries, Ltd. (California)
Logics International, Inc. (Delaware)
Compania Bristol-Myers Squibb de Centro America (Delaware)
Bristol-Myers Squibb de Costa Rica, S.A. (Costa Rica)
Compania Clairol de Argentina (Delaware)
Dalton Holdings Ltd. (Cayman Islands, B.W.I)
Grove Insurance Company Ltd. (Bermuda)
Intrafin S.A. (Switzerland)
Bristol-Myers Squibb (MEA) S.A. (Switzerland)
Linvatec Corporation (Florida)
Xomed-Treace, P.R., Inc. (Delaware)
Listo B.V. (Netherlands)
Listo International B.V. (Netherlands)
Listo Netherlands B.V. (Netherlands)
Orpex (France)
Listo Investment B.V. (Netherlands)
Mead Johnson & Company (doing business as) Bristol-Myers Squibb
U.S.Pharmaceutical and Mead Johnson Nutritional Group
(Delaware)
Mead Johnson de Mexico, S.A. de C.V. (Mexico)
Selecciones Mercantiles, S.A. de C.V. (Mexico)
Mead Johnson Ecuador, S.A. (Ecuador)
Mead Johnson (Guangzhou) Company (China)
E-10-2
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
----------------------------
SUBSIDIARY LIST
---------------
Mead Johnson International, Ltd. (Canada)
Bristol-Myers Squibb Argentina S.A. (Argentina)
Mead Johnson Jamaica Ltd. (Delaware)
Mead Johnson Limited (England)
Mead Johnson (Manufacturing) Jamaica Limited (Jamaica)
Mead Johnson (Philippines) Inc. (Philippines)
Mead Johnson Pharmaceutical, Inc. (Philippines)
Mead Johnson Farmaceutica Limitada (Portugal)
Medical Engineering Corporation (Delaware)
MEC Subsidiary Corporation (Wisconsin)
Monarch Crown Corporation (Delaware)
Oldcorp Productions Inc. (Delaware)
Palopic Inc. (Delaware)
PPI Music Corp. (Delaware)
OY Bristol-Myers Squibb (Finland) AB (Finland)
Route 22 Real Estate Holding Corporation (Delaware)
Squibb Industria Farmaceutica, S.A. (Spain)
Bristol-Myers S.A. (Spain)
Convatec, S.A. (Spain)
Apothecon, S.A. (Spain)
Squibb Corporation (Delaware)
Bristol-Myers Squibb Caribbean Corporation (Delaware)
E.R. Squibb & Sons, Inc. (Delaware)
Bristol-Myers Oncology Therapeutic Network, Inc. (Delaware)
Bristol-Myers Squibb GmbH (Germany)
Convatec G.m.b.H. (Germany)
Zimmer Chirurgie G.m.b.H. (Germany)
S&G Implants G.m.b.H. (Germany)
Agit Ges. Fur Informationssyskme und-Techniken mbH (Germany)
Bristol-Myers G.m.b.H. (Germany)
Bristol-Myers GES. m.b.H. (Austria)
Bristol Arzneimittel G.m.b.H. (Germany)
Carboplant Spezialimplante G.m.b.H. (Germany)
Orthoplant Endoprothetik G.m.b.H. (Germany)
Bristol-Myers Squibb Ges.m.b.H. (Austria)
Bristol Salor Pharma G.m.b.H. (Germany)
Bristol-Myers Squibb Zentrum Fur Forschung und
Fortbildung im Gesundheitswesen G.m.b.H. (Germany)
Elektrochemische Gesellschaft Hirschfelde mbH (Germany)
E.R. Squibb & Sons (N.Z.) Limited (New Zealand)
Princeton Pharmaceuticals Limited (New Zealand)
Laboratorio Farmaceutico Squibb, S.A. (Guatemala)
Salorpharma GmbH (Germany)
Squibb Pharma G.m.b.H. (Germany)
Squibb Von Heyden G.m.b.H. (Germany)
Unterstutzungrasse Bristol-Myers Squibb G.m.b.H.(Germany)
Von Heyden Pharma G.m.b.H. (Germany)
Bristol-Myers Squibb Holdings Limited (England)
Bristol Laboratories Limited (England)
Bristol-Myers Company Limited (England)
Convatec Limited (England)
Kingsdown Medical Consultants Ltd. (England)
Bristol Pharmaceutical and Drug Company Limited (England)
E-10-3
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
----------------------------
SUBSIDIARY LIST
---------------
Clairol Limited (England)
E.R. Squibb & Sons Limited (England)
Bristol-Myers Squibb Pharmaceutical Ltd. (England)
Zimmer Europe Limited (England)
Zimmer Limited (England)
Bristol-Myers Squibb Pharmaceuticals Limited (Ireland)
Bristol-Myers Squibb Pharmaceuticals Pty. Ltd. (Australia)
Bristol-Myers Squibb S.A. (France)
Bristol-Myers Squibb SpA (Italy)
Bristol-Foundation (Italy)
Bristol Italiana (SUD), S.p.A. (Italy)
Clairol International, S.p.A. (Italy)
Laboratori Guieu S.p.A. (Italy)
Laboratories Guieu France S.a.r.l. (France)
MI.BE.MA. S.r.l. (Italy)
Mead Johnson S.p.A. (Italy)
Zimmer S.r.L. (Italy)
Convatec Sp z.o.o. (Poland)
Convatec Spol s.r.o. (Czechoslovokia)
EWI Corporation (Delaware)
E.R. Squibb & Sons, Inc. (New Jersey)
E.R. Squibb & Sons Inter-American Corporation (Delaware)
E.R. Squibb & Sons de Venezuela, C.A. (Venezuela)
G.I.E. Institut de Recherche Squibb (France)
Laboratoires Convatec S.A.R.L. (France)
Laboratorios Linson, S.A. Productos Farmaceuticos (Argentina)
Societe Francaise de Complements Alimentaires S.A. (France)
Squibb ApS (Denmark)
Squibb of Bangladesh Limited (Pakistan)
Squibb Europe Inc. (Delaware)
Squibb (Far East) Limited (Hong Kong)
Squibb Manufacturing, Inc. (Delaware)
Squibb Pacific Ltd. (Hong Kong)
Squibb Surgicare Limited (England)
Swords Laboratories Limited (Ireland)
Bristol-Myers Squibb International Company (Ireland)
Lawrence Laboratories Ltd. (Ireland)
Linson Investments Limited (Cayman Islands)
Bristol-Myers Squibb de Mexico S.A. de C.V. (Mexico)
F.A.I.R. Laboratories Limited (England)
Fray, S.A. (Dominican Republic)
Industrias Linson, S.A. (Ecuador)
P.T. Squibb Indonesia (Indonesia)
Squibb Development Limited (England)
Squibb Pakistan (Pvt.) Ltd. (Pakistan)
Squibb Middle East S.A. (Panama)
Squibb Farmaceutica Portuguesa Limitada (Portugal)
Heyden Farmaceutica Portuguesa Limitada (Portugal)
Squibb (Thailand) Limited (Thailand)
Squibb Overseas Investments, Inc. (Delaware)
Squibb Properties, Inc. (Delaware)
345 BM Corporation (Delaware)
Bristol-Myers Company Pty. Limited (Australia)
E-10-4
<PAGE>
BRISTOL-MYERS SQUIBB COMPANY
----------------------------
SUBSIDIARY LIST
---------------
Joy Corporation Limited (Australia)
Crisena Corporation Pty. Limited (Australia)
United Hairdressing Supplies (VIC.) Pty. Limited (Australia)
Joy Cosmetics Engineering Pty. Limited (Australia)
United Hairdressing Supplies (N.S.W.) Pty. Limited (Australia)
Bristol-Myers Squibb A.G. (Switzerland)
Grove Products (Far East) Limited (England)
Wallingford Research, Inc. (Delaware)
Westwood Products, S.A. (Switzerland)
Stamford Holdings, B.V. (Netherlands)
Westwood-Squibb Pharmaceuticals Inc. (Delaware)
Xomed Treace Inc. (Delaware)
Zimmer, Inc. (Delaware)
Snyder Laboratories, Inc. (Delaware)
Zimmer of Canada Limited (Canada)
Zimmer Australia Pty. Limited (Australia)
Zimmer Pte. Ltd. (Singapore)
Zimmer New Zealand Limited (New Zealand)
Zimmer Caribe, Inc. (Delaware)
Zimmer S.A. (France)
Osmat S.A. (France)
Delmed S.A. (France)
Zimmer S.A. (Spain)
Zimmer Korea Co., Ltd. (Korea)
E-10-5
<PAGE>
Exhibit 23
CONSENT OF INDEPENDENT ACCOUNTANTS
-----------------------------------
We hereby consent to the incorporation by reference in the Prospectuses
constituting part of the Registration Statements on Form S-8 (Nos. 33-30856,
33-31055, 33-35586, 33-38411, 33-38587, 33-44788 and 33-52691), Post-Effective
Amendment No. 2 on Form S-8 (No. 33-30756-02) to Form S-4, Form S-3 (No.
33-33682) and Pre-Effective Amendment No. 1 on Form S-3 (No. 33-62496) of
Bristol-Myers Squibb Company of our report dated January 20, 1994 appearing on
page 50 of this Form 10-K.
/s/ Price Waterhouse
- --------------------
PRICE WATERHOUSE
New York, New York
March 28, 1994
E-11-1
